var title_f36_11_37040="Chest radiograph RDS";
var content_f36_11_37040=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 527px\">",
"   <div class=\"ttl\">",
"    Chest radiograph of neonatal respiratory distress syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 507px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two radiographs that demonstrate severe (A) and moderate (B) neonatal respiratory distress syndrome. Both demonstrate the characteristic low lung volumes, diffuse reticulogranular ground-glass appearance with air bronchograms.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_11_37040=[""].join("\n");
var outline_f36_11_37040=null;
var title_f36_11_37041="Subacromial palpation with extension";
var content_f36_11_37041=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subacromial palpation with extension",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD56kd/Mb526nvTfMf++350S/61/qaSvXR5Q7zH/vt+dKHf++350yrEMRkOB1HNKclBXZUIubshVZhGxLN+dRSXTRhdjMWboM05oWLtAx257+9ZkRZJj5/yvGcYPavNniG1ZHoQoJO5sfaJFQK7tk9FzT0vSq/MSPx4qiiutzK0vRU3KaiSZRHtlG4kA/jXNzO1jo5Ve5vQXCSMAzHDcDmoHMkKbQ5I6jmsSBLh51iUHCtVtXuJywUHagwTTU2mmDimrGzaSLIjLvbnkc1Bdzi3VtzMXHQZrf8ABnw/8W+K7Ca98NaNJfWkMxt5JBcwR4kCqxXDup6OvOMc1q3fwQ+JdzIWbwu+Tz/x/wBr/wDHa0jVnFaGcqcHucN5jlQwdsEZ60B3/vt+dd7afBL4kRRbJPC0h9CL+14/8i1MPgt8RsjPhab/AMDrT/47XoU8RFx956nBUoNS93Y8+Dv/AHm/Onb3/vN+degD4LfEUdPCs3/gdaf/AB2lHwX+I3/Qqzf+B1p/8dq/bU31M/YTXQ8/Dv8A3m/OnBn/ALzfnXfD4MfEX/oVpv8AwOtP/jtO/wCFMfEX/oVZv/A60/8AjtP21PuHsZ9jgd7/AN5vzo3v/fb8677/AIUz8Rf+hWm/8DrT/wCO0f8ACmfiL/0Ks3/gdaf/AB2j21PuP2U+x5+Xfpub86C7D+Jvzr0D/hTPxF/6FWb/AMDrT/47SH4M/EUn/kVZv/A60/8AjtUq1PuS6M+x5/vf+8350bn/AL7fnXoP/CmPiJ/0Ks3/AIHWn/x2j/hTHxEHTwtP/wCB1p/8dp+3p9xewn2PPgz93b86Nzf32/OvQP8AhTHxF7+Fpv8AwOtP/j1B+DPxF/6FWb/wOtP/AI9R7en3D2E+xwG5/wC8350m9sffb869A/4Ux8Rf+hWm/wDA60/+O0f8KY+Iuf8AkVZv/A60/wDjtHt6fcXsKnY8/wB74+8350b3/vt+degf8KY+Iv8A0Ks3/gdaf/HaP+FMfEX/AKFWb/wOtP8A47R7en3D2NTsefb3/vN+dBd8/eb869A/4Ux8Rf8AoVpv/A60/wDjtH/Cl/iL/wBCrN/4HWn/AMdo9vT7h7Gp2PPt7/32/OjzH/vt+deg/wDCl/iL/wBCtN/4HWn/AMdpP+FLfEX/AKFWb/wOtP8A47T9vT7h7Gp2PP8Ae/8Afb86N7/3m/OvQP8AhS/xG/6FWb/wOtP/AI7R/wAKW+I3/QrTf+B1p/8AHaXt6fcPY1Ox5/vf++350b3/ALzfnWp4o8N6z4U1VdN8R6e9hevCtwsbSxyZjZmUHMbMOqNxnPFZXTqcVompK6M5RcXZhvf+8350u9/7zfnSAHvwO9AUnBHehyXVgot7C73/AL7fnR5j/wB5vzpfLbHTvimlSCQetJSi9mNwkt0Lvb++350b3/vN+dNoqiR29/7zfnRvf+8fzptFIBd7/wB9vzpfMf8AvN+dN+tFAC73x95vzpd7/wB5vzptFAAXfP32/OjzHx99vzpCKMUWEOErdNzfnUkUjGRPnbqO9QmnRf61P94UmilJmdJ/rW+ppKdJ/rX+pptQjQUUpd4mR1PTIP0oABNSPC/BjlGMdK5cVNKNjqwsG5XM6TUSLlS/IBp9wVujvB+cjH19DVK+jcSHehx6kU4LLbLBI33d3rXm2vqj0Uak0xmtbRfwb1JHaqtzEBexjeVhkw4PofT8+KkRPMlIjzlfmA9s5qC4dC4HJ2MSB7HtSQzQS52uAOG5JHqelW7CULaTk4Cg8k+vYVzpkkMjkAhiOlSXF0yRRwj7qjJ9zS5QTPsz9j7/AJJ3rP8A2GZP/Se3r3SvBP2MXL/DHVmPU6zL/wCiIK97rZbGL3OZ8U+Lo9A1fStLj0jU9VvtSjnlhisfJBCw7N5JlkQf8tFwBknmotP+IXhS8s9Pmk13TrKW+TfDa3tzHBOfnaMjy2Och0ZeM8qRWb458M6rrnjzwne6deXmnWllbX8dze2Zg8yMyCHYoEquDu2NyFOMdRXH+O/CPieHw/qXhPwxZX8vhw6U0NmttJZnzrh95kN09wd/LENmMAktncp5DEeiW3jOwGseJLTVZLXTLbRrmC2+1XNyqJMZYElH3sBT8+MZOcZ9qtyeMvDEWlRanL4j0VNNmkMUd219EIXcdVV92CeDwDXlnijR9T0u61K91DTHu477xFo8lvCJI2a6CW8MbgbmwDvRh85APXOOa0m0zxra6hqeq6Xp95ptrrOqfaLmzsXs3vYYkt0jVh5zGDc7oS2C2Btxk5oA7XU/iB4Z03WdI0671eyjOq28lzbXBuYhCVUoB8xbq5f5cA52t6VOvi/R7Swjudd1nQbDzJJkQjUkaNhHJsbDsEyQSoYY+Vjtyep8+8G+HPEfh2HwXd3Wi3V3JYf2vb3VvDcW3mxLc3SyRP8AeSMrtQZC4xkYXjAueDPB2rWOv+HLnU9OQRWMmuu7M8b+Wbi7jeEjBJyyBunTocZxQB6FqHiTQ9NsbW91HWdMtLO6x5E890kcc2RkbGJw2RzxV+1vLa7sory0uIZ7SVBLHPG4ZHQjIYMOCMc5rxGCRvhv/wAI7e+IrSzZhpd1YRWkmoWsMkTefv8AkErqGVlKA7CzDCjac13Xg7S5/wDhSGkaVd2Dy3LaDHbyWTyeSzsYADGW/gJzjPb8KAOhsPFfh3UUd9P17SbpElSBmgvI3CyO21EODwzHgDqTwKqeKvGGn+HjZmaa1ZJL+Oxune5WMWm+NpNz5zj5QDg44YHNebweGPFkmmyN/Zl48FjPpU9rbak9l9tkFrOJHiWaAhGQKAEMhDbickA5q3qOi+Ir+/vNXm8LXBV/EdpqK2DXNs0rQRWgjLf6zyw24fd3de+OaAPRp/F/hq30qDU5/EOjxabcOY4bt72JYZGGchXLYJ4PAPapr7xLoVhpkGo3+taZbafcY8m6mu40ikz02uTg/ga86Ol+MbB76+0eyv7G21jV5L26s7M2bXtvH5EaLt81zBuZ42ZvmbhhjnNZvg/wr4k8Nf8ACNane6BNqj2dvqdpLYpcW/nQGe7Mscq5ZIiDGArbSuA2AOqgA9VbxT4fW8gtG13ShdT7fKhN3Hvk3KGXaucnKkEY6g5pLPxV4evbO7vLLXtJuLSzwLmaK8jdIM/32Bwv41wp8G6nqGkePIU0620a41vToLW0COjLDi0CGLcnIRXyvQcDIFZOu+Ftf8RWepSx+GjpG3QE0lLKSeBvtMnmo/GxyojQIwUsVJ8w8CgD0dPHPhJwhTxRoTB5fITGoQndJx8g+bluRx15qa78Safps+pHWdS0ewtLR4k82W/VWUuuQJVYKIyT90bjuHPHSuL8VeDLy+n+IzWelwuNU8Ow6fpxBjXfKqXIKDJ+UAtDycDpz8vFa+0nxnpupa9e6JazBr+409Xkge3e4aBLcpKYhKwj3h9o/ecYyRnigDsb3xjZLe+GE0t7bU7TXLuS1S7trlWjTZDJIWBUENzHtxkdfbFa2t67pGgwxza5qthpsMjbUe8uEhVj6AsRk15Z4V8I+I4dR0O5v7G5VYPEt3qMzXM1sZVgktHRXYQ4TcXbkIOpJ966P4naPqN9qel3uj6fq0t3bW9zCl1p09pmPzQmUkiufkdG2Lkj5ht460AdPd+LfDlndQ2154g0iC4m2GKKW9jR5N/3NoLZO7tjr2p8nifQItbGjS65paawSFFi13GJ8kbgPLzuyQQenQ5rx6bS9au5fF/h4eHra+1a+0Gw0+We3MMVpZyNC6kkMwcRg/MojVvuDgcVoeK9D8dandrp8kN9c2NnqVhLZvA9kls0MUkLPJI0hNx5uVc4XaOOrZ2kA9V/4SLRf7aGj/2xp39rkZ+w/ak8/GM/6vO7pz0pun+JNC1IXh07WtMuxZ5NyYLqOTyMZzvwfl6HrjpXnVj4b1yDSvEHhqXQd8moX1/cQ6/58PlxicSFJiCxl81d6pgJjA+9jqngvwxqljqCXOoaRrc7WOiS6fHFqM+mrby5MZ8hFt03MhKHDS4wP4cscAHq9pcwXlpDdWc0U9tMiyRSxOGSRCMhlI4IIIIIqWs/w8rpoGmLLpsWlSLaxBrCJlZLQ7BmJSoCkL90EDHHFaFAHx5+19d/ZvilYBYzJI+iwbR0HE9x1/OvD3vJnUs0iwopydoycV7R+2OzD4qaaqLknRYen/XeevGrXTZZBsmUAfePuaUq8orlvoVChGT5rajIbwzHAR2JH8fPFWSZPJJjIHbIH8quWOnySPtUbwvQbeB/jW3b6HOxBYYU+3Nc0qq3OqNBvZGDDAzIGaVt2cgB1Az6c1ftrpobhYtRt9sZOAxAZW/Ed66S08Mxy4Eqo2B3FTXHggXKnY/lt2x0P4VCrJPRmjw0rbGDqmmQx24uLSTdE3I5zxWN2zWxqVlfaIWs7o7VkUkHqGHtWQa97BTlOneR4ONpxp1LIbRS4pK7LHGFFFFFgCiiilYAoooosAU6P/WJ9RTafH/rF+oosBmyf61vqaYSFUk9KfJ/rH+pqrfE+Wqg4yea56k+SLZ0U488lEmgkEpyWCrTzGpTccsT90VnW/L/ADfdBxj1rQeUMQkZ/eNwPYV49Sbm7s9aEFBWRWuIHjQ5mUE/w5yKfbRpLbPbAqXPKk+tFzLApCJCWde7GnQQ+XmV2+c/wqOntUpmgljA8UziVWYjgFabdwEXIKrnceucD8fSrob5i0shViOFBzUVsfOmYszd/vdM/SgQwae5DFnO7GRzxUNxprbcgEv35rRllKRgEbR0BqGJnfq34d6XMVY+s/2MkMfwx1ZGGCNal/8AREFe914T+x5/yTnWcnP/ABOpP/Se3r3atlsc73CiiimIKKKKACuL8U+LdT03xVDoej6TY3szabNqckt5qJtEVI3RCoIifnLg5OBwcmu0rz/xn8OrPxh4yivddt7S60hdHnsdj/66Kd5Y2WWM4wpCq3zA5BPTBNAFmy+JmgSeHdG1W+a6tTqVl9vW1W1luJYogBudxErbUGfvnC+9S2fxA0+68YX+hR219Ilva211FeW1pPPFMJlkb7yRlVAVBhi2GLEDlSK5+x8LeNtOv11NJtA1HUjph0eRriWSFGjjkdoZ8LG3zkOQ8fCnAww6B2jeBtf8L+bbeHbuxeG40K10o3lxK6TW01ukwSZUCMsgJlB2llxt6mgDV8QfE3R9N8Oa9qNrDfz3mk2n2t7C5sri0ldCdqkCSINsLDBcKQuCTgCtG78faBZwQSXUuoRNMryLC+l3QmCJ96RovL3og/vsoX3rgE+GPiLUINbXVrq3ik1DQZdL8x9WutQYzuyt5h81FCIcfdQAD0PbZ1/wf4g1jWINeuLSy/tNrH7BPaW3iK9s4VCuzq4lhjVnzvYFGTjjDUAa3jr4jaVoPhzUrrTrkXmox6W+o2yQ2s1zFgoxiaVogQkbEdWZQRnB71o+P/E0nhjwTdazFB51yqxrEnlSSL5jsFUsEBbaC2ffpnJFcdfeAdfs/DGtaL4dg0MRaxo8WnStPdTotoyW5hIjGx2dMHjcwI5J3d+38a6Hc654Ql0q0eFLhmgIaUkJ+7lRzyAT0U44oAzLPx/pNjbW9vr+qF9Q2K9xJHpF1bRwCRysZmVw5t88D96wz14BFW7/AOIPhuxu9Ttri8ud+mFhfPHYXEkdthBJ+8kVCqjacgk88gZIIrnvFPgrXb288X2+lSaYdM8VRRR3U11I6zWeIhC5jQIyyZRQRlkw3rW5o3hBoLLxlYag8clnrl3JIgQlmEL2sMJD5A+bMbeowRz2ABoXHjLQLe81K0k1FPtOnTW1vdRrG7NHJcECFcAcliw6Zx3xg0tp4u0i51xNHD3sF/IZBEl3p9xbrMU+95byIqvgc/KTxz0rzfwz8JdV0/UvCWoajqNpPdW0kk+uFMn7XIpLW5Q7RwjHvjj3q/o3gbxSnjXQtX1u9gu1068uZ5rhtVuZTOskMsaBLUoIYSu9c7ScjPPYgHT2XxK8L3umx39peXktnMUWCRdNucXDNkhIv3eZW4OVTJGDkDBq54C8RP4n0y+vWQJHHqFxbRDyXiby0cqu9H+ZWx1BA57Cud0rwZrGj+FPA0Vt/Z13q/huPY0Ms7xQTboGibEgjZlI3ZB2HIBHGcjofAGj6no+lXqa2bM3t3f3F6wtGZo1EjlgAWAPGfSgDpqKKKACiiigAooooA+RP2rrf7R8XdNUdf7Gh59P39xXnmkW8Dt90bV45r039qR9nxYtMck6JAP/ACPcV5ho52SeWeAefwrkrbs7sNZJM6mGBQBsVR+FWUgHO7AHqe9QQPyMDrwK0Yh0zyfeuKVz0YtE1rGAoIHFbFrEp2ncQTWXENpByMj1rUtWYsCvQCp6jbIPEGiQ6xp0lvL97G6N8fcb1rxS7t5La6mt512yxsUYe4r6CiZsfMPlrzL4n6V5F/HqUS4jn+STHZx0P4j+Vezllfll7N7M8bNMPzQ9ot0cIc0U4jHNIRxXvHzwlJTsUUwExSGlopAFJTse1JigBKdH/rF+opB3p0Y/ep9RQBmS/wCsf6mqOoE7owKvS/6x/qap6go2o2OQa4cV/DO3DfxBkERZiAcYBJqxZqYfMlkHIU4qKxf5yccc1pyIsqx7cbcc15TPTRmxR4nO8ZZeT7mrcqu0fznA6DHGPalCIrMQvJ5PsaeXG5CwyEbAHYe9JlJjI41RwSe9MMRSXg4yc5FWLyEfaCYzuQDAI6ULnzDv6kYB9KQxkkU3l5PKjt2qa3QMoJXn61ItwTHgLgjginhVFwjKPlOM49aTGj1j4SfFef4deH73TINCh1RLq8a9WVr8wFcxxpt2+U2ceXnOe/Su7tv2kb+4YiPwXDnGf+Quf/jFeEx2geJVyMk5Xn866TRNNSGeKST/AFZO0kUe1aRSoxkz16L4/wCryqWj8E27gdcaweP/ACXq9afGzXrrb5Xgq0BIzhtZYY/8l64i2020xujfkcHHU+lblnBBHHheo569TU+3ka/VYHTH4veIgMnwbYY9f7af/wCRq5vXP2j7/Rb4Wt54MgMhTeCmrsVI/G3FPldWTCjAPWvNPipojXGnJqUI/eWhw4x1jJ/of51tQqc01GWxjXoKFNyjujv1/abumGR4Mh/8G5/+MU7/AIaZuv8AoTYP/Buf/jFfPMYwoqQDtXrfVqZ4/t5n0H/w0xdf9CbB/wCDc/8Axik/4aYu/wDoTYP/AAbn/wCMV8/befan0fVqYvrEj3//AIaYuv8AoTYP/Buf/kej/hpi7/6E2D/wbn/4xXgApe9L6tAPrEj37/hpi7/6E2D/AMG5/wDjFH/DS93/ANCbB/4Nz/8AGK+fyKM+2af1amHt5n0B/wANL3f/AEJsH/g3P/xij/hpi7/6E2D/AMG5/wDjFfP1FH1amH1iZ9A/8NMXf/Qmwf8Ag3P/AMYoP7TF2P8AmTYP/Buf/jFfPwHv+FGB/wDXo+rUxfWJn0B/w0zdf9CbB/4Nz/8AGKP+Gmbr/oTYP/Buf/jFfPpFJVfVaZP1mZ9Bf8NNXX/Qmwf+Dc//ABij/hpq6/6E2D/wbn/4xXz5Qaf1SmH1moe+Xv7Uc9pB5sngyIrnGF1ck/8AoioP+GrJP+hLTPp/ax/+MV88a4wEUCEZDPyPYVlxsp2uw5dsD6V5+Jiqc+WJ3YducOaR9PD9qqUrn/hCkx0/5C3/ANop6/tSzMSP+ELjyP8AqLn/AOMV80xAFyB68D1FSpgPhuCCDXNzs6eRHofxJ8byfETxZDrT6cmmeXZx2YhW5M+dryvuzsXGfMxjHasy0GyRSRzisCAlGLDseM1sWU3mXcS4IIxuHtWM9dTopq2h09kJWVc9Tzz2rTSUKo55Heq0JyvHFSSIQoPft9a5G7nelyo0IfmbJzj3q9bX0Med7qqjnJPFc7tu327nVAPXiqt62nmLyBcS3c7kgrFwqDvk04wJdRLQ7m11iyuDsSVWbPaqfjKO2uvD9xBKRukTcn+8ORXL6HDbQXAIVgenJ6Vc8fozWtre/alihjTb5X981pSbVRJbkVV+7blseX/XrRjB60shDSMQMAnOPSkr65bHxrdm0JR3pTSUE3ADijFLRQFxPyxSYOadSGgoSnRj94nPcUhHNOj/ANYvuRSAypP9a31NQXiboQR1qeT/AFrfU0yVsIM9M1zVoc8bHVRlyyuULQ480DqBuq7azk71PUrUHl7HmYDjr+FLCNs2TjBGK8dnqotWcgChnOSD+lOYYeVMcNgrVZE2yqM8Zx1rRRY8gOQSQcUhoht5jE7RSj6fjTpl8yJWTqvBxUk0KtGd/DA/Kf6VDbsF+62PUUh3JYwdgY/eB6HuKv2MImiUoTuU4K1TExKHZhuxHQirFnLsnUqcEjt3pMuLOhiRFgVic5O3HpW3ps7/AGeSCXcwI+V+4PvWJZIbi5RdvGc4Pc12tnYoksTqMjbhxXPM66avqXtEnLIBLkOBgjHUjvXQQOzJjOD1qlBHEcAJwBwa07RY1XkgH3rNG7ZJGp2nOazPE6K3h3UwwBBt3GPwrXMqdBzXOeM9Th0/QLppWA8xWiQH+IkYxWtP4lYwqfC7ni0Y+RRntUgwcEmo0xtGPSpBzX058sOFBpOO9BPHFIQoNGOKSlzQOwUVNBa3NwP9Gt5pR6pGW/lSXNrcWxAuYJoSenmIVz+dK6HyshP05pCDV2HTb2aISQ2szxnowWkbT7xAS1pcADqfLPFPmQ+V9ip+dJTgRzSEjNUSIRnNNI9adnvSM3pTRLQ2jGaB1oq0QZmtjMcRIzgmsq2TIweg+YVt6su+26d+tZER4IOMjpXk42LU7np4OV4WOl8M+HpdUQ3Mkpt7RG2bwu5nPoorYvPCkUQ2WtxJLJncUmXaxB7jH8q0fCNysnhOHbt3wSlJAPU85/EVsaoFikVzlrkAEDHC+n1NeRKo+ax9BTw8PZpnD3Vg1oFE2QeQeOo9KXRY913luDjANdRqSfabcuACDkjisSxU5YKpyD1xilzNon2STOuslGFDDgcYrctIYZMB+nbFYEEhKA55I7Vq2MpOFyR6Vizd6otTaFDeyqC2dpyBnAFQ6jolvYxrJbwoJwDhlHetmCYIAehps7faT0p87SI9mrnIRQtC2JOT1Jx3q1e2n9t6TLYzEK7fNE5/hcdP8Kj12Ypei2h4Y8tTLS4ht5FVpg8megPSnByjJSW5pKMXFxezPNriGS3nkhnQpLGxV1PUGo66/wCJYsm1S0mtHBuJYB9oA/vDgH64rka+toVPa01PufE4mkqVVwTvYQUHrS+tIa1MApKKKAFoxmikJoKTFp0f+sT3IphPHNOjP71PqKB3MqX/AFj/AFNRyLvXFSSf6x/qaQVla5rewxiAhHtg1XhdSAp6g9akkOyRvQiq0yYwR0PINeRWp8kj1aU+eKLFz8kgI5xg/WmNcFmDHsx4ohYyKFb7w4Brch8NuxRWfDEA4PesG7HRCDnsZ7XBMWw5wRnPcH1qkztknPPtW3faU1uExk4HUfWqMlmysxx0GT9KSaY3Bx3K8DyM4bPI4zWxZRSS5fj5SBwPWsyGLBI/LNdv4RsRNbmQYO1wxGOuKUnYqnG7sdBoOlssCGc7W4YH0rqIdqgAnn1FU40KKDilEy45O2ufc7dEbUZwARgCrBdFiO5wM9zXNS6ykA2rJED3Z24qhLdT6q6xQSPIGO0yBcKv0o5Rc5vXviLT7R/Jjma6u/4Yohkn6+lcT8X0uzo+izyKREZX346ByBjP4ZrsbDR7LTIsQIon/wCWj9ST9atXdpba5o0+n36eZESGIBweDng9jWlKShUTIq0nUpNHiiMNqnOMjvVy3sry45gtJ5B6rGTXuPhfwlpOlRFoLAC5/hlnHmHHsTWld25CkSW+V7GM9Pwr2nieyPAWH7s8S0vwprepXSQw2EsYY4aWUbVQepr1C2+Gfh8WyJMLuWdRh5BNt3H1AxwKvRBreZZYWLBeqng4rfEwISaM5RxnispVpS2NI0oo5J/hj4fKkqb5PTE2f6Vn2HgPRrXWVM3n3NuieYI5WG1jnAzj3r0Ga4Cxk1lXcZVTL/ExSP8ADOT/ADqPay7lqnHsMV/ItWSxSODygB8ij9BVDVLFdREK32Z4zJjDnPI549KvqhwsYB3yMXP07U/UttvDbgHhH/M4qLu5djGvogkkdvGMIOqiiWIyXEEA4RMuwHrUyozSNO/3j90VDBIVllcAu2cADvSuMydb8K6dfO0skYhlY8vH8pP9DXOX3w9vUQvZTpKOyyDafzrvo4rjm5mCZHI39F+gq5NaSSqGuZ3bcOFU7QK1jWnHqZypRl0PDNR0q+0x8X1s8Qzjf1U/iOKokH8K91v5dMsIWguQsjPwbdV8xiP9rPA/GuC1vw9o0zmTTZbqyYjO2WPfHn04OV/WtoY2ne0nYxngp2vFHDd6Sr+o6ZdacQbmNTExwk0bbo2PoD6+x5qjiu6MlJXRxSi4uzGSKHRlbkEVz0qMkzKw4zmuirI1eMrJvUf7X+NYYunzw06G2Fnyz9TT8Han9gu2SYk2twuyRR29GH0r02fEiiTh/NA+b046j614np9yscilwMA569K9M0a5lEKfZpykZwwjYbl/Advwr52rDW59Pha3u8sjYFvPBBPHcIqx53R4bJ96y3QI/wAg9+laL6nPJN5NxHCFZTymc57VTILZ5x71irrc6G09ia2kO0dK17CZS4J6CseFRg9s1ZtiwcbDn+tJgjpQx49M9a0rbag5PaseGQbVycirDMzKqITkmpkBU12zt7uTeM+YOjKcGqer6H53hW8FtGBd+XvV/wCLI5wD7jNXtRu109hbR28lxc4BPy8D8aLH+27go3lqkecOoftWtK8WmKceeDR41EzPGGcksepPWnVLcqFup1XIUSMB+ZqLvX10dkfET0kw7UUGimQFFHeimAUlLSd6ACljH7xceoptOj/1qd+aLDRly/6xseppB0pZP9Y31NJmsDcjuU3IT3ArT1PRjFY2MkKOySQK78dGPeqKjeyqP4iBXqdxaunhyExKCIwEcf7INcmJSaR1YdtXZ5HGgGBwD2b1r0jQpUvo7a42nesJR1/21riNf06Sxv5HxmKRsog7qe4961vDNxcWEgkHMeeUPWvNqRsethaqT12OuntTdRrtCM5/hxjH+NVp9A821M6BRKhKug6Vrx3NpeOjRxorv98YII/Cr82mxW0cs8AZc9fmOD+Fc92jvnBSVzyq9sWtJuQdjdDiup8Cv5JkjY8HkVq3ljFckGVRtHPSjTtKjtpFdG6dPaqbujnjDllc6SKRWwC3FaUOm286DeAa51eHx/OtG0vpI2A52is0jpsma50OxON8EbEdBjFCJDbSYt4wu306VWfUHdcKxU0W5LHgEj1PeqbEqaWrKEtwsVw6OdxPYVbs2Ec4JUjP61l3FheRX0s42MCcjcf51b09b67ujHNLFHgfKVQ/rSirlSkoq7O+01xJabCcmLGD7dqtzIV56kdfcetZegIbdZIJX3u+DuxgemK1icohP0P1r0I35Vc8So1ztx2MvULUkmVB9cVJpkYbTzGR0Zuat/8ALMqfQ1HaALEwHHzUySlPHujKsSPcdqqwSvPA8Ug/fQsN4HfnqPw5rQ1GXy4GdVBfOBmqHl4kjmJ+d1ZHxxnjIoAWORhNLNgEK+wj0Hc/rT79PNNujfd3k/pUSMPKlI6Mwzj3FPeQOlp68k/ypiIYhsScS8tDkg+o7VDp8SoxiYAnG8H19adfyCEtu/5aqFH4Hmqdteqb6Pcdp5HJ9qdhF3UDvnitlPy8M30qr4g1T7DAhjP+lTfLGT0QD+L8O1Ec4LSXIYHJwSOdvsa57xFL9q1qLYRsjh9e5JrGs3GF0dGHipTSZUtRtlaSRizMckt3rThjWTLKD7ntWWuWkI646c1s6c+RhxXm3PUsU9TsAYJDGih2XDRsuUlHow7/AF6iuC1vSo4Yjd2askIIEkLHJiJ9D1Iz69K9SjfzZhDtz6Y7VR1DSVuIZtqgeajIwI4bI/nXdhMU6Ls9jgxeEVVabnj/AGqtex+ZCdo5XkVo31lNYXLW9yjJIvr396q4r6FNTV1sz51qUHZ7o4+VDbXIIzsJyK9I0OUm0jIABArktSswQTjKn9DXR+HmP2KEck4rxMfR9nqe5l9b2mh0mN0isDnFNcEHBJxnpU0CZVec06WNiMqMkdq8u9z2LWCNwOvNWI5AjDjv3NUNxjILfyqZZRgZziiwXNy2mAHbJHStOwkWNw7E8HpXOQspABJUY7VbW5RAAxJOO1S0Fzp2Y3ZDrz7VW1GZ7S3lmbcI4UZye3Aqrp14MAKQPX3rRuFt77T7i3l/1cqMrDPPSqpr3lcmbfLoeFMxdmdvvMSx/Gm96c42MyZ+6SM0me5NfYrbQ+Kd76ie9FHelIz0oEAXIzmkwTRnjFG7mgBDSZpWPegjvTQg4pY+JF+tNP5U6P8A1qfUUWAypP8AWP8AU03NOl/1j/U02ua50lzSI/N1S0T+9KP51714e0wX1g0bg+WxIP0rxHwigk8Q2gIJCtnge1fTPgq0EejRsRy2Sa5cQ7tHZh1aLPO9e8JIiGwv08yAndBOowR9PQ+1cXqGh3OlBlkG+P8AhlA4Ye/oa+jrmzhnjaK4jDxN2PY+ormdX8ONHC+xRcWrDlSMkD3HeuScOY2hN035Hkmjus8Kbhnb+YraYzYCmZ2i/utT7nww9lcNPpRLxnlrdjyP90/0p8GJVKcqw6q3BB+lcc4uL1PSo1VNe6xYlBAJ/KpQnOAAB+lNRSOCOR1qVdp4Oag3ViMxnJJNWIghC/lTGGOgNIHxznAoHc0oY1x0zVhJEiG4npzWbFckcEgClaWOQN5j/QVDKuOvdVjBPmMF9hyT+ArT8Lut88q7Gi2qHXP3m7ZPp9K52O2829jWHarMQoIGAPrXd+GbKOzeZ2BeULhn9faunDwu7nPiakY02urN2KzSKzSRGLOcHJ4xS53K6+vzCpoT/o+zsMrVVD8+O4yDXYzywLfOAfTFRElEYjrupWP70D0FQSSblfn1/pSGVtVfNs23r1qGCQ4j88/umIYP3U+9Vr+XzrgwBiI4hl8Hlj2FQ39wU020CnBkZF/xp2E2Jc3TxST7AGgLccckAdveqk8pLIySERyDIKnv7fWp9SEU+iQSRuRvYFSp5UisvzCM287KGI3Iw4Gex/GqSJuXvtL3dnJFIxaeD5x7j1/Ksu/ZSof0xz6USAzp5lvII5kHBBxj1FYVxrkVjE/29QIehLHbmnYC22qNbSbopdkn0J3D0I9KLSGa9ea7lwodskDp9PpXM+HtStdZv7oQJKsMQBBc/eBPb6V6HaRI+kvHbjB2kYxmuLFSafKelg6a5ecp21uicnp61I5MUmTwBxkVm6VfBzJBIf3i5VlPUEVPNc5jw33un0rksdqtexs2SbbjzgwKlOoq9CFlyobg/wA6oaZH5kCtjCnrVmyxDeMrocn7p96EDitmVPEHhyDVrcxzjbIPuSY5X8f6V47qVnLp1/cWdyAJoXKMB617prOom3tSWIWKIGV3PYAZNeE6hfNqV9PfSH5rhjJ+B6fpXs5ZKV3HoeJmkYJRl1KzjcpBHUVoeH02woO1UFUuwVRkmui022MMagjt6daWa1IpKHUWUU5OTn0NuyjOCSeK01tyQNvT+dUbFcAY57dOta1jKsgYKpVl4KtXg3PobaGVc2hxn8//AK1UzC27C8fT1rppoupI/Cs6e1yBtzzycd6tMxaMkllBGP8A69MlllOeCcYxWn9lLruGOnHvQlptUvIdqJ8xcnAAHWqREnYp2088RMjfcHJycD8ayNS8YkLJb2OWd8qZM8D3HrWJr+tyapKYLTKWYPA6GT3b29qzIoNjZY5I6Y6CvYwuXrSdQ8bFZg1eNMnPrSjNJmgGvZPFF7YoBPSg8k0lAg6mkpTSHpQApxjHekDYUgikHWigBaWPHmL9ab0p0Z/ern1oAyZD+9f6mn2sLXFxFCn3nYKKjcEzMACSWwAK7rwn4aaF47q7X9+fup/cHqfeuKU+VHfCm5M6zw34ettPsRsBMhGd2OSa9g8Nr5dhFH6KM1ieHNLUWqSTrnj5F9Pc1v6bE9u4R+VJ+U/0ribb1Z22S0RoyRZHFRxDbxWisXy5NQSRYYkDmgkxNW0KO6BmtVCzd1HAb/69cbf6RHO5E8bJMn8Y4da9MUlfrVfUdOj1CPemFuAOv972NJpMmzTvE8lu9GvFGYyswHR1GG/Ef4VhXV8bJil7DJGR/EBkGvUZ7WSByroVcdQeKq3Vrb3iGO9gEg9SOfzrmlQX2TohjJLSauecWusWU5wlwmfRuD+tWWaNzlTwa0tX8ApOxfT7gOhOfJlHP0DVxd34M1vfeNDL9mmYhVVZi4jA9h3qPYybsdKxcUrm1JLHC3znHbNTxy2zsu4g/jXDaDDc6b4pi03xJLctJncFPIdP7wJ/w7GvpHTdI0z7JFNb20QIABYIufrnFWsLfdkvGLojjNP0i5lSGeK2dISRzt6j1J7Cu0XY1kGiUKF4YD+dbNq620wiwPKk5GefqKw7Iyb2aeBoVmLDYxBIGSAfx64rrhTUI2Rx1arqSuyzbMHtiOjdR71UuiY5tw7809VMW+M9VNR3L7kUN2OM0mJEEkwjV5W6AZrHsrpjaGWY8MXf/gP+RU+rMfswizgyME/DvWHqmow2wEWNzlQfLBx8vbPoPf2oSBsdcXK21u00x/eSEnHck9hWOt7dX13ECMQQggKoyAcdPrVeWb7bKsk8pAfgFQdzDuEHYe/er9vK9tIk4ASGIYWBeoX1PvWliLl6VMWxiXqjcfhU10EWylebakQQtIxHAAGSTWJqWrQafbG5upo4Ysk7pGxn6Dqa4vxN4zutftEsbWE2em/8tWb/AFlzz0/2V9u9OMb6IUnbUwrrVNRuHkFpdLFaFiYiynzFXt+PeqDWxnl86+nmu5fWViRVo4NN789K61Tijnc5PqEOrvouoWlxGuYc4lQDqvfHv3r13QtQhmjjmhcPbzAMrDpXjV7ALmBk/iHKn3qx4L8Qto9w1nesVtGbqf8Alm3+BrixlDn95HfgMRye5LY7Tx/Bd6bef2xpoBbgTL6gd/wpfDmuQ6zG7jCyHAkjzyvv9Ku3epJeW4RgHiI4PXcK4OCP+wfF0GxtlpcNt9sHt+BxXn04qUXF7np1XKnJTXw9f8z2vQgUKRuxKlgFPtU2jXC3dzJ5o5WQgD0wcVQ8PXAJQuc7Dx7VYso/sviK9QECPzPMH0YZ/nmsXodEu5yHxV10xvLoFmrtPNgTOBwqZzj6muOstIuJ9qqAi+/WvSPH2jI3iGPUY+IrtAGJ/vqMY/LFRabpwypIGPUit1jJUY8tPQ4Xg415c9TXyOasPD7QkMVJPqa1hZsseNuMdK7K2sFK5KnNOl0wMM45+ledUqSm+aTO+nGNNcsVocnaxEEZHHtWvDHuAH8WOverv9l4bIqSO1MZGVyP5VKZbkiuICy4HHOSR1qteW8iuSqj8uDWxFGQf8anaDzF6datMycjm4oSZUXA2Z5rm/ibeNaWNtplsCDd5aRv9gHp+Jr0FLRVkzjn865D4i+HNQ1S4t7qwRJVgiKGPdhuTnI7Gu7BcntVz7HDjXL2T5Nzy2NAgwv5+tOzT7iGW3kMdxG8cg6q64NR19OrNaHy7TT1FwKORSc+tL9aoQA0vemmiiwDj7U3NGT60UgENBoopgH1FKh/eJ65FNpY/wDWJj1FAjf8FaD5kx1C6X5QT5Skf+PV6boVibi4GB9KqWtptCQxKBk4AFdvosEdhErYBLcZ9K8WUuZ3PcjFRVkdBpxX7NHFICAnQgVpC0V0JR9yn0NZUcwCblXirFrMxYFcr7g1IGpbzFHEE7AMBwf7w/xqZlDDjrWdcJLOvUFh0PQ0+0uplYQ3SFT/AAv2b2J9aYE8iEc45psRKuD2q3kMMHg+lQvEOxpASz28VzHmVFde4IrIvNCPJtjkf3W6/nWxasTlG4q0o/hP3hxz3oJaTOFa2eGcLKpTnnIxXzB4z8W3uq6jeQ+eqWv2l3QRDazAMQNxHJr7TurWK6iaK5jDKwIPYjPoe1fL3xc+EdzoEk2qaQDPp3LZxyo9G9/fofrQ0KK5WeYx3N011FdmeSW4iIKs7FiAOg57V9RfCvXo9U0SD5s/KAR6D/63I/Cvla3lCAEd+lenfBzX/serNZu2Ec71Gex4P64NOLKktLn0fcxnyyucFTuVqy41ISRGLFgxcZOcZPIrYt3+0W4YcsB+YqjMnlzD0PFaEMrXPJjkHcYNU5l8xXTPXp7GrN3IRAyr1B3D8KrFg21l6Gs2UmYF9dJPeqj/ACR28ZaUngbjx+gzXh+s67qGr3tzPFPHb2skjNGI0y5XOASx9q9O+LklzZaJMbJVUXbLBNLj5kjOc4+vT8a8gXAAA4UcADsK3pQurszqSa0RdtNV1WzQrbalKAeu9Fcn6kjNTSa9rzoVOrFVPXbAgrN3Y6UA81tyLsZczGtCrz+dO8lxP3kmbcfw9Pwp/fmkY4pO1WkktCZXYE0ZppPrSZpkDifXis7VLQyjzYhlx1HqKv55xVizsp7x8QISB1bsKU3FK8i4KTfurUyfD+vS6VII5g0tpnBTPzJ/u/4Vr69MNdihNlFJGsfR5V259617Tw0iyiZ4lkm/vEdPwrXj0sAfPuOO+OleNVxNOM+aG57VKhVlDkm9C54W1J/s0Xnf67Gxz7jvXT3N35V5Yzbd3mxtCxzg5U5B/U1yMMS2dwGUYRuCCOjCug1G4jk0i2mH34JgT9CMH+lcjakrnoxWiTN67083Fjan7wEpO0nPUVcstO2qAVz2APenaJdxT2kcRb5yQa3YlXA6dMcelZTWpF2lYoLZsq5XkZ6U1xsc7uAela7AKp6Y/lWXqH3SRg9zzUNCUrjRsYDj8qcUjAyQSPWqNuzMzJngdOeRVlEYxglssOuO9CQ2Pa2DfdHTnjvRBCQWU9felJKZdG3cA+31py3BLbWYDPcjpTJt2HNbDdzxVHUmWI/Xj6ccVoG42kbhnPBx2qtewrKQw+YdxnpWidjM5eaOC83JfwJJEe7LuxWF4g+HsE0Zm0ZvIkxnynOUb6HtXa+XGuQ46cg461YsCAGhdgNpwPp2rop1qlJ3gzGrRp1VaaPnq9tLiwuntryF4Z06qw/X3qCvoDxN4YtNbtDHcp8wGUmUfNGfUe3tXhuuaXc6LqUtleLiROjDo6nowr3cJjFX0ejPCxeDdB8y1RQ7Up9aTNANdpxB3opKM0ABoFGaSgQd6dH/AKxM+optLH/rF57ilcZ9A6RahrrzHHyKetbkQ/eBCMgniooIVhi8odQcn3NW7NcyjI7V4h7jNBVATavSrthBxknFV4hyABV+H3wKBFxIlA+U805kJjZSMgioVGDlWqaOUjh/zpiK9vKwcxXAYAfdfFT3DhIdyrLLjptXmrHDr7GmAFKegXZlzXs7jMJWD6fMw/PiptJu5hMIJf3itnDtyc+9Wp7aOZcyLhuzDg1V0+MJfMpYHYODnGaegtbmwr/wvg+hpJY0kjeOVFkicbWVhkMPQikI64pwbI5qQPmz4v8AwXm077Trfg2J57HmSfThzJB3LR92X26j3FeYeCblbfXrJ3PyyMYmJ7buK+5AcHIJB9R2rxj4ufCddTkl1/wnAsWrKfNns0G1bnHO5B2k9uh+tOwX0sdV4M1Iz2UYkb96vyMPcV0N/DldyjI6/SvJ/BmrbLqAvuQXKglWGCrjqCOx6j8K9gtGWe3GejCquTHVHEx6paXep3+mwylryy2meMqRtDdCPUe4rQvUVMBR2xj6Vw3xK8H3mmXl/wCN9EuJv7UsVVnt8/I0S8H36dRyMZrq7LU4tb03T9TtctBeQrIvtkcg/Qgj8KXQdjD+IlmdQ8HX2xcvGnmKPoc14EpBGR6V9MvGs8E1u/3JFKH8Rivmu9tnsb24tJRiSCRomH0Nb0HujKr0ZEeue9KDTM/NSg1uZDjSZpOtBoADR0FJXWeG/DpYpdXyHqNkR7e5/wAKyrVo0Y80jWjRlWlyxKOieH5bwrNdAxwHkL0Lf4Cuys7GONERECRgYwBWlFbbVG1avxWwIyy8k8c18/iMTOs7s97D4eFFaGetjlhjNTrpzMAijA6cGtNYQq4UEN1yeTVyCDAyBnA4xxXKdN7HNappObVtqlmAyCOuazbWOa80qeONeqnAI7qckH0r0OOEH744PGB6e9INMsld2SEAuMMQcBvqK0jKwlOxy/hRXjuRkcqDuz0C46iu+sZFmjU4FYkGl28HyweYsf8Azy3cY9PpW9ahI0+XAqr3ZnUlfUmcHBA6Y61kzpnIYqx/2q1pHBHWsq6XcOqhh17ZoZnEqeT5b5HzKTzg8j6U9m2MCOU6EkdaZGJGyGYMCc9RxUcjSn5UX5c/Njt9KVzS1x0twBJs5Ugfz/pToyjLsI4HGM9PpUTwnIc9QMZFKzAMAWHXP+TTC1h90W2L5YKjODkZqGOVsFgdy8ZHcetWg7AE4+YHkE/rUDxjeTuyeGDAev8AOmSyrdklMp0IxgiobeViUOGWQDB98VYlfYNrAbgMhfcdKrwqS7PncWOVA7VotSWrm3Y3i3ERwQCuMk1xvxa0RbzQhqMKfv7M5JA5MZPI/A4NbdsXgmjYZwxIIA4HsTWvcwJfWM1tJ8yzRtGR7EYrSjN05qSOetTU4ODPmb6UDr7U+5ha3uJYXHzxO0Z+oOKjr6pO6ufLtWdhT7UlFJTEFBo7UhpAHSlj/wBan1FN6U6L/WL9RSYH1GQA2cd6t2+cggc1F5W0kkVpabGJVOPvLXintk0CsBnFWUZf4lotyHyrDB9KeF2TBXGVNMVxyqDyjU4Erw4yPWmzhoBvKb4/7y9RT4JElXdGwYfyosFx6MRypytT/fX0NQGM9U/EUscnOG4NAEqns1Q3Fqrc7QasYBGaFYjr0p3sIor5tufkkYD0PIq5DMzjJQE99h/pTnRX7c1A9nn5omKP7VWjEWo5FckK3I6jv+VP61lySOhC3cW7HRxwfzqaN5SM286yoP4ZBz+dLlGc3428HjVyb7SisGqJ82OizEdM+je/fvVrwdem90tTIrRzISkkbDBRhwQfxrcF6FOJ4nj/ANrqKYYLdLxruEjdc4EhU8MQOD9ccfhR0FbUqajJFvmgmwwlTayEZBUjBrzLwRpGo+GLfU9HuoidNgvvN06fdxJGwJK46jB9e5NenamVWRt8W9SBkjqK5vUJ4yQiKxxzjrTQMS6XZL5i9DyRXh3xasPsXiprhBiK9jEo/wB4cN/SvdFbfDHuGTtwRXnfxh0zz/Dkd4i5eylyT/sNwf1xTpStIU1dHjQNPU1FTgcV2HMSA5pVDOyogLOxwFAyTT7K1mvbhYbaMu5646Aepr0DQfD8emgSECW4I5fHT2FcuIxUaK13OnD4add6bGZ4d8OmCSO5vFV5QciPsn1967W2hUOFx3zSwQBifxBGPyq/BDyAcnHOK8KtXlVleR7tKjGlG0RYEyMOFyDxg1aiU4wRT40AB2jp1460rLk5xkAcgVjYtsei4I45zU8QAPBGR71CrYHHSlEg3Ajt2qlEhyLoO0Argc0FwRgnjrVVpvlznihZQeM1ViLloNk8jmrUEjb8diODmqKScAVLG+F6Hr1oEWnmBBLfL35qldFZCMPhxzhetDEnnK++aqyqCGySWzxt9aTZaRIchRlQCTjPQ06NW25AOOmQc5pqLM6gHbjvx/KrUMLj7r5Xtk5pXKYxY3dc7gV9OmPrUM8HyfN27dK0GXYAWxnp7mkdlxjAP17VRPMVY41BDY37hyc9R6VDIdpm8xDgDgA8AVaJXBwcADAPvVeRHWE+d353KehpibG3dtugD7f3icfX61n2WYGkDLyGIGe464q9LOkMBjkLEPja2PlYentTIokVSv3sk4AOcfU1SdiRyMlwpMYYSKMlR298U62doGJcsFYjaCelUraZbefLgdg3bIz2rTvk3Hap+Ugngd/ammJngnjeEW/i7V0UYXz2YD681h10PxBbf4v1Bh1JXP12jNc7X1dB3pxfkfK10lUkvMU9KBSUVozISjNBpKQC0sX+sX6im06P/WL9RSGfW1qhkXlgau28LQTLInTuPWs60jZoVeNjnvV60upEYq4rx7Hs3NG4i2usqVIwEsee4psU6yLjt6VYWPbyPyoAZA5UYPIqjf2jwObqy+U/xL2NXSpRmwOKfFIrgqfyqlcTK1hdrdRbl+VxwydxVh1VxyKxL+N9PvhPCMKeo9a2LWZJ4RIpyCKGuokxyu0R5+ZP5VNlWGVOQaafpUe0qSU4Pp2NIolzinByD6UxHDdeD3FKeKQE3ySLhgD9aqTWGDuhYq3tUgYg1Or8U0xWM4zTQHFzHuXpvAqtfD5ori3OEDAsF6H6itpiCCGwR6GsTVbfyUPksVDdqrcRJdASSKSTtK/nWPPHFEWZFAx3rVXDW6yt1GKxfEc4itJmTsp6VLK3M6wnE8PmDnLE/rVTxHbrqOjahYgZ86BwPY4yP1FVdGlMWmRYPzZY59OavROvDZ4DfNmjzB9j5jTOOevf61p6PpVxqcoWJdsQPzSHoPp6mt+DwqH1i9edh9lWd/KVT98ZOD9K6+ys44IwsaBFHYDpU4jHKC5YbmuHwLn709iDRNKg0+3EduuOfnc/eb61txQkDPfHXNEUOImCnLY4NTqnTcD8pGMHGTXjTm5u7PZhBQVkPt0zyNwPof6VaXcDk4Bz1PFV1YjO0j0xTlUK43ZJPIJPHvUIGW41Xgg5IpzfKTyKjjkPmYAwvY+tPK/hzVpGbIWJzknP0qJpCvcVaZBWXqcyQxscgVZmxZ79E+8/H1psOpK/CmuOvbuB5GMkxY/3VPSrmmzgMNrEqfWgEjuraYOATVxT8p/TmufsbgEAZ9q14pAcA81JS0JJQpXDNkjsT1pkZ3YG3b6Ed6kIBB7mmsjEjZgg9ulTYtMezSIAARgDuM/rVi0eZmy64XopFRJxgvuznBqWF5BjKce9AFlgHXBJ56kdaWXKgfMCSe3Wq012qFQ6jBPy84zUnys+3ICEZUZ61RBAEU5ZmO7PyjoKUvtkCTY2kfLjoKiaLDHLNIQcbWPI9xUV2TGMhSQx5Y9APegdrlC/uFB+zzFvK3Zz3BHofTpVrTUc4+bkA7cjJH1Pf8axLxmeba2MFsKckdumT0rUtr8W0cpYl3GOg9un6UxNWF1JlVkKxh2dsFunP+FaYlQ2yeYxU9M+hqtG0M8KyAfvD6n7o7VFqwk+znY3ztwdo/CmiWeVfFPTfsmurdxkNHdJkn/bHB/pXFV6d49tXudHVgSzxNk+x715iQQxBr6PAVuelbsfPZhS5KvMtmBoNJQTXYcIUUhpKACnxH96n1FMpYj+8T6igZ9c6RwGQ9iavvCCcgVl6a/7w46HmtxGA615B66KsZMcnPrWxDJkJnoRVCWJX5HBqWFmWDnqhzQMvlQ3NU7yBgPMiOHH61OkgPQ1KGDcU0S0Z4Md/alJBhhwfY1j6TObe4aCT7pJx7VpzKbS+B/geszWYDBP5qDgneP61RLOhDZGaN3NUbG486BcdatLwfelYdx/XnPPrT93GGqKgN60rDTJqcrYb2qNWyOKUn0pDJ2wRkVR1dd1oWH8NWY35waSVPMidD/EKAMm1O+ylXunP4Vyviy6RbHywclz+ddBZu0V+IH4WRWjI9xyK47xSypnPWJTn8TSky4op6TIBpsTuwC4JJPAxmsW91Ga6ElvCStsWyxHV/8A61RvcNPbpCMiBOAP7x96I4xkDaR+v41w18R9mB6GHwtvemJAg6JjgdO9XLeNgmFJx/EcdaYCF6A5PGcdBUwfgrkg9q4HK53pWLabAgyCDjv6VIFG0lBgdgKZbgMuDw3X5assvykdweMd6QmQlMZJzk49qljOEwmB3AoZlUgE/Mx6E0oEa9dvr0qkRIeF+XDZz15pcgHmoJrlVBJPP1rgPFvxFsdLL29iReXg4IU/Ip9z/QVtCDk7IxnNR3O21XVrewtWkmkVFHqep9K8z8Qa3f6pIRa4t7fPBbl2H9K53QfEF1rWsS/2rJ5juMxDGFQdwo7V10tmnlFoF5xj6VpKDpuzIhJT1RzlrI8TZZg2DjgdTXS6VchgDIRub+VYctpII1+XCnpx1p9k7x3EbZ59hUN3NFE9DsmKgGtqCTpiuR0u8bCq2T7muhtZgSMY/GswaaNyBuM9TU+cCs+B+e5NWSQ3/wCugSEncLmR85B6+tLFcK0O8yKCD0B5z9KiuSFQbQD/ALJqtbR/N5s2evzKOgpFj7yZHu4t3yqBkg/xewqybiKdIzGxUgZ4H+eKydajHCoGznkhsU3TlnG9pBu3cDn7tBVtDVS6EmGZSq/dzz8x9akmyswSZgiOpYN0/Oq9qk0bsjsCuMdMADsan1IPLGgZidw6AjqO4ponYzZoWlgcscsV3KSfu98mqMLs99bCVhsfngdweTmrzQPb3AnSTcjD7hGRVIpi+IVdoTgc568/1p2EX4HUzbcjaj/Lxhc56mrmxpL5kZlAXOUPb8fSsaJhOFWY4CE8jsM8ZrSt9s1wXE5EipuB65z/AI0IRn+IrdJkOxGyxK7s4V8ivFtSt3tb2WFxgqcV7dMrC2Z5jwpJKE8EnpXm/jyxCyx3cRVh9yTHr2Nell1Xkqcr6nn5hS56XMuhx9JRRxXvHz4UUmaKAAmiM/vU+opDSxf6xPqKQ0fWfhwechb+7W26kj3rnPBdyFlkib+LpXYNED0rytj1TPXd64IqxalmLI38QoeLb2ogXEikHn0piQsbkcEYIqzG4YVEw/esh69RSbGQ+1MB96izReW3DdUb3rOb/TbJ42A81On9RWk4MkRXvWI0xtL8MeN33hQJkWjTFPkY8g4xW+p3AHvWBex/ZtS3pxHMN6/Wtm0kDx0wRMxxTSfzpzDimfzpDAEipFkyajoPFG4ycjnjrSljwRUCyYODUqsp49aloZz3iKT7LqNpOvA81Sf5V514svhPrt5bRMfJikKsR/EQen0FekeJIVmubYSECKNhK5PGFU5P6CvHYJ/t97PdOB+/maTn0JJrkxU3GNkehgaalJyfQvQx+XHvxyBmomfLfKeD2qxIM4XPSq5TIznnPHavMZ6fUki+fhRn15q9HCEGVwzAce1JY22FCjawPOVFWpGSFtzE8dsVmNiMQoACgnHAJqbzRsGTzWRc6goYgN+XasPVvFum6ap+03Khx/Ap3MfwFawpuWxlOSS1Z10syHBOMjvXP+I/FenaLGWu5wJMfLEvLt+FeZeIPiJeXYaLSkNrGePMbmQ/TsK5Bbae7kM107ktyXc5Zq76ODlL4jgrYyMfhOg8TeNtT152gt91taNx5UZ+Zh/tGsK208DDTnP+yKuwxJCmI1x79zT+tepToRgjyquIlNkMjtbPBdQ8NAwIA9O4r1PRblLmCORDlXUEfjXmDAEEN0IxXT+Abw/Z2tnPzwPt69u1cuOp3SkjpwNTXlZ3cunJdA8bc96prpQS4KjIAHfqa2LJ847ir6RqST3PevIdz10zH03TmB6HaO571tRwiMcD25q2iqq9KVl+XjrUjbuNhYr6mrImx0GR71nSNtO4sc5xgUkhXYVYsRngD+VUS0izJIHcBMEsO/aobq9Nsoi8tgOASx4z/hUabI2Gzgjnk1RnuCzFyhdcDDE59qdiizqMqzgKTkoMkLTbG7le7h5KIpGQT1HfFUrlyi52nfjg+lLpxdwjFHU5zg+tHKbKKcbnVvKCZPm/dMMnnH/66WS3DwRko3ypnGeMdR+NZFy5WdF3leB8oGcn2rTjuGSwzKN0rZUKOh/+vQYMrTpI0dv5AClDjb2/+vWNdzzDeoQeYTuDg8EemK3ExEYsjy42GcscH8Kp3FpbtKkkJ2sowAcnPuapIi5nCdWt953AomGx/F6Z9xUul+bcz+dattXH71h+gqldQvEkkaIzpIQQuO2SPwq+ZntQoUsAUG3aM5A4z7UWC5auziR0YB1cbn59ehrzf4gNsniiBwpAbH4V3GoFmgKoxDN0z2+teW+KL43mqyEHKR/IOc9K7cDByqryOPHTUaT8zJzRSUnQ19AfOimkJNITRQNIKdEf3qf7wplOi/1qfUUDPpLSZmt7sMp6GvRrC8S4iU5GcV5naf65vrXVabKVQbTyK8rc9O+p1rBGGDUZt/mBAzVe1ufMQZq0oB6Ej6UhjLqNgVZVJwMcVHHcqTtkBB6c1dVnI5ck1FLEsiEsPmHemmKw0qMZU8VkeIrZpbJp4VzLD8xA/iXvWkDs4znFGSeo61QnqYG/7XoiSA7mhOQfarOlz8jng063tVtbue2AxDKCUHoD2rMtXMFw0TcMrUxHUHkA0lNtn8yIE1IUPXtSGMPtTGzmpsetJgUAQMpqNpDH1q6FGKq3YG04FDKRjeJ4f7R0ueFWw7xPHwcHlT/XFeNaDKXtoiw+cdR6Eda9N8QawunBV2l5HbCIOPqa83j0m9tZZ7iF45Y5HLiL7pGfQ152Ls7Hq4G6Tvsy/I5X5hg+570iMHIUdcZzWc90VbE26Nu6sMU+1vPMfZFuYjgBBmuFnbfU6exIRM5x6/4VR1WQandpb205SOLPnOg+8f7ufbvUdvb3MgIciJG6hWyxH4dK1bHSkKCGFVjUdcUowe7DmTdjxf4lQa1pOoJELmRrC4XMTxjGSOqkjuK4iOxlc7pTtzyc8mvpvx14WtdY8PwxozQyIxKkdFbGAfp6189TxSQTSQzIUljYqykdCK9rBcs42e6PDxznCd1sytBbRQ8quW/vGpzTTRn8q9BJLY81tvVh3pM0UZwKYhe1T6Jcmy1yJwcJONh+vaqpNRXBKoJF+9GwcfhWdaHPBo0oz5Jpns+lXAaMH1rehbge9cR4fuxJBFIDlXUEfjXXWcmVHNfPSVmfQRd0a8fI4PNSFT9DVaE5Aq2H+XHNRYspzwso3H5h7daz5/NVjkcdQAa3kjLD2qGWzL5z9z0xQgZzc7mQk+ZtY9j/ABc01ZVRCXJ3ucHAIGa07myCfOUyp4NU3RTlcHcPX+VUguRreZUBk9c5Gdxz2qxZ3W+aQBFjKjPuKrPa3CKSjKCemew9AKZAoTifaCPTqfrVBzGnsMp3hmcr9zkEk1bkkYNHvPz52nnjPbis62ukVQYQHYk5z1//AFVfiQgxzFRkEsRjoPpU2E5FxYHVo/Ndt330B5x71UmiaO8B3Dng59D2/lVoTM0gkxkbcBs/pTWgEjb2JHAHJ5znmqIuVL0kTtb7gXOAGA+6fb8OaW9jiCQhJFZmGCO2F60xI4/7SaRDmHbkyMe/T/GrRWNWVoCQZPkVSOcY5zSGYN6ClvMUII2knP8ADj0rx6Ri0jE9Sa9tu7D93NnO4qcZPJNeIyAiRweoJr18s3keVme0ROlBNNzRmvVPJsGaKKKYwp8f+sX6imU6P/Wp9RSYj6MsziVvZiP1ro7FyAK5mBiLyZe4bIro7I/JzXlnpM04ZvJkI529RWzaziRQc1iSDdCHHUVY02YDjPFDGjfQg058jkc+o9arQvz14q16elIZGFjYfL19DTTCeopzpk5HWmDd7incLFS/UqiS4w0bZ/CsTV4sXW4cbueK6O6HnWk0fQ7TzWDqQb7LCzcsBgmqIkW9GmYgxydcZBrXVuOawNKzuVhWyr0MaZMwz0FRHPSpY3HepCV7YpXsVuUzuH0qje3GxGJ4FazkEYAU/Q1iaxF5kTKAVpOQJHmni++Wa9hnAOIGIOOcqetOtgHUOvK9QR0IrQ1DT1QsWUfU1i6axhkmt9waNDmPHoe30FcdeCa5j0MLVs+Rl6VI3X50V/QYzTIbeKIZSBUJ6gCpI+Ru9KliCue/41w3szutcltyNwUYGfSta2jWJgeR9Kz7VNsgJXg8Z9K0fMwO2B1zVx1IloT3DqYmXAIx3rxn4yafbJLa6jaIE3t5Lgd+MivV57kEFFUnPTHeuM+JWjnVNCWK1YC6gfzsHowAORXRQlyVEzCvDnoyVrs8QNJxSZ4zSZr3T50U0lHWkJoACcn1pDyMHoeKM5pM0mM6rwPdbrQwOfmhYp+HavQrCTgepryDw9c/ZdZCk4Sdcf8AAhXqGmS71Bz1rw8TDlmz3cNU54I6m3bIFXI2OT2rMtZOlaK4PfNch0lyEjjOcelWEjBBIXOetZ8WV4P4Vdt5Tgg9aQhZrcOu0KuKomxjTAUbMelbCtvHPeho1I6Z+ophcwbqzdiFQ4XHY4qqNMycNEu3OSRyT+NdE0RGdoxUTKcnsadxmTFbtFuURDHQewq5b27Mx3YKsPmJ7ewq1EhyFIGfQd6nKFFwi89vSmhMjeJJBsAHloRgEYqC5SONZIg4Usck5yauo6mPGR6E9KoyRbHkCsWUZOOM/nTbEZMmfOiVS5ULhQnBb3NNtHkkO2aNgVGQGPAx7+tWXlecqWVU2kH5ewB71Jc3CJGsCKdr7s8dR/hSEVrmQNGHlGCR0HcV4ZqcflX86kEfOSM+ma9mkuDHBL+7wVBIU9MV5h41tfJv4bgA7Z0zz616WXz5Z27nBmEOanfsc9RTc0te0meKFGaKKdxBTo/9Yn1FNpY/9an1FS2M+ipxs1FT2YEV0OnHclc7qDfIsoxlGzW/o7Bl9jzXm9D0TUjPyY7VCoaGUgHg8ipsYfjpTZj8vuOlIRbtr94mAcEiuhhkWSJWU8MMg1yMJ811UdzXUwfJCijsKNyidu4phH5UrH92Dke9QrOhbAPSiw7kGpTi2tnlPpge5PQVg3Usz2MnmIgAGRg9K1dXtZL66tVVwIIyWK92ft+VUNctpLQ2lvglZnyzew5xVIhk2nR7Il9hViafYKiDrBAM9T0HrT7e2Eh33Bx3Cf40wKxe6nb91ux7VOljcMB50zD2BrQSZIxgYAHpVae7PIjUu3ooyaQ7EZtIouTI2R3zWDrmvJa5ijYyMOBgZJp962qXU3krA1vGfvSv2H09at6TY2tg25I98x6yvyx/wpNoaRxi6drGvSB7hWtbQnhX4Zh9K67SPCenwlLi6TzZEXYqHhMZ9O5rbkQqA2OT+dWLdXdASMFeh9KzeuhabWpjaz4chvoWktUWG5A+XaMK/sR/WuOjtmiZ0kBSVDgg9QfSvV1XewJOPp2rlfGenC3YXqDCsdr47ehrkxFFNcyOzDYhp8kjnoFABxg/SmTsC23J9wP5VE9yAu2N8AckgcmoRMDyOPUk9BXNFWO2RZjxvwMA929BWZ4lntotD1C5V1XybdyN3G75TxUd1exojHzBtHGM8tXmXxV1K/e1tbVSI7OZsyKvVsdAT6e1bQjzSUTKcuSDkcCM7VzxxQT6UE0ma94+bFpKQmkJoGBNIaQ0UDGTFk2yp9+Ng4/CvS/D92ssMbg8MARXmxGRg966nwXcH7GsZOWiYpXn42Gikehgp6uJ6bayZIwa1baQn6+9c9YyZVSOvetaBzwa8po9Q2EYN1FSKSMetVInyKspkrkDJFSBoRPkDdzVqNsjBGRWZG/GPXvVpGbPPSgRa2BsnvTAnfFKrep4NSA56dDSGU5DsZiPlx6cjmkzIVBLY46gVNdYCZG7OOx61TErLyyF06cnGDTAJ18tSxbKkcnPAqkbaRG8yJ0I6nHPH50jXCACNw3zHPBGBUpmitQsQKFm5AIxTQmZd1I26dZBgMMKygjOPaltZRdRBif3jnG5+w9AKW+uS8m1SFYnIwaz9Nm8hpZy2UX7oI9c1SEGsNlLlUK4RdrN0JrlfHFt5uixuB80AVvwIro9Zfy4HkkYq0n3h2B9azNaxNpEmR1jIP0rWnLknGSIqQ54Sj5HltFHQkHtR2r6M+a2ClpM0hNMQppUP71PqKZmnR/6xPqKBo+iJhugkWtXwzNvhjJ6j5TWSpyD71Y8LS7LyaE9juFeeegdicYNUrmXnGatO2FrKmY+bUAamjJvnz2FdNkAYrC8PLlZCRWsS0j7IwSfaqSG9hbj96gXJC9TjvVdmEeBGCzegq7JbmJf3zBAOw+8aozlnGyJfLQ/maokfFemI/LjzjxnrtFQ6hBLdywsGZhDlmA5yTVi0sgMM3WrVvGImlCnILZqblpHPBJBM0rsJMcKB/CKu2EnnSgkFgOvHFRuhh1CROx+YVftWyQqjH4UmwSMzU1dmZ7f5QvVfb2qbRi0i5AII4NTyW5F64P+rIyTWlbpFDGEhQAdScYpDIXh3n7v5VAITDKDJgL1yRWpnBQDvWbrL7nRB25xSAs71JDKoYn+I9qmQd25zUFmmIF3VYyM+lAEkJw+PWodbtludOnjcZBWh5xGwA5YnpVhgzghiCp7Chq61F6Hjt1GbWYxSAHacY9vWsPUdRBk2AZAPyxofmJ960PiZdT2clqlq3ltOzRyP3AXpiuX050jRVGNzA8nkk151RcjserRn7WKZs2yhmjmlIyh6AcLx2rnvGdi19pshC/OFMi8dMV0dttIxngY6frTLtRcwyvg7ANi+9Yxm4yUjeUFKLieCGkJrV8T6e+maxPAVwhO9D7Gsivo4SU4qSPmZwcJOL6C5pKKKskKSijvQMPSt3wkGSWZh90uP5VhGut8K2+bDzO7MTXJjGlTOvBpuodlYSYCnsa3IHyorBslwoBzitW3bBxXjM9ixrQtjkYq9C9ZcRzjmrkLnNQBo4HGDUiNgYyeaqo64zUqnoc0gLkbgdalRwBkjOKojcMnNJ5rBcHJpgXh8zA5yvoainlBRjs3L04PAqm11jnbxUMl6OScFV6rnn8qLBZjJIGUNI8ShW46Y21IxiVCYgZJ+gz0xVA3lzKnzqDjoCeT9RTRuaIs568U7A0UdTmcPh2AOOMDGPp9KyLQ3EhdMq+87lYemeoFbF7JDtCoPMcp0PIrF0YzCGfLAIkmFGOQCOa0RDH6v5twi7jlZJAmenSnahH/AKLJGvAC4H5UyaUS6nbRR/6pMkZ71PduG3L+XvSk9UXFXR5HMNssgPUMRTd1WtWj8vUbhR03EiqlfSwd4pnzNSNpNBmiiiqICnRn94n1FMp0X+sT6igD6DtX37sGksJfs+toTwH4NUNOn/eFc96l1BjHcxSDsc1wHezv5HymfasyR8ufWp7ebzbONx3ANUpjiWoGdl4cgZ7MEcbjyfQVtvJHaqFiHz+tczoepvb2ggdSUzkEda00votw3KVJ6E1WvQNC2RJO26Q1KkaKOg/Go45lccGpD0qWMTlVJHT+VNtlxEZJDgMc1DcyfMsYPU5P0p8rZiGThRyTT2QEF3Asl0skf93FOg2xln/hTv6mmQTmVmUYCgcetNuTxDAOrku30FKw7k1wS8iqBgYB49atxJnv8i8VVjJklVVH7wDn0HuanllCqI4uSO/rT21ENmuT5jBB04FV1gMjh5OtPVVj+aQ8+lQXd8sKHnnsPWklcGy1c3kdugQHLdhVZLiRyWbgVRhVpGMkxPNWCxb5EHHerSJvctQfO5dmx71fEybFyw6cKOprHluI0xEX+b+6vJq7B5vlAqqwrjq3LUMaPn74r6xv8eXOn7CILI7WYjq7gN/LArLsZz97gY6ZrofiHYR33jLxAcfOAg3dy21QDXGwmSGQ20y4kibDZ71xYin1O3CVPsnW21wMMOSGGDWvDtEShl4AwB2A9a5ezkKlm7dB7mt+2lMkZjyVLDBIrgkj0os4n4maY0llHfKMmJsHH9015oe1fQer2cd7ZyWxGR5eMY614LqNq9jfTW0gIaNiOa9bLqt48j6HkZjStNTXUrUUlBr0TzQOKCaSikVYXtXofhSILpkAIxlc152ehr1LQU22sKgdFH8q4Me/dSO/L17zZtQwjAxwauRoMZI5pkCjGD6VahQcmvIuerYfECPXFXE6io4V3ADFWAhHGMYpXE0SL04zmnqT260IMc9qftG3OOtBIoc5ODz70hbIPOD0oGe2KikbaxCjJPbtQCQM6qvzMVA9e9QOIpG3grwP4etJKPunh/YdDUSKz/M52heAq0xjzIXk2x8gcHGMmmuksitwqbVzjPUVG0iwkhPlJ56Z3H0qO7aUx5K5Y9OOaaJK94SmQQIw4zjGccdDWTpCqZ7hf3nlu2Dxx0rU1ENJaPIAdzqcH19jWdpkT/2W8kkm0ITkY5Jq0SyiQ0etoq5IWL0469qu3fzKGx1H+cVTdm/tGMucN5J6HPerLybkIHDAZApy3NIbHnXiQY1abjk4NZea2vFmDqKuO61iV72Hd6UWfO4lWqyQtFJS10HOFOi/1qfUU2nRf6xPqKTGeyaSuTExYknGa2dTiUwAknI5oorgO9nQ6AN2nkEkgdKe0YMwyTRRSe4GzZRgRjrV1UDphskUUVRCJbctHLsViVHrWxESYxmiikykVlG+6bPsKbqeRtQEheSfeiin1BbFSAmMh1JzSWUjTTzzOfnHyDHQD2oopIbNkRLFGqJkBuSe5psoEafLxRRSGjNmdmY5JqhAnnTs8hJKnA9qKKoll2QbIztrKa5lZ2QOVH+zRRQJmnbwpFFuXO4jJY9TSu7sQu4gccCiikxnkqL9s1O5uJyxlmvXVyD1AJAH6Vk+MdPhjvLSaPerzZV8HriiiorfAy6HxorWkYT5QTgNgVvWSDcDk9aKK8mR7UTUWMZByepryr4o6fBHrsMqAq80eXx3IOKKK6MD/GRz47+Azizapnq1H2ZPVqKK9s8NB9lT1aj7Mnq1FFACx2qGRBluWH869T0uBVRME8cUUV52O6HpZf1N+GFSucn1q5BCpPJNFFeWemWool3DrVyOJSvOTzRRSJJBEoPek8sAcE0UUyRWiUYxntTDCrytnOBniiigCOa2j2EkZqOSJQAASMjP0oooBkS26BcnLEHGTULEiR4/4c0UVSEZ9z/rY4v4DjI9aS1tozvY5znOO1FFVElnOzoG1SM8j5TwOnWtCSBGty3IZeQRRRVSLhscT4wtkNxC3IJHNc99mT1aiivawn8JHhY3+MxfsyerUn2ZPVqKK6jkD7Mnq1Pjtk8xeW6iiikCP//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen M Simons, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_11_37041=[""].join("\n");
var outline_f36_11_37041=null;
var title_f36_11_37042="Ciprofloxacin and dexamethasone: Pediatric drug information";
var content_f36_11_37042=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ciprofloxacin and dexamethasone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?16/13/16595?source=see_link\">",
"    see \"Ciprofloxacin and dexamethasone: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/1/1044?source=see_link\">",
"    see \"Ciprofloxacin and dexamethasone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F151783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ciprodex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F854897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ciprodex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1046320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic/Corticosteroid, Otic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1046315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?16/13/16595?source=see_link\">",
"      see \"Ciprofloxacin and dexamethasone: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Otic: Children &ge;6 months and Adults: Acute otitis media in patients with tympanostomy tubes or acute otitis externa: Instill 4 drops into affected ear(s) twice daily for 7 days",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F151770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Suspension, otic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ciprodex&reg;: Ciprofloxacin 0.3% and dexamethasone 0.1% (7.5 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F151760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1046323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     To avoid dizziness which may result from the instillation of a cold solution, warm bottle in hand for 1-2 minutes. Shake suspension well before using; avoid contamination of the tip of the bottle to fingers, ear, or any surfaces. Patient should lie with affected ear upward and maintain position for 60 seconds after suspension is instilled.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Acute otitis media with tympanostomy tubes: Instill drops then gently press the tragus 5 times in a pumping motion to allow the drops to pass through the tube into the middle ear.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Acute otitis externa: Gently pull the outer ear lobe upward and backward to allow the drops to flow down into the ear canal.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1046317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature; avoid freezing; protect from light",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1046322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute otitis media in pediatric patients with tympanostomy tubes due to",
"     <i>",
"      S. aureus",
"     </i>",
"     ,",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     ,",
"     <i>",
"      H. influenzae",
"     </i>",
"     ,",
"     <i>",
"      M. catarrhalis",
"     </i>",
"     , or",
"     <i>",
"      P. aeruginosa",
"     </i>",
"     ; acute otitis externa in children and adults due to",
"     <i>",
"      S. aureus",
"     </i>",
"     or",
"     <i>",
"      P. aeruginosa",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F151804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Discomfort, pain, pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Ear congestion, ear erythema, ear residue, ear tingling, hearing decreased, irritability, taste perversion",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1046326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ciprofloxacin, other quinolones, dexamethasone, or any component; herpes simplex or other viral infections of the external ear canal",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1046314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      For otic use only;",
"     </b>",
"     do not administer parenterally or ophthalmically",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F151765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F151767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F151776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination. Refer to individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1046325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Time to peak serum concentration: 15 minutes to 2 hours post dose application",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1046319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/1/1044?source=see_link\">",
"      see \"Ciprofloxacin and dexamethasone: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Keep infected ear(s) clean and dry. Avoid swimming unless otherwise instructed by physician. Discontinue otic suspension and notify physician immediately if rash or an allergic reaction occurs.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Roland PS, Dohar JE, Lanier BJ, et al, &ldquo;Topical Ciprofloxacin/Dexamethasone Otic Suspension is Superior to Ofloxacin Otic Solution in the Treatment of Granulation Tissue in Children With Acute Otitis Media With Otorrhea Through Tympanostomy Tubes,&rdquo;",
"      <i>",
"       Otolaryngol Head Neck Surg",
"      </i>",
"      , 2004, 130(6):736-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/11/37042/abstract-text/15195060/pubmed\" id=\"15195060\" target=\"_blank\">",
"        15195060",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12922 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-9EF4B3CCD6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_11_37042=[""].join("\n");
var outline_f36_11_37042=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151783\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854897\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046320\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046315\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151770\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151760\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046323\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046317\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046322\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151804\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046326\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046314\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299047\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151765\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151767\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151776\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046325\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046319\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12922\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12922|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?16/13/16595?source=related_link\">",
"      Ciprofloxacin and dexamethasone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/1/1044?source=related_link\">",
"      Ciprofloxacin and dexamethasone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_11_37043="Levofloxacin (ophthalmic): Drug information";
var content_f36_11_37043=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Levofloxacin (ophthalmic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?23/63/24564?source=see_link\">",
"    see \"Levofloxacin (ophthalmic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/11/5299?source=see_link\">",
"    see \"Levofloxacin (ophthalmic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8398379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Iquix&reg;;",
"     </li>",
"     <li>",
"      Quixin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8400747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Ophthalmic;",
"     </li>",
"     <li>",
"      Antibiotic, Quinolone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8406516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Conjunctivitis",
"     </b>",
"     (0.5% ophthalmic solution): Ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Treatment day 1 and day 2: Instill 1-2 drops into affected eye(s) every 2 hours while awake, up to 8 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Treatment day 3 through day 7: Instill 1-2 drops into affected eye(s) every 4 hours while awake, up to 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Corneal ulceration",
"     </b>",
"     (1.5% ophthalmic solution): Ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Treatment day 1 through day 3: Instill 1-2 drops into affected eye(s) every 30 minutes to 2 hours while awake and 4-6 hours after retiring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Treatment day 4 through completion: Instill 1-2 drops into affected eye(s) every 1-4 hours while awake.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8406515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/11/5299?source=see_link\">",
"      see \"Levofloxacin (ophthalmic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Conjunctivitis (bacterial):",
"     </b>",
"     Ophthalmic: Children &ge;1 year: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Corneal ulceration:",
"     </b>",
"     Ophthalmic: Children &ge;6 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8406517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16265570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. However, dosage adjustment unlikely due to low systemic absorption.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16265571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. However, dosage adjustment unlikely due to low systemic absorption.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8408140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic [drops]: 0.5% (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Iquix&reg;: 1.5% (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Quixin&reg;: 0.5% (5 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8398381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8400758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Treatment of bacterial conjunctivitis caused by susceptible organisms (Quixin&reg; 0.5% ophthalmic solution); treatment of corneal ulcer caused by susceptible organisms (Iquix&reg; 1.5% ophthalmic solution)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8398369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Levofloxacin may be confused with levETIRAcetam, levodopa, levothyroxine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8404713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Taste disturbance (8% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Decreased vision (transient), foreign body sensation, transient ocular burning, ocular pain or discomfort, photophobia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reaction, lid edema, ocular dryness, ocular itching",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8401451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to levofloxacin, any component of the formulation, or other quinolones",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8401452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity: Serious hypersensitivity reactions have been reported with systemic use of fluoroquinolones.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may lead to overgrowth of nonsusceptible organisms, including fungi. Discontinue use and institute appropriate alternative therapy if superinfection is suspected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;1 year of age for Quixin&reg; and in children &lt;6 years of age for Iquix&reg;.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ophthalmic solution: For topical use only. Do not inject subconjunctivally or introduce into anterior chamber of the eye. Contact lenses should not be worn during treatment for bacterial conjunctivitis. Indications for ophthalmic solutions are product concentration-specific and should not be used interchangeably.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8404717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8400760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8400761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal studies; therefore, the manufacturer classifies levofloxacin ophthalmic as pregnancy category C. When administered orally or I.V., levofloxacin crosses the placenta. Refer to the Levofloxacin (Systemic) monograph for details. The amount of levofloxacin available systemically following topical application of the ophthalmic drops is significantly less in comparison to oral or I.V. doses.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8401444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F8401450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When administered orally or I.V., levofloxacin enters breast milk. Refer to the Levofloxacin (Systemic) monograph for details. The amount of levofloxacin available systemically following topical application of the ophthalmic drops is significantly less in comparison to oral or I.V. doses. The manufacturer recommends that caution be exercised when administering levofloxacin eye drops to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Levofloxacin Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (5 mL): $75.00",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F11390232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Afloc (KP);",
"     </li>",
"     <li>",
"      Cravit (KP, SG, TH, TW);",
"     </li>",
"     <li>",
"      Cravit Ophthalmic (CL, HK, ID, MY);",
"     </li>",
"     <li>",
"      Floquin DPS (IN);",
"     </li>",
"     <li>",
"      Lefocin (KP);",
"     </li>",
"     <li>",
"      Levomax (CO);",
"     </li>",
"     <li>",
"      Levosta (KP);",
"     </li>",
"     <li>",
"      Levotra (KP);",
"     </li>",
"     <li>",
"      Levoxacin (KP);",
"     </li>",
"     <li>",
"      Levunid (PE);",
"     </li>",
"     <li>",
"      Oftaquix (BG, CZ, DE, DK, EE, FI, GB, GR, IE, IT, NL, PH, PL, PT, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8404748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As the S(-) enantiomer of the fluoroquinolone, ofloxacin, levofloxacin, inhibits DNA-gyrase in susceptible organisms thereby inhibits relaxation of supercoiled DNA and promotes breakage of DNA strands. DNA gyrase (topoisomerase II), is an essential bacterial enzyme that maintains the superhelical structure of DNA and is required for DNA replication and transcription, DNA repair, recombination, and transposition.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9775819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Only small amounts are absorbed systemically after ophthalmic instillation",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10096 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-AC55A795B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_11_37043=[""].join("\n");
var outline_f36_11_37043=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8398379\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8400747\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8406516\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8406515\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8406517\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265570\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265571\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8408140\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8398381\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8400758\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8398369\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8404713\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8401451\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8401452\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299594\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8404717\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8400760\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8400761\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8401444\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8401450\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322261\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390232\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8404748\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9775819\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10096\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10096|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?23/63/24564?source=related_link\">",
"      Levofloxacin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/11/5299?source=related_link\">",
"      Levofloxacin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?16/8/16521?source=related_link\">",
"      Levofloxacin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/32/13830?source=related_link\">",
"      Levofloxacin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?23/13/23768?source=related_link\">",
"      Levofloxacin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_11_37044="Foscarnet: Patient drug information";
var content_f36_11_37044=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Foscarnet: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"     see \"Foscarnet: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/4/24646?source=see_link\">",
"     see \"Foscarnet: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14934198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Foscavir&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F174168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Foscavir&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700776",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause kidney function to get worse. Talk with your doctor if you have kidney disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700749",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause seizures in some patients. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691885",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat herpes infections.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691682",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat a viral infection of the eyes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702165",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to foscarnet or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3431441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Most of the time, this drug will be given in a hospital or doctor's office. If stored at home, follow how to store as you were told by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11739 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-D3C9B8B2AC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_11_37044=[""].join("\n");
var outline_f36_11_37044=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14934198\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174168\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026064\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026066\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026065\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026070\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026071\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026073\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026068\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026069\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026074\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026075\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=related_link\">",
"      Foscarnet: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/4/24646?source=related_link\">",
"      Foscarnet: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_11_37045="Pretreatment evaluation of adults with systemic sclerosis (scleroderma)";
var content_f36_11_37045=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pretreatment evaluation of adults with systemic sclerosis (scleroderma)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/11/37045/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/11/37045/contributors\">",
"     Christopher P Denton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/11/37045/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/11/37045/contributors\">",
"     John S Axford, DSc, MD, FRCP, FRCPCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/11/37045/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/11/37045/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/11/37045/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scleroderma encompasses a spectrum of related disorders, most of which share a characteristic clinical feature of skin thickening due to an excess of collagen fibers.",
"   </p>",
"   <p>",
"    The classification of scleroderma is presented separately, but a brief summary is included for the purpose of this overview of treatment. The simplest division of the scleroderma-related disorders is into localized and systemic forms of the disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44087?source=see_link\">",
"     \"Classification of scleroderma disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Localized scleroderma can be divided into (",
"    <a class=\"graphic graphic_table graphicRef60398 \" href=\"mobipreview.htm?1/22/1388\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Morphea",
"     </li>",
"     <li>",
"      Linear scleroderma",
"     </li>",
"     <li>",
"      En coup de sabre",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    By comparison, the extent of skin involvement and the accompanying pattern of internal organ involvement form the basis for the most widely used classification of systemic sclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37045/abstract/1\">",
"     1",
"    </a>",
"    ]. The principal subsets of systemic sclerosis are (",
"    <a class=\"graphic graphic_table graphicRef80559 \" href=\"mobipreview.htm?3/41/3741\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diffuse cutaneous systemic sclerosis (dcSSc)",
"     </li>",
"     <li>",
"      Limited cutaneous systemic sclerosis (lcSSc)",
"     </li>",
"     <li>",
"      Systemic sclerosis sine scleroderma (patients with only internal organ involvement)",
"     </li>",
"     <li>",
"      Environmentally induced scleroderma",
"     </li>",
"     <li>",
"      Overlap syndromes (features of systemic sclerosis which coexist with elements of other rheumatic disorders)",
"     </li>",
"     <li>",
"      Pre-scleroderma (patients with the Raynaud phenomenon plus positive autoantibodies",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      abnormal nailfold capillaroscopy)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, certain autoantibodies found in systemic sclerosis are associated with subsets of the disease. The presence of some of these autoantibodies may also predict the risk of future organ involvement (",
"    <a class=\"graphic graphic_table graphicRef59732 \" href=\"mobipreview.htm?10/18/10541\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The etiology and pathogenesis of the scleroderma disorders are poorly understood (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/65?source=see_link\">",
"     \"Risk factors for and possible causes of systemic sclerosis (scleroderma)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/63/19450?source=see_link\">",
"     \"Pathogenesis of systemic sclerosis (scleroderma)\"",
"    </a>",
"    ), and, as a consequence, treatment of these conditions is difficult, incomplete, and not curative. Despite these difficulties, a differentiation between localized and systemic disease and an understanding of the systemic sclerosis subsets, disease staging, organ involvement, and pathogenesis permit the most effective use of available therapies and the adoption of a strategy of disease containment.",
"   </p>",
"   <p>",
"    The medical history, physical examination, laboratory tests, and imaging studies that lead to an initial diagnosis of systemic sclerosis provide much of the information necessary to determine the distribution of organ involvement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43095?source=see_link\">",
"     \"Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/34/29224?source=see_link\">",
"     \"Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment decisions are informed by a thorough pretreatment assessment of the extent and type of organ involvement which may also help determine whether organ dysfunction is related to potentially reversible inflammation or vasoconstriction (active disease) or due to damage that is irreversible with current therapies (eg, fibrosis or ischemic necrosis). This topic summarizes clinically useful and generally available approaches for assessing disease activity, organ damage, and residual function in adults with systemic sclerosis.",
"   </p>",
"   <p>",
"    Overviews of the treatment of SSc in adults and children are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13642?source=see_link\">",
"     \"Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39433?source=see_link\">",
"     \"Juvenile systemic sclerosis (scleroderma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The organ based pretreatment assessment, described below, is more extensive than that recommended by an international group of scleroderma researchers for evaluating scleroderma activity and severity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37045/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These important consensus documents are based upon a minimal essential dataset and a desire in research studies to standardize assessment across centers and to provide guidelines that are applicable in a reasonably large number of countries and in recognition of limited availability of testing resources in some settings.",
"   </p>",
"   <p>",
"    A multifaceted approach to patient evaluation is necessary in clinical practice, as this provides a much more robust picture of clinically significant manifestations. Composite activity or severity scores for diffuse and limited disease subsets have not yet been fully validated but may well be adapted once they have been more widely applied, as was the case for the first scleroderma severity score [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37045/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRETREATMENT ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all of the following tests are necessary in every patient with scleroderma. However, assessment of the extent of skin involvement, renal function, pulmonary function, and the presence or absence of parenchymal lung disease by high resolution CT scanning, as well as the estimation of pulmonary arterial pressure by echocardiography, is recommended for all patients who have systemic sclerosis as part of the initial evaluation. For patients who present in an emergent fashion (eg, with scleroderma renal crisis), some components of the suggested assessment may need to be deferred until the patient is sufficiently stable to undergo the recommended tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cutaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin involvement in the scleroderma disorders is characterized by variable sclerosis or thickening of the skin. The hands and face are generally the first areas involved, and the hands typically show the most severe changes, especially in the early stages of disease. The distribution and extent of skin involvement may be valuable for determining prognosis as well as allowing accurate disease classification. A &ldquo;skin score&rdquo; based on the degree of thickening or tethering at various standardized anatomic sites is used in scleroderma clinical research and may be used in clinical practice to follow the course of cutaneous involvement.",
"   </p>",
"   <p>",
"    Great emphasis is placed upon the skin score as a validated method of assessing disease activity, progression, or stability.",
"   </p>",
"   <p>",
"    The skin score is a semiquantitative assessment of the extent of total skin sclerosis. The most widely used scoring system grades skin sclerosis at 17 sites, with scores at each site being 0 (normal), 1 (mild thickening), 2 (moderate thickening), or 3 (severe thickening) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37045/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is generally agreed that rolling skin between index finger and thumb provides the most effective way for estimating thickness of the skin in moving from grades 1 to 3. In late stage disease, this may be hampered by tethering to underlying structures; grade 3 is completely fixed (&ldquo;hide-bound&rdquo;). In practice, standardization between assessors examining the same patients and use of single observers maintain the skin score selected as a valid and useful tool to assess diffuse cutaneous SSc. Dermal thickness may be reliably estimated using an ultrasound probe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37045/abstract/5\">",
"     5",
"    </a>",
"    ], and other tools have been used in clinical trials, such as the durometer. No instrument has outperformed the modified Rodnan skin score in clinical practice.",
"   </p>",
"   <p>",
"    The skin score cannot be used as a surrogate index for organ-based involvement, but it may be prognostically valuable. As an example, in one study of 134 patients with diffuse skin involvement, a skin score of 20 or more was the third most powerful predictor of mortality after cardiac and pulmonary involvement (respective odds ratios 4.2, 4.0, and 3.6) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37045/abstract/6\">",
"     6",
"    </a>",
"    ]. A skin score of 20 or more was also the second most powerful predictor of the development of scleroderma renal crisis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Renal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Baseline measurement and subsequent periodic monitoring of blood pressure, serum creatinine, estimated glomerular filtration rate (GFR), and an estimate of proteinuria (either from a 24-hour urine collection or a urine protein to creatinine ratio) allow patients who have, or those who may be developing, scleroderma renal crisis to be identified. A GFR of less than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    is considered highly significant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37045/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common methods utilized in the United States to estimate the GFR are the creatinine clearance and the plasma creatinine concentration; by comparison, European clinicians frequently use other methods, particularly the clearance of 51-Cr-EDTA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link\">",
"     \"Assessment of kidney function\"",
"    </a>",
"    .) The calculator (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/61/10194?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) will calculate the creatinine clearance using data from a specific patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Gastrointestinal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal, small bowel, colonic, and anorectal function may be affected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Esophageal",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with dysphagia, upper gastrointestinal contrast radiography is recommended to rule out stricture or neoplasm. In the absence of a mechanical obstruction, esophageal manometry may help to better define swallowing difficulty. Myositis may lead to pharyngeal or esophageal weakness, and measurement of serum muscle enzymes (eg, creatine kinase and aldolase) may be helpful in assessing for inflammatory muscle disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Small bowel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with diarrhea, weight loss, or evidence of malnutrition or malabsorption should have their nutritional status formally evaluated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13831?source=see_link\">",
"     \"Nutrition support in critically ill patients: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Malabsorption of fat is assessed by measurement of a 24-hour stool collection and testing of serum levels of carotene. Deficiency of fat soluble vitamins may be indicated by prolonged protime and activated partial thromboplastin time (PT and aPTT) that correct with supplemental vitamin K administration.",
"   </p>",
"   <p>",
"    Malabsorption of carbohydrates can be tested for in a variety of ways (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38232?source=see_link\">",
"     \"Clinical features and diagnosis of malabsorption\"",
"    </a>",
"    ), but an empiric trial of antibiotics may be appropriate if bacterial overgrowth is suspected as the cause of diarrhea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Large bowel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of constipation or anorectal incontinence should be routinely assessed. Endoanal ultrasound, pelvic magnetic resonance imaging (MRI), and anal manometry can be used to more accurately define pathology in patients with symptoms of anorectal dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pulmonary",
"    </span>",
"    &nbsp;&mdash;&nbsp;A plain chest radiograph, prone high-resolution chest CT scan (HRCT), pulmonary function tests (including lung volumes, diffusing capacity for carbon monoxide [DLCO]), and echocardiography (to assess for the presence of pulmonary hypertension) are recommended.",
"   </p>",
"   <p>",
"    In selected patients with abnormal findings suggesting parenchymal lung disease, bronchoalveolar lavage (BAL) or lung biopsy may be necessary to determine whether the abnormalities are due to active inflammation or to fibrotic interstitial lung disease. Emerging data do not support the utility of routine BAL, but it can be of value in selected cases, especially to exclude infection or other pathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37045/abstract/8\">",
"     8",
"    </a>",
"    ]. HRCT has been shown to accurately assess the extent of disease and to predict the histological subtype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37045/abstract/9\">",
"     9",
"    </a>",
"    ]. There is a simple staging algorithm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37045/abstract/10\">",
"     10",
"    </a>",
"    ] for assessing whether lung fibrosis is mild or extensive and whether it has a low or high probability of progression. This system is being used in many European scleroderma centers to make treatment decisions (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35382?source=see_link\">",
"     \"Evaluation for and diagnosis of lung disease in systemic sclerosis (scleroderma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with symptoms suggestive of pulmonary hypertension, whose pulmonary arterial pressures cannot be estimated noninvasively (eg, those who have no tricuspid regurgitation), may need right heart catheterization to assess prognosis and to guide treatment. Measurement of pro-brain natriuretic peptide (pro-BNP) may be a valuable noninvasive indicator in this situation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37045/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cardiac",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients should have a screening EKG. If there is any suspicion of myocarditis or pericarditis, serum CK and troponin (either troponin I or troponin T depending upon availability), an electrocardiogram (ECG), and an echocardiogram are recommended. Cardiac magnetic resonance imaging may provide the best tool for identifying myocardial involvement with fibrosis or inflammation, but it is not usually a routine tool [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37045/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Musculoskeletal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of joint mobility and functional abilities may be necessary to tailor appropriate physical and occupational therapy. Measurement of muscle enzymes (creatine kinase and aldolase) is recommended initially to exclude myositis. Repeat testing is needed only if symptoms or physical findings of muscle weakness develop during the course of the disease. If myositis is suspected clinically or on the basis of muscle enzymes elevated more than fourfold, then electromyography (EMG) and muscle biopsy may be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Functional testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scleroderma-specific functional assessment has been explored using the scleroderma health assessment questionnaire (SHAQ). The disability index has been shown to correlate with other outcome measures in clinical trial cohorts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37045/abstract/13\">",
"     13",
"    </a>",
"    ]. A scleroderma functional score has been validated against the HAQ-disability index [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37045/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The goal of pretreatment assessment of patients with SSc is to determine which organs are involved, how much functional impairment is present, and, if possible, whether the damage is due to potentially reversible inflammation or fibrosis.",
"     </li>",
"     <li>",
"      Assessment of the extent of skin involvement, renal function, pulmonary function, and the presence or absence of parenchymal lung disease by high resolution CT scanning, as well as estimation of pulmonary arterial pressure by echocardiography, is recommended for all patients who have systemic sclerosis.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37045/abstract/1\">",
"      Valentini G, Silman AJ, Veale D. Assessment of disease activity. Clin Exp Rheumatol 2003; 21:S39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37045/abstract/2\">",
"      Medsger TA Jr, Bombardieri S, Czirjak L, et al. Assessment of disease severity and prognosis. Clin Exp Rheumatol 2003; 21:S42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37045/abstract/3\">",
"      Medsger TA Jr, Silman AJ, Steen VD, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999; 26:2159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37045/abstract/4\">",
"      Black CM. Measurement of skin involvement in scleroderma. J Rheumatol 1995; 22:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37045/abstract/5\">",
"      Moore TL, Lunt M, McManus B, et al. Seventeen-point dermal ultrasound scoring system--a reliable measure of skin thickness in patients with systemic sclerosis. Rheumatology (Oxford) 2003; 42:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37045/abstract/6\">",
"      Clements PJ, Hurwitz EL, Wong WK, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum 2000; 43:2445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37045/abstract/7\">",
"      Kingdon EJ, Knight CJ, Dustan K, et al. Calculated glomerular filtration rate is a useful screening tool to identify scleroderma patients with renal impairment. Rheumatology (Oxford) 2003; 42:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37045/abstract/8\">",
"      Goh NS, Veeraraghavan S, Desai SR, et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum 2007; 56:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37045/abstract/9\">",
"      Desai SR, Veeraraghavan S, Hansell DM, et al. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology 2004; 232:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37045/abstract/10\">",
"      Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37045/abstract/11\">",
"      Mukerjee D, Yap LB, Holmes AM, et al. Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. Respir Med 2003; 97:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37045/abstract/12\">",
"      Hachulla AL, Launay D, Gaxotte V, et al. Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis 2009; 68:1878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37045/abstract/13\">",
"      Clements PJ, Wong WK, Hurwitz EL, et al. The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. Arthritis Rheum 2001; 44:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37045/abstract/14\">",
"      Smyth AE, MacGregor AJ, Mukerjee D, et al. A cross-sectional comparison of three self-reported functional indices in scleroderma. Rheumatology (Oxford) 2003; 42:732.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7544 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-B28792CD2A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_11_37045=[""].join("\n");
var outline_f36_11_37045=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRETREATMENT ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cutaneous",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Renal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Gastrointestinal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Esophageal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Small bowel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Large bowel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pulmonary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cardiac",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Musculoskeletal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Functional testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7544\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7544|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/22/1388\" title=\"table 1\">",
"      Localized scleroderma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/41/3741\" title=\"table 2\">",
"      Systemic sclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/18/10541\" title=\"table 3\">",
"      Autoantibodies in scleroderma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/61/10194?source=related_link\" title=\"calculator 1\">",
"      Calculator: Glomerular filtration rate estimate by abbreviated MDRD study equation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44087?source=related_link\">",
"      Classification of scleroderma disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38232?source=related_link\">",
"      Clinical features and diagnosis of malabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43095?source=related_link\">",
"      Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35382?source=related_link\">",
"      Evaluation for and diagnosis of lung disease in systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39433?source=related_link\">",
"      Juvenile systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13831?source=related_link\">",
"      Nutrition support in critically ill patients: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/34/29224?source=related_link\">",
"      Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13642?source=related_link\">",
"      Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/63/19450?source=related_link\">",
"      Pathogenesis of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/65?source=related_link\">",
"      Risk factors for and possible causes of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_11_37046="Ferrous sulfate: Drug information";
var content_f36_11_37046=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ferrous sulfate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/22/5477?source=see_link\">",
"    see \"Ferrous sulfate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/62/15334?source=see_link\">",
"    see \"Ferrous sulfate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F170907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Feosol&reg; [OTC];",
"     </li>",
"     <li>",
"      Fer-In-Sol&reg; [OTC];",
"     </li>",
"     <li>",
"      Fer-iron [OTC];",
"     </li>",
"     <li>",
"      MyKidz Iron 10&trade; [OTC];",
"     </li>",
"     <li>",
"      Slow FE&reg; [OTC];",
"     </li>",
"     <li>",
"      Slow Release [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F170908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Ferrous Sulfate&reg;;",
"     </li>",
"     <li>",
"      Fer-In-Sol&reg;;",
"     </li>",
"     <li>",
"      Ferodan&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F170948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Iron Salt",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F170912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Multiple concentrations of ferrous sulfate oral liquid exist; close attention must be paid to the concentration when ordering and administering ferrous sulfate; incorrect selection or substitution of one ferrous sulfate liquid for another without proper dosage volume adjustment may result in serious over- or underdosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dietary Reference Intake: Dose is RDA presented as elemental iron unless otherwise noted:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     19-50 years: Males: 8 mg/day; Females: 18 mg/day; Pregnant females: 27 mg/day; Lactating females: 9 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;50 years: 8 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Dose expressed in terms of ferrous sulfate:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Treatment of iron deficiency anemia:",
"     </b>",
"     Oral: 300 mg twice daily up to 300 mg 4 times/day or 250 mg (extended release) 1-2 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Prophylaxis of iron deficiency:",
"     </b>",
"     Oral: 300 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F170929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/62/15334?source=see_link\">",
"      see \"Ferrous sulfate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Multiple concentrations of ferrous sulfate oral liquid exist; close attention must be paid to the concentration when ordering and administering ferrous sulfate; incorrect selection or substitution of one ferrous sulfate liquid for another without proper dosage volume adjustment may result in serious over- or underdosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dietary Reference Intake: Dose is RDA presented as elemental iron unless otherwise noted:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0-6 months: 0.27 mg/day (adequate intake)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7-12 months: 11 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3 years: 7 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-8 years: 10 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-13 years: 8 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     14-18 years: Males: 11 mg/day; Females: 15 mg/day; Pregnant females: 27 mg/day; Lactating females: 10 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Dosage expressed in terms of elemental iron:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Treatment of severe iron-deficiency anemia:",
"     </b>",
"     Oral: 4-6 mg Fe/kg/day in 3 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Treatment of mild-to-moderate iron-deficiency anemia:",
"     </b>",
"     Oral: 3 mg Fe/kg/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Prophylaxis:",
"     </b>",
"     Oral: 1-2 mg Fe/kg/day up to a maximum of 15 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F170913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lower doses (15-50 mg elemental iron/day) may have similar efficacy and less GI adverse events (eg, nausea, constipation) as compared to higher doses (eg, 150 mg elemental iron/day) (Rimon, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F170889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elixir, oral: 220 mg/5 mL (473 mL, 480 mL) [elemental iron 44 mg/5 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral: 300 mg/5 mL (5 mL) [elemental iron ~60 mg/5 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral [drops]: 75 mg/mL (50 mL) [elemental iron 15 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fer-In-Sol&reg;: 75 mg/mL (50 mL) [gluten free; contains ethanol 0.2%, sodium bisulfite; elemental iron 15 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fer-iron: 75 mg/mL (50 mL) [contains ethanol 0.2%, sodium bisulfite; lemon flavor; elemental iron 15 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MyKidz Iron 10&trade;: 75 mg/1.5 mL (118 mL) [dye free, ethanol free; contains propylene glycol, sodium 12 mg/1.5 mL; strawberry-banana flavor; elemental iron 15 mg/1.5 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 324 mg [elemental iron 65 mg], 325 mg [elemental iron 65 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral [exsiccated]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Feosol&reg;: 200 mg [elemental iron 65 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, enteric coated, oral: 324 mg [elemental iron 65 mg], 325 mg [elemental iron 65 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: 140 mg [elemental iron 45 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, slow release, oral: 160 mg [elemental iron 50 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Slow FE&reg;: 142 mg [elemental iron 45 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Slow Release: 140 mg [elemental iron 45 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F170874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F170892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken with water or juice on an empty stomach; administer ferrous sulfate 2 hours prior to, or 4 hours after antacids",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F170891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of iron-deficiency anemias",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F170955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Feosol&reg; may be confused with Fer-In-Sol&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Fer-In-Sol&reg; may be confused with Feosol&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Slow FE&reg; may be confused with Slow-K&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Multiple concentrations of liquid iron preparations exist. Fer-In-Sol&reg; drops (manufactured by Mead Johnson) and a limited number of generic products are available at a concentration of 15 mg/mL. However, a suspension product, MyKidz Iron 10&trade; drops, is available at a concentration of 15 mg/1.5 mL. Check concentration closely prior to dispensing. Prescriptions written in milliliters (mL) should be clarified.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F170946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Constipation, dark stools, epigastric pain, GI irritation, nausea, stomach cramping, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, heartburn",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Discoloration of urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Liquid preparations may temporarily stain the teeth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Contact irritation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F170895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to iron salts or any component of the formulation; hemochromatosis, hemolytic anemia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F170878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal disease: Avoid in patients with peptic ulcer, enteritis, or ulcerative colitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood transfusion recipients: Avoid in patients receiving frequent blood transfusions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Anemia in the elderly is often caused by &ldquo;anemia of chronic disease&rdquo; or associated with inflammation rather than blood loss. Iron stores are usually normal or increased, with a serum ferritin &gt;50 ng/mL and a decreased total iron binding capacity. Hence, the &ldquo;anemia of chronic disease&rdquo; is not secondary to iron deficiency but the inability of the reticuloendothelial system to reclaim available iron stores.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatrics: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. Keep this product out of the reach of children. In case of accidental overdose call the poison control center immediately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Premature infants: Avoid use in premature infants until the vitamin E stores, deficient at birth, are replenished.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Duration of therapy: Administration of iron for &gt;6 months should be avoided except in patients with continuous bleeding or menorrhagia.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F170883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Iron Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Iron Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral iron supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefdinir: Iron Salts may decrease the serum concentration of Cefdinir. Red-appearing, non-bloody stools may also develop due to the formation of an insoluble iron-cefdinir complex.  Management: Avoid concurrent cefdinir and oral iron when possible.  Separating doses by several hours may minimize interaction.  Iron-containing infant formulas do not appear to interact with cefdinir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Iron Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dimercaprol: May enhance the nephrotoxic effect of Iron Salts.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Iron Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any orally administered polyvalent cation (e.g., iron-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May decrease the absorption of Iron Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levodopa: Iron Salts may decrease the serum concentration of Levodopa. Only applies to oral iron preparations.  Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levothyroxine: Iron Salts may decrease the serum concentration of Levothyroxine.  Management: Separate oral administration of iron salts and levothyroxine by at least 4 hours.  Separation of doses is not required with parenterally administered iron salts or levothyroxine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methyldopa: Iron Salts may decrease the serum concentration of Methyldopa.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pancrelipase: May decrease the absorption of Iron Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PenicillAMINE: Iron Salts may decrease the absorption of PenicillAMINE. Only oral iron salts are a concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Iron Salts may decrease the absorption of Phosphate Supplements.  Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, oral iron salt administration.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May decrease the absorption of Iron Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Iron Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Iron Salts may decrease the absorption of Tetracycline Derivatives. Only a concern with orally administered products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Iron Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Iron Salts.  Management: Trientine manufacturer recommends avoiding concurrent administration with oral iron salts due to the risk for impaired GI absorption of both trientine and the iron salt. Short courses of iron may be used however separate administration by at least 2 hours",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F170904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Cereals, dietary fiber, tea, coffee, eggs, and milk may decrease absorption.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6789293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is recommended that pregnant women meet the dietary requirements of iron with diet and/or supplements in order to prevent adverse events associated with iron deficiency anemia in pregnancy. Treatment of iron deficiency anemia in pregnant women is the same as in nonpregnant women and in most cases, oral iron preparations may be used. Except in severe cases of maternal anemia, the fetus achieves normal iron stores regardless of maternal concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6789295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6789296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Iron is normally found in breast milk. Breast milk or iron fortified formulas generally provide enough iron to meet the recommended dietary requirements of infants. The amount of iron in breast milk is generally not influenced by maternal iron status.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F170898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken with water or juice on an empty stomach; may be administered with food to prevent irritation; however, not with cereals, dietary fiber, tea, coffee, eggs, or milk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elemental iron content of iron salts in ferrous sulfate is 20% (ie, 300 mg ferrous sulfate is equivalent to 60 mg ferrous iron)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dietary sources of iron include beans, cereal (enriched), clams, beef, lentils, liver, oysters, shrimp, and turkey. Foods that enhance dietary absorption of iron include broccoli, grapefruit, orange juice, peppers and strawberries. Foods that decrease dietary absorption of iron include coffee, dairy products, soy products, spinach, and tea.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F170897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Elixir",
"     </b>",
"     (Ferrous Sulfate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     220 (44 Fe) mg/5 mL (473 mL): $6.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Spatone pur-Absorb Iron Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/20 mL (20 mL): $0.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Fer-In-Sol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 (15 Fe) mg/mL (50 mL): $10.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ferrous Sulfate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 (15 Fe) mg/mL (50 mL): $5.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Ferrous Sulfate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 (60 Fe) mg/5 mL (5 mL): $0.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Ferrous Sulfate ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     140 (45 Fe) mg (30): $5.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Slow Fe Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     142 (45 Fe) mg (60): $13.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     160 (50 Fe) mg (60): $13.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Ferrous Sulfate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     324 (65 Fe) mg (100): $6.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     325 (65 Fe) mg (100): $15.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Feosol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     45 mg (40): $7.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 (65 Fe) mg (120): $10.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ferrous Sulfate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     83 mg (100): $2.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     134 mg (250): $4.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     325 (65 Fe) mg (100): $3.39",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F170887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum iron, total iron binding capacity, reticulocyte count, hemoglobin",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F170890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Serum iron:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Males: 75-175 mcg/dL (SI: 13.4-31.3 micromole/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Females: 65-165 mcg/dL (SI: 11.6-29.5 micromole/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Total iron binding capacity: 230-430 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Transferrin: 204-360 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Percent transferrin saturation: 20% to 50%",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F170899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aktiferrin (HU);",
"     </li>",
"     <li>",
"      Brisofer (PH);",
"     </li>",
"     <li>",
"      Conferon (HU);",
"     </li>",
"     <li>",
"      Duroferon (FI, NO, SE);",
"     </li>",
"     <li>",
"      Eribell (PY);",
"     </li>",
"     <li>",
"      Femas (JP);",
"     </li>",
"     <li>",
"      Feosol (PH);",
"     </li>",
"     <li>",
"      Feospan (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, HK, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Fer-In-Sol (AR, BR, CN, CZ, GR, HK, PE, VE);",
"     </li>",
"     <li>",
"      Ferglobin (PH);",
"     </li>",
"     <li>",
"      Ferlea (AR);",
"     </li>",
"     <li>",
"      Fero-Gradumet (BE, ES, LU, NL, PL);",
"     </li>",
"     <li>",
"      Ferro Duretter (DK);",
"     </li>",
"     <li>",
"      Ferro-grad (IT);",
"     </li>",
"     <li>",
"      Ferro-Gradumet (AE, AT, AU, BG, BH, CH, CY, EG, HU, ID, IL, IQ, IR, JO, KW, LB, LY, OM, PT, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Ferro-Liquid (AU);",
"     </li>",
"     <li>",
"      Ferrogamma (DE);",
"     </li>",
"     <li>",
"      Ferrograd (GB, IE);",
"     </li>",
"     <li>",
"      Ferrolent (CR, DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Ferrophor (DE);",
"     </li>",
"     <li>",
"      Ferroplex &rdquo;Era&rdquo; (DK);",
"     </li>",
"     <li>",
"      Ferrostatin (JP);",
"     </li>",
"     <li>",
"      Ferrosterol (UY);",
"     </li>",
"     <li>",
"      Haemoprotect (DE);",
"     </li>",
"     <li>",
"      Hemobion (MX);",
"     </li>",
"     <li>",
"      Inshel (TW);",
"     </li>",
"     <li>",
"      Kidiron (TH);",
"     </li>",
"     <li>",
"      Liquifer (NL);",
"     </li>",
"     <li>",
"      Microfer (GR);",
"     </li>",
"     <li>",
"      Mol-Iron (CO);",
"     </li>",
"     <li>",
"      Plastufer (DE);",
"     </li>",
"     <li>",
"      Plexafer (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Retafer (FI, HR, MY);",
"     </li>",
"     <li>",
"      Slow-Fe (AE, BB, BH, BM, BS, BZ, CY, EG, GY, IQ, IR, JM, JO, KW, LB, LY, OM, QA, SA, SR, SY, TT, YE);",
"     </li>",
"     <li>",
"      Tardyferon (ES, FR, HU, IL, LU);",
"     </li>",
"     <li>",
"      Venofer (DK)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F170877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Replaces iron, found in hemoglobin, myoglobin, and other enzymes; allows the transportation of oxygen via hemoglobin",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F170894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Hematologic response: Oral: ~3-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: Reticulocytosis: 5-10 days; hemoglobin increases within 2-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Iron is absorbed in the duodenum and upper jejunum; in persons with normal serum iron stores, 10% of an oral dose is absorbed; this is increased to 20% to 30% in persons with inadequate iron stores. Food and achlorhydria will decrease absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: To transferrin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine, sweat, sloughing of the intestinal mucosa, and menses",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists, &ldquo;ACOG Practice Bulletin No. 95: Anemia in Pregnancy,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2008, 112(1):201-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/11/37046/abstract-text/18591330/pubmed\" id=\"18591330\" target=\"_blank\">",
"        18591330",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baker WF Jr, &ldquo;Iron Deficiency in Pregnancy, Obstetrics, and Gynecology,&rdquo;",
"      <i>",
"       Hematol Oncol Clin North Am",
"      </i>",
"      , 2000, 14(5):1061-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/11/37046/abstract-text/11005034/pubmed\" id=\"11005034\" target=\"_blank\">",
"        11005034",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of  Medicine),",
"      <i>",
"       Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc",
"      </i>",
"      , Washington, DC: National Academy Press, 2001.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lipschitz DA, &ldquo;The Anemia of Chronic Disease,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1990, 38(11):1258-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/11/37046/abstract-text/2123218/pubmed\" id=\"2123218\" target=\"_blank\">",
"        2123218",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marx JJM, &ldquo;Normal Iron Absorption and Decreased Red Cell Iron Uptake in the Aged,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1979, 53:204-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/11/37046/abstract-text/760850/pubmed\" id=\"760850\" target=\"_blank\">",
"        760850",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Nutrition During Lactation.&rdquo; Subcommittee on Nutrition During Lactation, Committee on Nutritional Status During Pregnancy and Lactation, Food and Nutrition Board Institute of Medicine, National Academy of Sciences Washington, DC: National Academy Press, 1991. Available at",
"      <a href=\"file://www.nap.edu\" target=\"_blank\">",
"       file://www.nap.edu",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Recommendations to Prevent and Control Iron Deficiency in the United States. Centers for Disease Control and Prevention,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 1998, 47(RR-3):1-29.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/11/37046/abstract-text/9563847/pubmed\" id=\"9563847\" target=\"_blank\">",
"        9563847",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rimon E, Kagansky N, Kagansky M, et al, &ldquo;Are We Giving Too Much Iron? Low-Dose Iron Therapy is Effective in Octogenarians,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 2005, 118(10):1142-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/11/37046/abstract-text/16194646/pubmed\" id=\"16194646\" target=\"_blank\">",
"        16194646",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Routine Iron Supplementation During Pregnancy. Review Article. US Preventive Services Task Force,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1993, 270(23):2848-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/11/37046/abstract-text/8133626/pubmed\" id=\"8133626\" target=\"_blank\">",
"        8133626",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8444 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-7CA0D077E0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_11_37046=[""].join("\n");
var outline_f36_11_37046=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170907\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170908\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170948\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170912\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170929\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170913\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170889\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170874\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170892\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170891\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170955\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170946\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170895\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170878\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299324\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170883\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170904\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6789293\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6789295\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6789296\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170898\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170897\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170887\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170890\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170899\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170877\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170894\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8444\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8444|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/22/5477?source=related_link\">",
"      Ferrous sulfate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/62/15334?source=related_link\">",
"      Ferrous sulfate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_11_37047="Acebutolol: Drug information";
var content_f36_11_37047=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Acebutolol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/47/12021?source=see_link\">",
"    see \"Acebutolol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F129226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Sectral&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F129227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Acebutolol&reg;;",
"     </li>",
"     <li>",
"      Ava-Acebutolol;",
"     </li>",
"     <li>",
"      Mylan-Acebutolol;",
"     </li>",
"     <li>",
"      Mylan-Acebutolol (Type S);",
"     </li>",
"     <li>",
"      Nu-Acebutolol;",
"     </li>",
"     <li>",
"      Rhotral;",
"     </li>",
"     <li>",
"      Sandoz-Acebutolol;",
"     </li>",
"     <li>",
"      Sectral&reg;;",
"     </li>",
"     <li>",
"      Teva-Acebutolol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F129265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiarrhythmic Agent, Class II;",
"     </li>",
"     <li>",
"      Beta-Blocker With Intrinsic Sympathomimetic Activity",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F129230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Angina, ventricular arrhythmia:",
"     </b>",
"     Oral: 400 mg/day in 2 divided doses; maintenance: 600-1200 mg/day in divided doses; maximum: 1200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: 400-800 mg/day (larger doses may be divided); maximum: 1200 mg/day; usual dose range (JNC 7): 200-800 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic stable angina (unlabeled use):",
"     </b>",
"     Oral: Usual dose: 400-1200 mg/day in 2 divided doses (Gibbons, 2003); low doses (ie, 400 mg/day) may also be given as once daily (Pina, 1988)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F129231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Consider dose reduction due to age-related increase in bioavailability; do not exceed 800 mg/day.  In the management of hypertension, consider lower initial dose (eg, 200-400 mg/day) and titrate to response (Aronow, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F129232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     25-49 mL/minute: Reduce dose by 50%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;25 mL/minute: Reduce dose by 75%.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F129233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no dosage adjustments provided in manufacturer's labeling;use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F129199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride: 200 mg, 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sectral&reg;: 200 mg, 400 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F129183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F129203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F129202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension; management of ventricular arrhythmias",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F5359979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of chronic stable angina (",
"     <b>",
"      Note:",
"     </b>",
"     Not recommended for patients with prior MI)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F129272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Sectral&reg; may be confused with Seconal&reg;, Septra&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F129263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Central nervous system: Fatigue (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (2%), edema (2%), bradycardia, hypotension, CHF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (6%), dizziness (6%), insomnia (3%), depression (2%), abnormal dreams (2%), anxiety, hyper-/hypoesthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (2%), pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation (4%), diarrhea (4%), dyspepsia (4%), nausea (4%), flatulence (3%), abdominal pain, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Micturition frequency (3%), dysuria, impotence, nocturia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia (2%), back pain, joint pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Abnormal vision (2%), conjunctivitis, dry eyes, eye pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (4%), rhinitis (2%), cough (1%), pharyngitis, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Alkaline phosphatase increased, anorexia, AV block, bilirubin increased, cold extremities, drug-induced lupus-like syndrome, exacerbate pre-existing renal insufficiency, facial edema, hepatotoxic reaction, lichen planus, palpitation, pleurisy, pneumonitis, pulmonary granulomas, systemic lupus erythematosus, transaminases increased, urinary retention, ventricular arrhythmia, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Potential adverse effects (based on experience with other beta-blocking agents) include agranulocytosis, allergic reactions, alopecia (reversible), catatonia, claudication, depression (reversible), disorientation, emotional lability, erythematous rash, ischemic colitis, laryngospasm, mesenteric artery thrombosis, Peyronie's disease, purpura, respiratory distress, short-term memory loss, slightly clouded sensorium, thrombocytopenia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F129206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Overt cardiac failure; cardiogenic shock; persistently-severe bradycardia or second- and third-degree heart block (except in patients with a functioning artificial pacemaker)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F129187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse events:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchospastic disease: In general, patients with bronchospastic disease should not receive beta-blockers; for patients with bronchospastic disease who do not respond to or cannot tolerate other therapies, initial low doses of acebutolol may be employed and used cautiously with close monitoring. Ensure patient has an inhaled beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonist immediately available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conduction abnormality: Consider pre-existing conditions such as sick sinus syndrome before initiating.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may potentiate hypoglycemia and/or mask signs and symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF): Beta-blockers with intrinsic sympathomimetic activity (eg, acebutolol) are likely to worsen survival in patients with HF and should be avoided. Beta-blockers shown to improve survival in clinical trials should be used in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mesenteric vascular disease: Can precipitate or aggravate symptoms of arterial insufficiency in patients with mesenteric vascular disease. Use with caution in these patients. Observe closely for progression of arterial obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral vascular disease (PVD) and Raynaud's disease: May precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud's disease. Use with caution and monitor for progression of arterial obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pheochromocytoma (untreated): Adequate alpha",
"     <sub>",
"      1",
"     </sub>",
"     -receptor blockade is required prior to use of any beta-blocker.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psoriasis: Beta-blocker use has been associated with induction or exacerbation of psoriasis, but cause and effect have not been firmly established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disease: Use with caution in patients with a history of psychiatric illness; may cause or exacerbate CNS depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment, especially the elderly. Elimination of the metabolite, diacetolol, is reduced resulting in a two- to threefold increase in its half-life.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If hyperthyroidism is suspected, carefully manage and monitor; abrupt withdrawal may precipitate thyroid storm. Alterations in thyroid function tests may be observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Calcium channel blockers: Use with caution in patients on concurrent verapamil or diltiazem; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac glycosides: Use with caution in patients receiving digoxin; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inhaled anesthetic agents: Use with caution in patients receiving inhaled anesthetic agents known to depress myocardial contractility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use reduced doses in elderly patients; concentrations of acebutolol and diacetolol are significantly higher in the elderly. Dose should not exceed 800 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abrupt withdrawal: Beta-blocker therapy should not be withdrawn abruptly (particularly in patients with CAD), but gradually tapered to avoid acute tachycardia, hypertension, and/or ischemia. Severe exacerbation of angina, ventricular arrhythmias, and myocardial infarction (MI) have been reported following abrupt withdrawal of beta-blocker therapy. Temporary but prompt resumption of beta-blocker therapy may be indicated with worsening of angina or acute coronary insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Major surgery: Chronic beta-blocker therapy should not be routinely withdrawn prior to major surgery.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F129260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F129192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Beta-Blockers (Beta1 Selective) may diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: Beta-Blockers may enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifabutin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Beta-Blockers (Beta1 Selective) may diminish the bronchodilatory effect of Theophylline Derivatives.  Management: Monitor for reduced theophylline efficacy during concomitant use with any beta-blocker.  Beta-1 selective agents are less likely to antagonize theophylline than nonselective agents, but selectivity may be lost at higher doses.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F129221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Peak serum acebutolol levels may be slightly decreased if taken with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid dong quai if using for hypertension (has estrogenic activity). Avoid yohimbe, ginseng (may worsen hypertension).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F129195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F129209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were not observed in animal reproduction studies; therefore, acebutolol is classified as pregnancy category C. Acebutolol and diacetolol (active metabolite) cross the placenta. In a cohort study, an increased risk of cardiovascular defects was observed following maternal use of beta-blockers during pregnancy. Intrauterine growth restriction (IUGR), small placentas, as well as fetal/neonatal bradycardia, hypoglycemia, and/or respiratory depression have been observed following",
"     <i>",
"      in utero",
"     </i>",
"     exposure to beta-blockers as a class. Adequate facilities for monitoring infants at birth should be available. Untreated chronic maternal hypertension and pre-eclampsia are also associated with adverse events in the fetus, infant, and mother. The plasma elimination half-life of acebutolol is longer in pregnant women at term. Acebutolol has been evaluated for the treatment of hypertension in pregnancy, but other agents may be more appropriate for use.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F129235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP recommends &ldquo;use with caution&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F129210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acebutolol and diacetolol (active metabolite) are excreted into breast milk. Bradycardia, hypotension, and tachypnea (transient) were observed in a nursing infant. Breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F129211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F129208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Acebutolol HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $100.73",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (100): $133.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Sectral Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $399.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (100): $530.75",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F129197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood glucose (especially in patients with diabetes mellitus); blood pressure, orthostatic hypotension, heart rate, CNS effects, ECG",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F129212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      ACB (NZ);",
"     </li>",
"     <li>",
"      Acecor (CZ);",
"     </li>",
"     <li>",
"      Acepin (TW);",
"     </li>",
"     <li>",
"      Acetanol (JP);",
"     </li>",
"     <li>",
"      Beloc (CN);",
"     </li>",
"     <li>",
"      Butobloc (ZA);",
"     </li>",
"     <li>",
"      Diasectral (DK, FI);",
"     </li>",
"     <li>",
"      Flebutol (VE);",
"     </li>",
"     <li>",
"      Grifobutol (CN);",
"     </li>",
"     <li>",
"      Prent (CH, DE, IT, PT, TR);",
"     </li>",
"     <li>",
"      Rhodiasectral (AR);",
"     </li>",
"     <li>",
"      Sectral (AE, AT, BB, BE, BG, BH, BM, BR, BS, BZ, CH, CY, CZ, EG, ES, FR, GB, GY, HK, IE, IL, IN, IQ, IR, IT, JM, JO, JP, KW, LB, LU, LY, NL, OM, PL, QA, SA, SG, SR, SY, TT, TW, YE, ZA);",
"     </li>",
"     <li>",
"      Sectral LP (FR);",
"     </li>",
"     <li>",
"      Sincer (TW);",
"     </li>",
"     <li>",
"      Wesfalin (AR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F129186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitively blocks beta",
"     <sub>",
"      1",
"     </sub>",
"     -adrenergic receptors with little or no effect on beta",
"     <sub>",
"      2",
"     </sub>",
"     -receptors except at high doses; exhibits membrane stabilizing and intrinsic sympathomimetic activity",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F129205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: 40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 1.2 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~26%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive first-pass effect to equipotent and cardioselective diacetolol metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Acebutolol: 40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Parent drug: 3-4 hours; Metabolite: 8-13 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (50% to 60%); urine (30% to 40%); diacetolol eliminated primarily in the urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;American Academy of Pediatrics Committee on Drugs. The Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/11/37047/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, &ldquo;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, The Society of Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2007, 50(7):1-157.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/11/37047/abstract-text/17692738/pubmed\" id=\"17692738\" target=\"_blank\">",
"        17692738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe DT, Armstrong PW, et al. &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2004, 44(3):671-719.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/11/37047/abstract-text/15358045/pubmed\" id=\"15358045\" target=\"_blank\">",
"        15358045",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronow WS, Fleg JL, Pepine CJ, et al, &ldquo;ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(21):2434-506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/11/37047/abstract-text/21518977/pubmed\" id=\"21518977\" target=\"_blank\">",
"        21518977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boutroy MJ, Bianchetti G, Dubruc C, et al, &ldquo;To Nurse When Receiving Acebutolol: Is It Dangerous for the Neonate?&rdquo;",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 1986, 30(6):737-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/11/37047/abstract-text/3770068/pubmed\" id=\"3770068\" target=\"_blank\">",
"        3770068",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brauchli YB, Jick SS, Curtin F, et al, &ldquo;Association Between Beta-Blockers, Other Antihypertensive Drugs and Psoriasis: Population-Based Case-Control Study,&rdquo;",
"      <i>",
"       Br J Dermatol",
"      </i>",
"      , 2008, 158(6):1299-307.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/11/37047/abstract-text/18410416/pubmed\" id=\"18410416\" target=\"_blank\">",
"        18410416",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/11/37047/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dumez Y, Tchobroutsky C, Hornych H, et al, &ldquo;Neonatal Effects of Maternal Administration of Acebutolol,&rdquo;",
"      <i>",
"       Br Med J (Clin Res Ed)",
"      </i>",
"      , 1981, 283(6299):1077-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/11/37047/abstract-text/6794766/pubmed\" id=\"6794766\" target=\"_blank\">",
"        6794766",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/11/37047/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fleisher LA, Beckman JA, Brown KA, et al, &ldquo;2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 54(22):e13-118.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/11/37047/abstract-text/19926002/pubmed\" id=\"19926002\" target=\"_blank\">",
"        19926002",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Geffner DL and Hershman JM, &ldquo;beta-Adrenergic Blockade for the Treatment of Hyperthyroidism,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 1992, 93(1):61-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/11/37047/abstract-text/1352658/pubmed\" id=\"1352658\" target=\"_blank\">",
"        1352658",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gibbons RJ, Abrams J, Chatterjee K, et al, &ldquo;ACC/AHA 2002 Guideline Update for the Management of Patients With Chronic Stable Angina - Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina),&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2003, 41(1):159-68.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/11/37047/abstract-text/12570960/pubmed\" id=\"12570960\" target=\"_blank\">",
"        12570960",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gibbons RJ, Chatterjee K, Daley J, et al, &ldquo;ACC/AHA/ACP-ASIM Guidelines for the Management of Patients With Chronic Stable Angina: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1999, 33(7):2092-197.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/11/37047/abstract-text/10362225/pubmed\" id=\"10362225\" target=\"_blank\">",
"        10362225",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lang DM, &ldquo;Anaphylactoid and Anaphylactic Reactions. Hazards of Beta-Blockers,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1995, 12(5):299-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/11/37047/abstract-text/7669259/pubmed\" id=\"7669259\" target=\"_blank\">",
"        7669259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/11/37047/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pi&ntilde;a IL, Smith EV, and Weidler DJ, &ldquo;Low-dose Acebutolol Given Once Daily in the Treatment of Chronic Angina Pectoris,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1988, 28(5):427-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/11/37047/abstract-text/3392240/pubmed\" id=\"3392240\" target=\"_blank\">",
"        3392240",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ryan TJ, Anderson JL, Antman EM, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1996, 28(5):1328-428.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/11/37047/abstract-text/8890834/pubmed\" id=\"8890834\" target=\"_blank\">",
"        8890834",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sch&ouml;n MP and Boehncke WH, &ldquo;Psoriasis,&rdquo;",
"      <i>",
"       N Eng J Med",
"      </i>",
"      , 2005, 352(18):1899-1912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/11/37047/abstract-text/15872205/pubmed\" id=\"15872205\" target=\"_blank\">",
"        15872205",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      UK Prospective Diabetes Study Group, &ldquo;Efficacy of Atenolol and Captopril in Reducing Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes: UKPDS 39,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 1998, 317(7160):713-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/11/37047/abstract-text/9732338/pubmed\" id=\"9732338\" target=\"_blank\">",
"        9732338",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vozeh S, Schmidlin O, and Taeschner W, &ldquo;Pharmacokinetic Drug Data,&rdquo;",
"      <i>",
"       Clin Pharmacokinetics",
"      </i>",
"      , 1988, 15(4):254-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/11/37047/abstract-text/3191648/pubmed\" id=\"3191648\" target=\"_blank\">",
"        3191648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9233 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-201.211.0.116-33F4385FB5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_11_37047=[""].join("\n");
var outline_f36_11_37047=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129226\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129227\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129265\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129230\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129231\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129232\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129233\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129199\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129183\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129203\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129202\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5359979\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129272\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129263\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129206\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129187\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129260\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129192\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129221\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129195\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129209\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129235\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129210\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129211\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129208\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129197\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129212\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129186\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129205\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9233\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9233|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/47/12021?source=related_link\">",
"      Acebutolol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_11_37048="Pain syndromes in autosomal dominant polycystic kidney disease";
var content_f36_11_37048=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pain syndromes in autosomal dominant polycystic kidney disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/11/37048/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/11/37048/contributors\">",
"     Theodore I Steinman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/11/37048/contributors\">",
"     Samir M Parikh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/11/37048/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/11/37048/contributors\">",
"     Ronald D Perrone, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/11/37048/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/11/37048/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/11/37048/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H8112364\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over 60 percent of patients with autosomal dominant polycystic kidney disease (ADPKD) have abdominal and flank pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37048/abstract/1\">",
"     1",
"    </a>",
"    ]. Abdominal pain is typically related to the kidney cysts, but may also be related to liver cysts. Pain may be acute or chronic.",
"   </p>",
"   <p>",
"    Most patients can be effectively treated but a minority develop chronic pain that is debilitating [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37048/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A thorough history provides the best clues to the underlying cause of pain, and radiographic studies are an important adjunct to making the diagnosis. Pain is often not well managed because there is the reflex response of many clinicians to give narcotics for complaints of pain without understanding the etiology.",
"   </p>",
"   <p>",
"    This topic provides an overview of the pathophysiology and common presentations of pain in ADPKD, and a stepwise approach to its initial management, focusing on pain related to the kidneys.",
"   </p>",
"   <p>",
"    The general management and the renal and extrarenal manifestations of ADPKD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/27/27066?source=see_link\">",
"     \"Course and treatment of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30903?source=see_link\">",
"     \"Renal manifestations of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/33/30233?source=see_link\">",
"     \"Extrarenal manifestations of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8112419\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY OF KIDNEY-RELATED PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The kidneys and ureters are densely innervated by sympathetic, parasympathetic, and sensory afferent fibers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37048/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. (",
"    <a class=\"graphic graphic_figure graphicRef57942 \" href=\"mobipreview.htm?39/62/40934\">",
"     figure 1",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    This innervation is extensively cross-connected with nerve fibers to other visceral structures. As a result, pain related to the kidney (as any visceral pain) may be poorly localized and can be associated with nausea due to the proximity of the sensory fibers to the vagus. The pain can also be referred to a distant cutaneous site (resulting in tenderness) since the activated sensory afferent nerves also have receptive fields on the skin in corresponding dermatomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37048/abstract/6\">",
"     6",
"    </a>",
"    ]. As an example, stimulation of the renal pelvis produces pain at the costovertebral angle and can also cause referred pain in the testicle or ovary.",
"   </p>",
"   <p>",
"    Kidney pain may be precipitated by ischemia, inflammation, torsion or traction of the renal pedicle, and distension of the capsule.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8112426\">",
"    <span class=\"h1\">",
"     PAIN SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;ADPKD-associated pain may be acute or chronic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37048/abstract/2\">",
"     2",
"    </a>",
"    ]. Chronic pain is generally due to the enlarged cystic kidneys causing stretching of the capsule or traction on the renal pedicle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37048/abstract/7\">",
"     7",
"    </a>",
"    ]. Mechanical pain may also occur due to enlarging cysts that result in lumbar lordosis. Acute pain may be caused by cyst infection, cyst hemorrhage, and movement of a kidney stone (nephrolithiasis). Acute causes must be excluded in all patients with ADPKD who present with abdominal or flank pain. (See",
"    <a class=\"local\" href=\"#H8112694\">",
"     'Evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8112433\">",
"    <span class=\"h2\">",
"     Acute pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common causes of acute pain are cyst infection, cyst",
"    <span class=\"nowrap\">",
"     rupture/hemorrhage,",
"    </span>",
"    and nephrolithiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37048/abstract/8\">",
"     8",
"    </a>",
"    ]. These conditions may be differentiated to some degree by patterns of pain and associated signs and symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8112440\">",
"    <span class=\"h3\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infected cysts cause the sudden onset of diffuse flank pain that is typically unilateral. Radiation of pain outside of the localized area is uncommon, and the discomfort is not relieved by position change. As with any kidney infection, fever, nausea, malaise and leukocytosis may be present. If the infected cyst is walled off and does not communicate with the urinary tract, the urine sediment may be bland and the urine culture negative. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13561?source=see_link\">",
"     \"Acute uncomplicated cystitis and pyelonephritis in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute pyelonephritis and infected cysts may be difficult to differentiate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37048/abstract/2\">",
"     2",
"    </a>",
"    ]. The diagnosis and management of cyst infection is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/44/4807?source=see_link\">",
"     \"Urinary tract infection in autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8112484\">",
"    <span class=\"h3\">",
"     Cyst rupture/hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ruptured cysts present with the sudden onset of pain that is thought to be due to an acute increase in cyst size with distention of the renal capsule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37048/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients often have point tenderness, in contrast to those with cyst infection who describe diffuse pain. However, mild diffuse flank pain may occur when a superficial cyst ruptures and causes a subcapsular hematoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37048/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Less commonly, patients describe ipsilateral shoulder pain, particularly when an upper pole cyst ruptures and irritates the diaphragm, or acute abdominal pain when a large hepatic or renal cyst rupture involves surrounding viscera [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37048/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 50 percent of ADPKD patients with ruptured cysts have gross hematuria due to the ruptured cyst communicating with the collecting system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37048/abstract/12\">",
"     12",
"    </a>",
"    ]. Episodes of hematuria usually resolve in two to seven days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37048/abstract/2\">",
"     2",
"    </a>",
"    ]. However excessive bleeding can lead to clot formation with urinary tract obstruction and severe renal colic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30903?source=see_link&amp;anchor=H2#H2\">",
"     \"Renal manifestations of autosomal dominant polycystic kidney disease\", section on 'Hematuria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bleeding is typically managed conservatively with intravenous volume repletion, topical heat, and judicious narcotic administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37048/abstract/11,13\">",
"     11,13",
"    </a>",
"    ]. Ureteral stenting is usually not necessary unless obstruction due to clots persists beyond two weeks. Rarely, prolonged and severe bleeding may require percutaneous transarterial embolization or nephrectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37048/abstract/14\">",
"     14",
"    </a>",
"    ]. Embolization itself can cause severe pain related to parenchymal ischemia and can result in loss of kidney function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37048/abstract/15\">",
"     15",
"    </a>",
"    ]. Therefore, this procedure should only be considered in cases of severe intractable bleeding.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     Desmopressin",
"    </a>",
"    (dDAVP) has been used successfully in a few cases of",
"    <span class=\"nowrap\">",
"     protracted/intractable",
"    </span>",
"    bleeding in ADPKD patients with end stage renal disease (ESRD). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/30/10727?source=see_link&amp;anchor=H7704093#H7704093\">",
"     \"Platelet dysfunction in uremia\", section on 'Desmopressin (dDAVP)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute pain may also result from infection, hemorrhage, or less commonly, rupture of hepatic cysts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37048/abstract/16\">",
"     16",
"    </a>",
"    ]. Discussion of the management of cystic liver disease is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/33/30233?source=see_link&amp;anchor=H9#H9\">",
"     \"Extrarenal manifestations of autosomal dominant polycystic kidney disease\", section on 'Hepatic cysts'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/58/8104?source=see_link&amp;anchor=H22#H22\">",
"     \"Diagnosis and management of cystic lesions of the liver\", section on 'Polycystic liver disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8112503\">",
"    <span class=\"h3\">",
"     Nephrolithiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kidney stones occur in approximately 20 to 35 percent of patients with ADPKD, and approximately two-thirds are symptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37048/abstract/12\">",
"     12",
"    </a>",
"    ]. The pathogenesis, diagnosis and management of nephrolithiasis in ADPKD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30903?source=see_link&amp;anchor=H5#H5\">",
"     \"Renal manifestations of autosomal dominant polycystic kidney disease\", section on 'Nephrolithiasis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20266?source=see_link&amp;anchor=H4#H4\">",
"     \"Diagnosis and acute management of suspected nephrolithiasis in adults\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8112540\">",
"    <span class=\"h2\">",
"     Chronic pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic pain is common among patients with ADPKD. In one study, among 171 patients with ADPKD, low back pain and abdominal pain were reported by 71 and 61 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37048/abstract/17\">",
"     17",
"    </a>",
"    ]. Chronic pain is generally caused by cyst enlargement resulting in stretching of the capsule, traction on the renal pedicle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37048/abstract/7\">",
"     7",
"    </a>",
"    ], or mechanical (ie, musculoskeletal) back pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37048/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pain may begin with an acute episode and persist after the cause has been treated, or develop gradually over several years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37048/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A detailed history of pain location, duration, and associated symptoms will help to differentiate pain due to cyst formation from that due to mechanical (musculoskeletal back pain). As an example, patients with mechanical back pain may describe exacerbation of pain with movements that increase the load on involved muscle groups (such as bending forward or to the side, or ambulating). Chronic abdominal pain in an anterior location is generally related to kidney or hepatic cyst formation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8112554\">",
"    <span class=\"h3\">",
"     Renal cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enlarging cysts cause chronic pain by compressing surrounding tissues, placing traction on the renal pedicle, or distending the renal capsule. Although the severity of pain generally correlates with the size of the kidneys, there is often little or no relationship between the severity of pain and the size or number of the kidney cysts: patients with small cysts may have severe pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37048/abstract/2,19\">",
"     2,19",
"    </a>",
"    ]. There is no correlation between kidney function and pain due to cysts; severe pain may occur among patients who have completely normal kidney function and in general pain tends to start early in the course of disease before kidney function begins to decline.",
"   </p>",
"   <p>",
"    Pain related to cyst formation tends to be a steady, nagging discomfort that is exacerbated by walking or prolonged standing. It can also be associated with early satiety, if massive cysts compress the greater curvature of the stomach",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    duodenum.",
"   </p>",
"   <p>",
"    Patients can frequently pinpoint the pain with one finger, which is more often in an abdominal location rather than flank or lumbar. However, in our experience, the location of the pain described by the patient does not always correspond to the largest cyst(s) noted on imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8112590\">",
"    <span class=\"h3\">",
"     Hepatic cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic cysts may contribute to chronic abdominal or flank pain, although early satiety is much more commonly observed than pain among patients with hepatic cysts, in whom the enlarged cystic liver may occupy the entire abdominal cavity. In general early satiety is more common among ADPKD patients who have both renal and hepatic cysts than among those with renal cysts alone. However, severe pain may occur; among affected patients, pain is generally most severe when the patient is erect, tends to be progressive and may be resistant to therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37048/abstract/17\">",
"     17",
"    </a>",
"    ]. The management of hepatic cysts is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/33/30233?source=see_link&amp;anchor=H9#H9\">",
"     \"Extrarenal manifestations of autosomal dominant polycystic kidney disease\", section on 'Hepatic cysts'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/58/8104?source=see_link&amp;anchor=H22#H22\">",
"     \"Diagnosis and management of cystic lesions of the liver\", section on 'Polycystic liver disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1038616317\">",
"    <span class=\"h3\">",
"     Mechanical back pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with ADPKD, musculoskeletal back pain is probably caused by unbalanced or abnormal load on the spine and lumbodorsal muscles created by enlarged abdominal viscera (the kidneys in extreme cases of ADPKD may weigh as much as 3 to 4 kg, in contrast to the normal weight of 0.3 kg in a 70 kg man) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37048/abstract/20\">",
"     20",
"    </a>",
"    ]. Consistent with this hypothesis is the observation of paraspinal muscle group hypertrophy on magnetic resonance imaging in ADPKD patients with back pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37048/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mechanical back pain is insidious in onset and tends to worsen over time. Asymmetric cyst enlargement can lead to lateralization of pain and kyphosis, and the increased abdominal girth due to the enlarged kidneys (and possibly liver) can accentuate lumbar lordosis. These chronic alterations in posture can accelerate the development of degenerative changes in the spine, and may predispose to spinal stenosis, which can further worsen back pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8112694\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to determine the etiology of pain in an individual with ADPKD, since some causes may result in severe systemic illness (such cyst infection with septicemia).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16218241\">",
"    <span class=\"h2\">",
"     Abdominal and/or flank pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of abdominal or back pain in patient ADPKD differs from that of the general population only in the focus on excluding diagnoses that are more prevalent in this population, including renal cyst-related causes (hemorrhage, rupture or infection), pancreatic cysts, hernias, and diverticulitis. The evaluation of abdominal pain in the general population is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/36/19018?source=see_link\">",
"     \"Diagnostic approach to abdominal pain in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/50/41770?source=see_link\">",
"     \"Evaluation of the adult with abdominal pain in the emergency department\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16874?source=see_link\">",
"     \"Differential diagnosis of abdominal pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A systematic history assists in focusing the physical exam and directs the subsequent evaluation, thus may prevent unnecessary investigational and imaging studies. The history should elicit the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Location and radiation of pain",
"     </li>",
"     <li>",
"      Quality of pain",
"     </li>",
"     <li>",
"      Rapidity of onset",
"     </li>",
"     <li>",
"      Frequency, intensity and duration of pain",
"     </li>",
"     <li>",
"      Associated symptoms and abnormalities (eg, hematuria, fever)",
"     </li>",
"     <li>",
"      Precipitating and relieving factors",
"     </li>",
"     <li>",
"      Effect of activity or position on pain",
"     </li>",
"     <li>",
"      Relationship with food (eg, early satiety)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The physical exam should be directed at excluding causes of acute illness such as pyelonephritis, and can be focused on the region affected by the pain. The temperature and pulse should be obtained, and the presence of diffuse or localized abdominal or flank tenderness, or musculoskeletal pain, should be determined. The comprehensive evaluation of patients with abdominal pain, back pain and headache are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/24/40323?source=see_link\">",
"     \"History and physical examination in adults with abdominal pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/10/18601?source=see_link\">",
"     \"Approach to the diagnosis and evaluation of low back pain in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34615?source=see_link\">",
"     \"Evaluation of headache in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A urinalysis and urine culture with antimicrobial susceptibility testing should be performed; these tests may distinguish between acute pyelonephritis versus cyst infection and rupture and nephrolithiasis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/44/4807?source=see_link&amp;anchor=H4#H4\">",
"     \"Urinary tract infection in autosomal dominant polycystic kidney disease\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with leukocyturia and a positive urine culture in the setting of acute flank pain are presumed to have pyelonephritis or cyst infection and should be treated with appropriate antibiotics. Standard radiologic imaging is generally not useful in this setting given its lack of specificity for cyst infection among patients with ADPKD. Although PET scans may be more accurate in identifying cyst infections among such patients, PET scans are generally not performed unless patients are severely ill and other imaging modalities are ineffective or cannot be performed. The imaging and management of presumed cyst infections is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/44/4807?source=see_link&amp;anchor=H6#H6\">",
"     \"Urinary tract infection in autosomal dominant polycystic kidney disease\", section on 'Antimicrobial therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients who do not have leukocyturia, imaging tests (ultrasound or non-contrast computed tomography (CT)) are usually performed. A noncontrast CT is more sensitive for the detection of nephrolithiasis and is generally the preferred test for patients with ADPKD and acute onset flank or abdominal pain. A noncontrast CT will not differentiate between cyst infection and hemorrhage however.",
"   </p>",
"   <p>",
"    Once acute causes of pain are excluded, the patient may be presumed to have chronic pain associated with cyst enlargement. (See",
"    <a class=\"local\" href=\"#H8112540\">",
"     'Chronic pain'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16218248\">",
"    <span class=\"h2\">",
"     Back pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of back pain is complex and requires a thorough evaluation that is not different from the general population. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/28/1480?source=see_link\">",
"     \"Lumbar spinal stenosis: Pathophysiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with chronic pain suspected to be of musculoskeletal origin, who do not have associated symptoms, part of the evaluation may include a trial of simple pain management techniques, which may prove to be diagnostic. (See",
"    <a class=\"local\" href=\"#H8112916\">",
"     'Physical maneuvers'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Among ADPKD patients who have chronic back pain, MRI may reveal evidence of",
"    <span class=\"nowrap\">",
"     paraspinal/lumbodorsal",
"    </span>",
"    muscle hypertrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37048/abstract/11\">",
"     11",
"    </a>",
"    ]. However MRI is generally NOT done for this indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16218195\">",
"    <span class=\"h2\">",
"     Recurrent pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain may recur, especially several months after back exercises are discontinued. Recurrent pain may also be related to continuous cyst growth. Generally the pattern of pain is similar to the initial presentation and repeat imaging is not necessary. The onset of a different pattern of pain or new associated symptoms may warrant further investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8112795\">",
"    <span class=\"h1\">",
"     PAIN MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The focus of this section is on the noninvasive management of pain related to cyst enlargement and possibly associated mechanical back pain. Surgical interventions to treat ADPKD-related abdominal and flank pain are discussed elsewhere.",
"   </p>",
"   <p>",
"    The management of kidney infection and nephrolithiasis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/44/4807?source=see_link\">",
"     \"Urinary tract infection in autosomal dominant polycystic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30903?source=see_link&amp;anchor=H5#H5\">",
"     \"Renal manifestations of autosomal dominant polycystic kidney disease\", section on 'Nephrolithiasis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20266?source=see_link\">",
"     \"Diagnosis and acute management of suspected nephrolithiasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no trials to provide guidance regarding the optimal management of chronic pain in the setting of enlarging cystic kidneys, and most of the approaches described in this section are standard pain clinic management strategies. These pain management options should be pursued in a sequential fashion, building from low-risk maneuvers and medications for mild intermittent pain, to more complex medication regimens and physical or invasive interventions for moderate to severe chronic pain. Invasive interventions are rarely required.",
"   </p>",
"   <p>",
"    As with the management of chronic pain of any cause, establishing a good rapport with the patient is important. This requires a nonjudgmental attitude on the part of the provider, particularly since pain cannot be objectively measured. We emphasize to our patients that chronic pain often cannot be \"cured\"; rather, the goal is to adequately control pain in order to reduce interference with the desired lifestyle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8112908\">",
"    <span class=\"h2\">",
"     Noninvasive approaches",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8112916\">",
"    <span class=\"h3\">",
"     Physical maneuvers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among ADPKD patients with chronic back pain, it is critical to maintain mobility, which may be done with physical therapy. If pain is sufficiently severe to limit the efficacy of physical therapy, concomitant medical therapy is indicated. Otherwise a step-wise approach beginning with physical therapy is appropriate.",
"   </p>",
"   <p>",
"    There are a variety of physical interventions, which have not been formally evaluated for the treatment of pain associated with ADPKD, but are relatively free of risk if appropriately performed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/24/19850?source=see_link&amp;anchor=H15#H15\">",
"     \"Subacute and chronic low back pain: Pharmacologic and noninterventional treatment\", section on 'Activity and physical treatments'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For mechanical back pain:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ice massage and heating pads, which may be particularly beneficial for muscle spasms.",
"     </li>",
"     <li>",
"      Psychophysical methods to improve body posture and mechanics, such as the Alexander technique [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/11/37048/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. The Alexander technique involves individualized, hands-on instruction to improve balance, posture, and coordination, as well as recognition of harmful habits of muscle use in order to avoid painful movements. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/43/6841?source=see_link&amp;anchor=H10#H10\">",
"       \"Exercise-based therapy for low back pain\", section on 'Alexander technique'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For pain possibly related to enlarged kidneys pulling on the renal pedicle, wearing a support garment or corset may provide relief.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8112935\">",
"    <span class=\"h3\">",
"     Non-narcotic analgesics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of acute pain among ADPKD patients depends in part upon the underlying estimated glomerular filtration rate (eGFR). Among patients with a normal eGFR, we use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    , alone or in combination. NSAIDs or COX-2 inhibitors may be used for a maximum of five to seven days, and we generally avoid these medications in patients at risk for NSAID- or COX-2 inhibitor-associated acute kidney injury (such as those over age 65 years, with concurrent heart failure, or on either diuretics or renin-angiotensin system inhibitors) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37048/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24582?source=see_link\">",
"     \"NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13066?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of selective COX-2 inhibitors\", section on 'Acute renal failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with reduced eGFR, we usually treat pain with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , given its relatively low toxicity profile. Dosing can start at 650 mg every 6 hours and be increased to 1000 mg every six hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37048/abstract/24\">",
"     24",
"    </a>",
"    ]. However, concomitant chronic alcohol consumption may lead to acetaminophen toxicity with this regimen, thus alcohol drinking must be limited or this regimen should not used in heavy alcohol users [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37048/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/43/25274?source=see_link&amp;anchor=H5#H5\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis\", section on 'Clinical factors influencing toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients who have a reduced eGFR and pain that is not adequately relieved by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , we use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    . For patients with eGFR &gt;30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2, we suggest a dose of 50 to 100 mg every four to six hours. The dose should be adjusted for patients with eGFR &le;30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m2.",
"   </p>",
"   <p>",
"    For patients with reduced eGFR who cannot take or do not respond to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    , we use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    . We begin at 0.1",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and titrate upward over several weeks as tolerated in order to achieve pain control.",
"   </p>",
"   <p>",
"    When added to a local anesthetic for epidural, spinal, or peripheral blockade,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    can prolong and intensify anesthesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37048/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Oral or transdermal clonidine preparations may also be useful as adjuncts to narcotics for moderate pain, permitting modest dose reduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37048/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. Clonidine may be safely given with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    . Patients who are on clonidine should be observed closely for hypotension, or, if medication is abruptly withdrawn, hypertension.",
"   </p>",
"   <p>",
"    Anecdotal reports have suggested that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    may be useful for the treatment of chronic pain, although there are no controlled studies that have been conducted in the ADPKD population using this pain medication for pain relief. Dose reduction of gabapentin is required for patients with reduced eGFR. Tricyclic antidepressants may also be useful adjuncts to help control pain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8112988\">",
"    <span class=\"h3\">",
"     Opioids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Narcotic analgesics may be required for the management of acute moderate to severe pain. Opioids may be more effective when used in combination with other analgesic medications, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    . In patients with elevated serum creatinine, opioid drugs must be dosed less frequency to avoid accumulation of active metabolites, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/44/11976?source=see_link\">",
"     meperidine",
"    </a>",
"    completely avoided. A general overview of opioid use and cautions with renal impairment are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=see_link&amp;anchor=H19#H19\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\", section on 'Use in renal failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intractable chronic pain can be treated with either long-acting oral or transdermal agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    patch).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8113023\">",
"    <span class=\"h3\">",
"     Other interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not specifically studied in patients with ADPKD, a variety of other approaches have been used for the management of chronic pain, particularly neuropathic or chronic back pain, or visceral pain due to intraabdominal cancers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/38/21098?source=see_link&amp;anchor=H380437018#H380437018\">",
"     \"Cancer pain management: Interventional therapies\", section on 'Analgesic and anesthetic nerve blocks'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These interventions may provide temporary benefit, and can be tried in patients with chronic pain that persists despite medical therapy, particularly in those settings where surgery does not offer a possible curative result (eg, cyst decompression) or is an extreme measure (eg, nephrectomy).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Transcutaneous electrical nerve stimulation (TENS)",
"      </strong>",
"      &mdash; In our experience, some ADPKD patients with chronic, dull pain may benefit from intermittent TENS, although clinical trials in chronic back pain have not consistently shown benefit. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/24/19850?source=see_link&amp;anchor=H31#H31\">",
"       \"Subacute and chronic low back pain: Pharmacologic and noninterventional treatment\", section on 'Transcutaneous electrical nerve stimulation'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      We suggest a two-week trial of TENS; patients who respond to TENS may use it long term with few side effects.",
"     </li>",
"     <li>",
"      <strong>",
"       Acupuncture",
"      </strong>",
"      &mdash; A trial of acupuncture is warranted in ADPKD-related pain as effectiveness has been demonstrated in the management of renal colic [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/11/37048/abstract/31\">",
"       31",
"      </a>",
"      ] and lithotripsy-related pain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/11/37048/abstract/32\">",
"       32",
"      </a>",
"      ]. Acupuncture performed by an experienced operator is associated with minimal risk.",
"     </li>",
"     <li>",
"      <strong>",
"       Spinal cord stimulation",
"      </strong>",
"      &mdash; Spinal cord stimulation may be beneficial in selected patients with moderate to severe intractable mechanical back pain or visceral pain due to cyst enlargement. This requires implantation of a device that precludes future magnetic resonance imaging (MRI) studies.",
"     </li>",
"     <li>",
"      <strong>",
"       Celiac plexus blockade",
"      </strong>",
"      &mdash; Since both the sympathetic and parasympathetic supply to the kidney pass through the celiac plexus, celiac plexus blockade may be of benefit in the treatment of visceral pain due to cyst enlargement.",
"     </li>",
"     <li>",
"      <strong>",
"       Neuraxial medications",
"      </strong>",
"      &mdash; Opioids and local anesthetics can be administered directly into the epidural or intrathecal space, and may be useful in the management of mechanical back pain. However, dose-dependent side effects include motor blockade and urinary retention, and long term use may result in tolerance and even hyperalgesia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/11/37048/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8113083\">",
"    <span class=\"h2\">",
"     Invasive management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients experience substantial pain relief with non-invasive management. However, pain recurrence is common, and surgical intervention may be required if the pain is persistent or disabling, or controlled only with opiates. Surgical options for the treatment of persistent pain due to enlarged kidney and hepatic cysts are discussed elsewhere.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8114047\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain in the flank and abdomen is common among patients with autosomal dominant polycystic kidney disease (ADPKD). Acute pain suggests a superimposed condition such as cyst hemorrhage or infection, or nephrolithiasis. Chronic pain is generally due to the enlarged cystic kidneys causing stretching of the capsule or traction on the renal pedicle, mechanical back pain, or hepatic cyst enlargement. (See",
"      <a class=\"local\" href=\"#H8112364\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8112426\">",
"       'Pain syndromes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8112590\">",
"       'Hepatic cysts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A systematic history helps to focus the physical examination and directs the work-up. A urinalysis is particularly useful in the investigation of acute abdominal or flank pain. Imaging tests are performed if the cause of pain remains unclear after the history, comprehensive physical examination and urinalysis. (See",
"      <a class=\"local\" href=\"#H8112694\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no trials to provide guidance regarding the optimal management of chronic pain in the setting of enlarging cystic kidneys or liver. We use standard pain clinic management strategies that are modified for patients with potentially reduced kidney function. For most ADPKD patients with acute or chronic pain we suggest the following approach: (see",
"      <a class=\"local\" href=\"#H8112795\">",
"       'Pain management'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For the initial management of pain possibly related to cystic kidney enlargement or mechanical back pain, we suggest a trial of physical interventions. (See",
"      <a class=\"local\" href=\"#H8112916\">",
"       'Physical maneuvers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the treatment of pain in patients with normal kidney function, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/50/42792?source=see_link\">",
"       tramadol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      , alone or in combination. NSAIDs or COX-2 inhibitors may be used for a maximum of five to seven days, although we generally avoid these medications in patients at risk for NSAID- or COX-2 inhibitor-associated acute kidney injury (such as those over age 65 years, with concurrent heart failure, or on either diuretics or renin-angiotensin system inhibitors). (See",
"      <a class=\"local\" href=\"#H8112935\">",
"       'Non-narcotic analgesics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the treatment of pain in patients with reduced estimated glomerular filtration rate (eGFR), we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      , given its relatively low toxicity profile. High-dose acetaminophen should not be used in heavy alcohol drinkers. For persistent pain, we suggest adding",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/50/42792?source=see_link\">",
"       tramadol",
"      </a>",
"      to acetaminophen. The preferred dose among patients with eGFR &gt;30",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 is 50 to 100 mg every four to six hours. The dose should be reduced among patients with eGFR &le;30",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2. Oral or transdermal",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      may also be used if tramadol is ineffective. We administer clonidine 0.1",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      and titrate the dose upward over several weeks. Clonidine may be safely given with acetaminophen or tramadol. Patients who are on clonidine should be observed closely for hypotension, or, if medication is abruptly withdrawn, hypertension. (See",
"      <a class=\"local\" href=\"#H8112935\">",
"       'Non-narcotic analgesics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Narcotic analgesics may be required to treat moderate to severe pain that is unresponsive to other measures. In patients with elevated serum creatinine, opioid drugs must be dosed less frequency to avoid accumulation of active metabolites, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/44/11976?source=see_link\">",
"       meperidine",
"      </a>",
"      completely avoided. (See",
"      <a class=\"local\" href=\"#H8112988\">",
"       'Opioids'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=see_link&amp;anchor=H19#H19\">",
"       \"Cancer pain management with opioids: Optimizing analgesia\", section on 'Use in renal failure'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although not specifically studied in patients with ADPKD, a variety of other interventions have been used for the management of chronic pain. These are associated with little risk and can be tried in patients with chronic pain that persists despite medical therapy. (See",
"      <a class=\"local\" href=\"#H8113023\">",
"       'Other interventions'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Surgical intervention may be employed for patients with persistent pain despite an adequate trial of medical and noninvasive therapies. (See",
"      <a class=\"local\" href=\"#H8113083\">",
"       'Invasive management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37048/abstract/1\">",
"      Gabow PA. Autosomal dominant polycystic kidney disease--more than a renal disease. Am J Kidney Dis 1990; 16:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37048/abstract/2\">",
"      Hogan MC, Norby SM. Evaluation and management of pain in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis 2010; 17:e1.",
"     </a>",
"    </li>",
"    <li>",
"     Ansell, J, Gee, W, Bonica, J. Chapter 62: Diseases of the kidney and ureter. Management of Pain. ed Bonica J (Philadelphia: Lea &amp; Febiger) 1990; 2nd edition, volume 2:1232.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37048/abstract/4\">",
"      Ammons WS. Renal afferent input to thoracolumbar spinal neurons of the cat. Am J Physiol 1986; 250:R435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37048/abstract/5\">",
"      Ammons WS. Bowditch Lecture. Renal afferent inputs to ascending spinal pathways. Am J Physiol 1992; 262:R165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37048/abstract/6\">",
"      Nam TS, Baik EJ, Shin YU, et al. Mechanism of transmission and modulation of renal pain in cats; effects of transcutaneous electrical nerve stimulation on renal pain. Yonsei Med J 1995; 36:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37048/abstract/7\">",
"      Gabow PA. Autosomal dominant polycystic kidney disease. N Engl J Med 1993; 329:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37048/abstract/8\">",
"      Gibson P, Watson ML. Cyst infection in polycystic kidney disease: a clinical challenge. Nephrol Dial Transplant 1998; 13:2455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37048/abstract/9\">",
"      Ravich L, Lerman PH, Drabkin J. Ruptured renal cyst in polycystic disease. Urology 1976; 7:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37048/abstract/10\">",
"      Carels RA, van Bommel EF. Ruptured giant liver cyst: a rare cause of acute abdomen in a haemodialysis patient with autosomal dominant polycystic kidney disease. Neth J Med 2002; 60:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37048/abstract/11\">",
"      Bajwa ZH, Gupta S, Warfield CA, Steinman TI. Pain management in polycystic kidney disease. Kidney Int 2001; 60:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37048/abstract/12\">",
"      Delaney VB, Adler S, Bruns FJ, et al. Autosomal dominant polycystic kidney disease: presentation, complications, and prognosis. Am J Kidney Dis 1985; 5:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37048/abstract/13\">",
"      Bennett WM, Elzinga LW, Barry JM. Polycystic kidney disease: II. Diagnosis and management. Hosp Pract (Off Ed) 1992; 27:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37048/abstract/14\">",
"      Ubara Y, Katori H, Tagami T, et al. Transcatheter renal arterial embolization therapy on a patient with polycystic kidney disease on hemodialysis. Am J Kidney Dis 1999; 34:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37048/abstract/15\">",
"      Tarrass F, Benjelloun M. Acute abdomen caused by spontaneous renal cyst rupture in an ADPKD haemodialysed patient. Nephrology (Carlton) 2008; 13:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37048/abstract/16\">",
"      Chauveau D, Fakhouri F, Gr&uuml;nfeld JP. Liver involvement in autosomal-dominant polycystic kidney disease: therapeutic dilemma. J Am Soc Nephrol 2000; 11:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37048/abstract/17\">",
"      Bajwa ZH, Sial KA, Malik AB, Steinman TI. Pain patterns in patients with polycystic kidney disease. Kidney Int 2004; 66:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37048/abstract/18\">",
"      Milutinovic J, Fialkow PJ, Agodoa LY, et al. Autosomal dominant polycystic kidney disease: symptoms and clinical findings. Q J Med 1984; 53:511.",
"     </a>",
"    </li>",
"    <li>",
"     Segura, JW, King, BF, Jowsey, SG. Chronic pain and its medical and surgical management in renal cystuc diseases. In: Polycystic Kidney Disease, Watson, ML, Torres, VE (Eds), Oxford University Press, Oxford 1996. p.462.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37048/abstract/20\">",
"      Grantham JJ, Torres VE, Chapman AB, et al. Volume progression in polycystic kidney disease. N Engl J Med 2006; 354:2122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37048/abstract/21\">",
"      Ernst E, Canter PH. The Alexander technique: a systematic review of controlled clinical trials. Forsch Komplementarmed Klass Naturheilkd 2003; 10:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37048/abstract/22\">",
"      Maher CG. Effective physical treatment for chronic low back pain. Orthop Clin North Am 2004; 35:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37048/abstract/23\">",
"      de Mattos AM, Olyaei AJ, Bennett WM. Pharmacology of immunosuppressive medications used in renal diseases and transplantation. Am J Kidney Dis 1996; 28:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37048/abstract/24\">",
"      Henrich WL, Agodoa LE, Barrett B, et al. Analgesics and the kidney: summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the National Kidney Foundation. Am J Kidney Dis 1996; 27:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37048/abstract/25\">",
"      Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA 1994; 272:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37048/abstract/26\">",
"      Eisenach JC, De Kock M, Klimscha W. alpha(2)-adrenergic agonists for regional anesthesia. A clinical review of clonidine (1984-1995). Anesthesiology 1996; 85:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37048/abstract/27\">",
"      Tryba M, Gehling M. Clonidine--a potent analgesic adjuvant. Curr Opin Anaesthesiol 2002; 15:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37048/abstract/28\">",
"      Smith H, Elliott J. Alpha(2) receptors and agonists in pain management. Curr Opin Anaesthesiol 2001; 14:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37048/abstract/29\">",
"      Dimou P, Paraskeva A, Papilas K, Fassoulaki A. Transdermal clonidine: does it affect pain after abdominal hysterectomy? Acta Anaesthesiol Belg 2003; 54:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37048/abstract/30\">",
"      Goyagi T, Tanaka M, Nishikawa T. Oral clonidine premedication enhances postoperative analgesia by epidural morphine. Anesth Analg 1999; 89:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37048/abstract/31\">",
"      Lee YH, Lee WC, Chen MT, et al. Acupuncture in the treatment of renal colic. J Urol 1992; 147:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37048/abstract/32\">",
"      Resim S, Gumusalan Y, Ekerbicer HC, et al. Effectiveness of electro-acupuncture compared to sedo-analgesics in relieving pain during shockwave lithotripsy. Urol Res 2005; 33:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37048/abstract/33\">",
"      Osenbach RK, Harvey S. Neuraxial infusion in patients with chronic intractable cancer and noncancer pain. Curr Pain Headache Rep 2001; 5:241.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14015 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-7DB0BEB7E6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_11_37048=[""].join("\n");
var outline_f36_11_37048=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8114047\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8112364\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8112419\">",
"      PATHOPHYSIOLOGY OF KIDNEY-RELATED PAIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8112426\">",
"      PAIN SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8112433\">",
"      Acute pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8112440\">",
"      - Infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8112484\">",
"      - Cyst rupture/hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8112503\">",
"      - Nephrolithiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8112540\">",
"      Chronic pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8112554\">",
"      - Renal cysts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8112590\">",
"      - Hepatic cysts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1038616317\">",
"      - Mechanical back pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8112694\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16218241\">",
"      Abdominal and/or flank pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16218248\">",
"      Back pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16218195\">",
"      Recurrent pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8112795\">",
"      PAIN MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8112908\">",
"      Noninvasive approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8112916\">",
"      - Physical maneuvers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8112935\">",
"      - Non-narcotic analgesics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8112988\">",
"      - Opioids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8113023\">",
"      - Other interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8113083\">",
"      Invasive management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8114047\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/14015\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/14015|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/62/40934\" title=\"figure 1\">",
"      Innervation of the kidney",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/43/25274?source=related_link\">",
"      Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13561?source=related_link\">",
"      Acute uncomplicated cystitis and pyelonephritis in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/10/18601?source=related_link\">",
"      Approach to the diagnosis and evaluation of low back pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=related_link\">",
"      Cancer pain management with opioids: Optimizing analgesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/38/21098?source=related_link\">",
"      Cancer pain management: Interventional therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/27/27066?source=related_link\">",
"      Course and treatment of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20266?source=related_link\">",
"      Diagnosis and acute management of suspected nephrolithiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/58/8104?source=related_link\">",
"      Diagnosis and management of cystic lesions of the liver",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/36/19018?source=related_link\">",
"      Diagnostic approach to abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16874?source=related_link\">",
"      Differential diagnosis of abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34615?source=related_link\">",
"      Evaluation of headache in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/50/41770?source=related_link\">",
"      Evaluation of the adult with abdominal pain in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/43/6841?source=related_link\">",
"      Exercise-based therapy for low back pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/33/30233?source=related_link\">",
"      Extrarenal manifestations of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/24/40323?source=related_link\">",
"      History and physical examination in adults with abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/28/1480?source=related_link\">",
"      Lumbar spinal stenosis: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24582?source=related_link\">",
"      NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13066?source=related_link\">",
"      Overview of selective COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42778?source=related_link\">",
"      Overview of the treatment of chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/30/10727?source=related_link\">",
"      Platelet dysfunction in uremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30903?source=related_link\">",
"      Renal manifestations of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/24/19850?source=related_link\">",
"      Subacute and chronic low back pain: Pharmacologic and noninterventional treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/44/4807?source=related_link\">",
"      Urinary tract infection in autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_11_37049="Congenital syphilis: Evaluation, management, and prevention";
var content_f36_11_37049=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Congenital syphilis: Evaluation, management, and prevention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/11/37049/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/11/37049/contributors\">",
"     Simon R Dobson, MD, FRCP(C)",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/11/37049/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/11/37049/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/11/37049/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/11/37049/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/11/37049/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/11/37049/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H12404245\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital syphilis occurs when the spirochete",
"    <em>",
"     Treponema pallidum",
"    </em>",
"    is transmitted from a pregnant woman to her fetus. Infection can result in stillbirth, prematurity, or a wide spectrum of clinical manifestations; only severe cases are clinically apparent at birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evaluation, management, and prevention of congenital syphilis will be discussed here. The clinical features and diagnosis of congenital syphilis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/31/17914?source=see_link\">",
"     \"Congenital syphilis: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Syphilis in pregnancy and acquired syphilis also are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/61/4057?source=see_link\">",
"       \"Syphilis in pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/55/12150?source=see_link\">",
"       \"Pathophysiology, transmission, and natural history of syphilis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/9/37017?source=see_link\">",
"       \"Pathogenesis, clinical manifestations, and treatment of early syphilis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/48/776?source=see_link\">",
"       \"Pathogenesis, clinical manifestations, and treatment of late syphilis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/44/26312?source=see_link\">",
"       \"Neurosyphilis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/44/39624?source=see_link\">",
"       \"Diagnostic testing for syphilis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/25/18837?source=see_link\">",
"       \"Laboratory monitoring of patients undergoing treatment for syphilis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21000446\">",
"    <span class=\"h1\">",
"     EVALUATION AND MANAGEMENT OF INFANTS &lt;1 MONTH OF AGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vagaries of the maternal history of syphilis and signs or lack of signs in the newborn in combination with the potential consequences of delayed or missed diagnosis of congenital syphilis demand a &ldquo;safety first&rdquo; approach to both diagnosis and treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/2\">",
"     2",
"    </a>",
"    ]. The US Centers for Disease Control and Prevention (CDC) and the American Academy of Pediatrics Committee on Infectious Diseases (AAP) provide guidelines for the evaluation and management of congenital syphilis (",
"    <a class=\"graphic graphic_algorithm graphicRef51559 \" href=\"mobipreview.htm?21/62/22499\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef80812 \" href=\"mobipreview.htm?20/42/21166\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21000461\">",
"    <span class=\"h2\">",
"     Initial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of congenital syphilis should be suspected in all infants whose mothers have reactive nontreponemal and treponemal tests for syphilis; the treponemal test is necessary to exclude a false-positive nontreponemal result. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/61/4057?source=see_link&amp;anchor=H13#H13\">",
"     \"Syphilis in pregnancy\", section on 'Serologic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial evaluation of infants born to mothers who have reactive nontreponemal and treponemal test results should include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A quantitative nontreponemal test (Venereal Disease Research Laboratory test [VDRL] or rapid plasma reagin [RPR]) on infant serum; testing umbilical cord blood could yield a false positive result if the cord blood is contaminated with maternal blood. The nontreponemal test that is performed on the infant should be the same as that which was done on the mother so that the infant&rsquo;s titers can be compared with the mother&rsquo;s titers.",
"     </li>",
"     <li>",
"      Physical examination for evidence of congenital syphilis (",
"      <a class=\"graphic graphic_table graphicRef67809 \" href=\"mobipreview.htm?10/17/10526\">",
"       table 2",
"      </a>",
"      ) and darkfield microscopic examination (",
"      <a class=\"graphic graphic_picture graphicRef72322 \" href=\"mobipreview.htm?19/58/20399\">",
"       picture 1",
"      </a>",
"      ) or direct fluorescent antibody (DFA) staining of suspicious lesions or body fluids (eg, nasal discharge). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/31/17914?source=see_link&amp;anchor=H28809272#H28809272\">",
"       \"Congenital syphilis: Clinical features and diagnosis\", section on 'Early congenital syphilis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/31/17914?source=see_link&amp;anchor=H18050031#H18050031\">",
"       \"Congenital syphilis: Clinical features and diagnosis\", section on 'Diagnostic tests'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pathologic examination of the placenta or umbilical cord with specific fluorescent antitreponemal antibody staining",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional evaluation depends upon the findings from the initial evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21000468\">",
"    <span class=\"h2\">",
"     Subsequent evaluation and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The subsequent evaluation depends upon clinical, serologic, and epidemiologic factors, including (",
"    <a class=\"graphic graphic_algorithm graphicRef51559 \" href=\"mobipreview.htm?21/62/22499\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef80812 \" href=\"mobipreview.htm?20/42/21166\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The neonate&rsquo;s syphilis serology (nonreactive or reactive; and if reactive, whether the infant&rsquo;s titer is at least fourfold [two dilutions] higher than the corresponding maternal titer)",
"     </li>",
"     <li>",
"      The mother&rsquo;s risk factors for syphilis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/61/4057?source=see_link&amp;anchor=H3#H3\">",
"       \"Syphilis in pregnancy\", section on 'Incidence and epidemiology'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The mother&rsquo;s syphilis serology (in relation to previous tests",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      treatment and in relation to the neonate&rsquo;s titers)",
"     </li>",
"     <li>",
"      If the mother has been treated for syphilis:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The timing of the treatment (before or during pregnancy; more or less than four weeks before delivery)",
"     </li>",
"     <li>",
"      The adequacy of therapy (",
"      <a class=\"graphic graphic_table graphicRef73418 \" href=\"mobipreview.htm?0/11/188\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The likelihood of failure of maternal therapy to prevent congenital disease (higher maternal titers and unknown duration of maternal syphilis are associated with failure of maternal therapy to prevent congenital disease) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/5\">",
"       5",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21000475\">",
"    <span class=\"h3\">",
"     Proven or highly probable disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital syphilis is proven or highly probable if the infant has at least one of the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An abnormal physical examination that is consistent with congenital syphilis (",
"      <a class=\"graphic graphic_table graphicRef67809 \" href=\"mobipreview.htm?10/17/10526\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      A serum VDRL or RPR titer that is &ge;fourfold the corresponding maternal titer (eg, neonate&rsquo;s titer 1:32 and maternal titer 1:8)",
"     </li>",
"     <li>",
"      A positive darkfield (",
"      <a class=\"graphic graphic_picture graphicRef72322 \" href=\"mobipreview.htm?19/58/20399\">",
"       picture 1",
"      </a>",
"      ) or fluorescent antibody test of body fluid(s), placenta, or umbilical cord",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infants with proven or highly probable congenital syphilis should undergo the following evaluation (",
"    <a class=\"graphic graphic_algorithm graphicRef51559 \" href=\"mobipreview.htm?21/62/22499\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef80812 \" href=\"mobipreview.htm?20/42/21166\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cerebrospinal fluid (CSF) examination for cell count, protein, and VDRL",
"     </li>",
"     <li>",
"      Complete blood count (CBC) with differential and platelet count",
"     </li>",
"     <li>",
"      Additional tests as clinically indicated: long-bone radiographs (for lack of movement of extremity), chest radiograph (for signs of lower respiratory tract disease), liver function tests (for hepatomegaly, jaundice), cranial ultrasound (for neurologic manifestations), ophthalmologic examination, and auditory brainstem response (for concerns about hearing)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We recommend that infants with proven or highly probable congenital syphilis be treated with 10 days of parenteral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/46/14054?source=see_link\">",
"     penicillin G",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H21001160\">",
"     'Ten-day regimens'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    To prevent long-term morbidity, central nervous system syphilis is presumed in neonates with clinical, radiographic, or laboratory abnormalities compatible with syphilis. Although CSF results do not alter the treatment, examination of the CSF is necessary to determine the need for subsequent monitoring and to provide a baseline for monitoring the response to therapy. (See",
"    <a class=\"local\" href=\"#H21003190\">",
"     'CSF evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21000482\">",
"    <span class=\"h3\">",
"     At-risk neonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants born to women with syphilis or a history of syphilis remain &ldquo;at risk&rdquo; for syphilis even if the infant has a normal physical examination and VDRL or RPR that is nonreactive or less than fourfold the maternal titer (eg, neonate&rsquo;s titer 1:8 and maternal titer 1:16). The evaluation and treatment of at-risk neonates varies depending upon the mother&rsquo;s history of syphilis and syphilis treatment and the treatment plan for the infant (",
"    <a class=\"graphic graphic_algorithm graphicRef51559 \" href=\"mobipreview.htm?21/62/22499\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef80812 \" href=\"mobipreview.htm?20/42/21166\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21000490\">",
"    <span class=\"h4\">",
"     Infant VDRL or RPR nonreactive",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neonate who has a normal physical examination and nonreactive VDRL or RPR does not require additional evaluation (",
"    <a class=\"graphic graphic_algorithm graphicRef51559 \" href=\"mobipreview.htm?21/62/22499\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef80812 \" href=\"mobipreview.htm?20/42/21166\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Such infants require treatment if the mother was not treated, was",
"    <span class=\"nowrap\">",
"     inadequately/suboptimally",
"    </span>",
"    treated (",
"    <a class=\"graphic graphic_table graphicRef73418 \" href=\"mobipreview.htm?0/11/188\">",
"     table 3",
"    </a>",
"    ), or has evidence of reinfection or relapse (indicated by &ge;fourfold increase in titers after treatment)",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/4\">",
"     4",
"    </a>",
"    ]. Some experts would also opt to treat such infants even if their mothers were adequately treated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/2,3,6\">",
"     2,3,6",
"    </a>",
"    ]. Our preference is to treat such infants whose mothers were adequately treated because a single dose of penicillin is relatively benign compared with the risk of missed disease. (See",
"    <a class=\"local\" href=\"#H21001153\">",
"     'Single-dose regimen'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Treatment for neonates with nonreactive VDRL or RPR and normal physical examination generally consists of a single dose of intramuscular (IM) benzathine penicillin. (See",
"    <a class=\"local\" href=\"#H21001153\">",
"     'Single-dose regimen'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21000497\">",
"    <span class=\"h4\">",
"     Mother not treated or inadequately treated",
"    </span>",
"    &nbsp;&mdash;&nbsp;The likelihood of congenital",
"    <em>",
"     T. pallidum",
"    </em>",
"    infection is increased if the mother was not treated or inadequately treated, and such infants are presumed to have congenital syphilis (",
"    <a class=\"graphic graphic_table graphicRef73418 \" href=\"mobipreview.htm?0/11/188\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. For neonates who have a normal physical examination, reactive VDRL or RPR &lt;fourfold the maternal titer, and whose mothers were not treated or were inadequately treated, the CDC and AAP recommend the following evaluation (",
"    <a class=\"graphic graphic_algorithm graphicRef51559 \" href=\"mobipreview.htm?21/62/22499\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef80812 \" href=\"mobipreview.htm?20/42/21166\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      CSF VDRL, cell count, and protein",
"     </li>",
"     <li>",
"      CBC with differential and platelet count",
"     </li>",
"     <li>",
"      Other tests as clinically indicated (eg, chest radiographs, long-bone radiographs, eye examination, liver function tests, neuroimaging, and auditory brainstem response)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We recommend a full 10-day course of parenteral penicillin if any part of the evaluation is abnormal or not performed, or if the CSF examination cannot be interpreted because it is contaminated with blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21001160\">",
"     'Ten-day regimens'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The neonate may be treated with a single dose of IM benzathine penicillin if all three tests are performed, the results are normal, and follow-up of the infant is assured [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21001153\">",
"     'Single-dose regimen'",
"    </a>",
"    below.) Nonetheless, many experts prefer to treat such infants with a full 10-day course, particularly if the mother has secondary syphilis at delivery or seroconverted during the pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21001160\">",
"     'Ten-day regimens'",
"    </a>",
"    below.) Our preference is for the 10-day course. For infants who will be treated with a 10-day course of penicillin, complete evaluation is not necessary but may help to establish the diagnosis and need for long-term CSF follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21003190\">",
"     'CSF evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21000504\">",
"    <span class=\"h4\">",
"     Mother adequately treated during pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;No additional evaluation is necessary for the asymptomatic neonate with reactive serology whose mother was treated",
"    <strong>",
"     during",
"    </strong>",
"    pregnancy, provided that all of the following criteria are met (",
"    <a class=\"graphic graphic_algorithm graphicRef51559 \" href=\"mobipreview.htm?21/62/22499\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef80812 \" href=\"mobipreview.htm?20/42/21166\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The infant has a normal physical examination",
"     </li>",
"     <li>",
"      The infant&rsquo;s VDRL or RPR titer is reactive but less than fourfold the maternal titer",
"     </li>",
"     <li>",
"      Mother received adequate therapy during pregnancy that was suitable for the stage of her infection and had an appropriate response (ie, VDRL or RPR titers decreased fourfold after therapy for early syphilis; VDRL or RPR remained stable and low [VDRL &le;1:2; RPR &le;1:4] for late syphilis)",
"     </li>",
"     <li>",
"      Mother was treated more than four weeks before delivery",
"     </li>",
"     <li>",
"      Mother has no evidence of relapse or reinfection; relapse or reinfection are indicated by a &ge;fourfold increase in titer",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In accord with the AAP and CDC, we suggest that neonates who meet the above criteria be treated with a single dose of IM benzathine penicillin (",
"    <a class=\"graphic graphic_algorithm graphicRef51559 \" href=\"mobipreview.htm?21/62/22499\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21001153\">",
"     'Single-dose regimen'",
"    </a>",
"    below.) Infection of the fetus may occur despite appropriate maternal therapy during pregnancy. The reported failure rates of maternal treatment to prevent congenital infection range from 2 to 14 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/5,13-15\">",
"     5,13-15",
"    </a>",
"    ]; higher rates are more frequent in mothers with secondary syphilis. Treating the infant at birth may prevent the development of clinical disease if maternal therapy during pregnancy did not prevent fetal infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an alternative, some specialists opt not to treat such infants, but to provide close (ie, monthly) serologic follow-up, and provide treatment if the infant&rsquo;s titers do not decline as expected for transplacentally acquired antibody. (See",
"    <a class=\"local\" href=\"#H21003421\">",
"     'Nontreponemal tests'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21000512\">",
"    <span class=\"h4\">",
"     Mother adequately treated before pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;No additional evaluation is necessary for the asymptomatic neonate whose mother was treated",
"    <strong>",
"     before",
"    </strong>",
"    pregnancy, provided that",
"    <strong>",
"     all",
"    </strong>",
"    of the following criteria are met [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The infant has a normal physical examination",
"     </li>",
"     <li>",
"      The infant&rsquo;s VDRL or RPR titer is &lt;fourfold the maternal titer",
"     </li>",
"     <li>",
"      Mother was appropriately and adequately treated before pregnancy",
"     </li>",
"     <li>",
"      Mother&rsquo;s VDRL or RPR titer remained low and stable before and during pregnancy and at delivery (ie, VDRL &lt;1:2; RPR &lt;1:4)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In accord with the AAP and CDC, we suggest that infants in this category do not require treatment with penicillin (",
"    <a class=\"graphic graphic_algorithm graphicRef51559 \" href=\"mobipreview.htm?21/62/22499\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef80812 \" href=\"mobipreview.htm?20/42/21166\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. However, some experts would provide a single dose of IM benzathine penicillin if follow-up is uncertain (to protect the infant in the unlikely event that the mother was reinfected). (See",
"    <a class=\"local\" href=\"#H21001153\">",
"     'Single-dose regimen'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21000520\">",
"    <span class=\"h1\">",
"     EVALUATION AND MANAGEMENT OF CHILDREN &gt;1 MONTH OF AGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who are identified as having reactive serologic tests for syphilis after one month of age should have maternal serology and records reviewed to assess whether the child has congenital or acquired syphilis, although this distinction may be difficult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/1,18\">",
"     1,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evaluation of such children may include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cerebrospinal fluid (CSF) analysis for Venereal Disease Research Laboratory test (VDRL), white blood cell count, and protein",
"     </li>",
"     <li>",
"      Complete blood count (CBC) with differential and platelet count",
"     </li>",
"     <li>",
"      Evaluation and testing for HIV infection",
"     </li>",
"     <li>",
"      Other tests as clinically indicated (eg, long-bone radiographs, chest radiograph, liver function tests, abdominal ultrasonography, ophthalmologic examination, auditory brain stem response, and neuroimaging studies)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The distinction between congenital and acquired syphilis can be difficult and ultimately may rest upon maternal history and clinical judgment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/1\">",
"     1",
"    </a>",
"    ]. CSF and CBC abnormalities may occur in both congenital and acquired syphilis, but radiographic changes in the metaphysis and epiphysis are more suggestive of congenital syphilis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/31/17914?source=see_link&amp;anchor=H114349489#H114349489\">",
"     \"Congenital syphilis: Clinical features and diagnosis\", section on 'Long-bone radiographs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a young child, the possibility of sexual abuse should be considered as a cause of acquired syphilis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35258?source=see_link&amp;anchor=H27#H27\">",
"     \"Evaluation of sexual abuse in children and adolescents\", section on 'STIs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children who are diagnosed with congenital syphilis after one month of age (including those with previously untreated late congenital syphilis) require parenteral penicillin therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21003096\">",
"     '&gt;1 month of age'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H80101538\">",
"    <span class=\"h1\">",
"     EVALUATION OF SIBLINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of the siblings of an index case of congenital syphilis may be warranted if such an evaluation did not occur previously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21001146\">",
"    <span class=\"h1\">",
"     PENICILLIN THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parenteral penicillin is the drug of choice for the treatment of congenital syphilis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Penicillin is the only drug with documented efficacy, and it has minimal toxicity.",
"    <em>",
"     T. pallidum",
"    </em>",
"    is extremely sensitive to penicillin, as defined by experimental animal work [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/2\">",
"     2",
"    </a>",
"    ]. The minimal inhibitory concentration (MIC) for penicillin is approximately 0.004 units (or 0.0025",
"    <span class=\"nowrap\">",
"     microg/mL).",
"    </span>",
"    There is no evidence of increasing spirochete resistance to penicillin, but such evidence would come only from the recognition of therapeutic failures.",
"   </p>",
"   <p>",
"    Effective treatment of syphilis requires maintenance of a minimal inhibitory concentration (MIC) of 0.03",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    of penicillin in serum (or cerebrospinal fluid) for 7 to 10 days. Current regimens are designed to achieve and maintain several times the necessary MIC and to avoid penicillinfree intervals during therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21002590\">",
"    <span class=\"h2\">",
"     &lt;1 month of age",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21001153\">",
"    <span class=\"h3\">",
"     Single-dose regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The single-dose regimen for treatment of congenital syphilis is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benzathine",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/46/14054?source=see_link\">",
"       penicillin G",
"      </a>",
"      (50,000",
"      <span class=\"nowrap\">",
"       units/kg,",
"      </span>",
"      intramuscularly [IM] as a single dose)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two randomized trials have evaluated the efficacy of single-dose penicillin therapy in",
"    <span class=\"nowrap\">",
"     preventing/treating",
"    </span>",
"    congenital syphilis in asymptomatic infants born to mothers with no treatment or",
"    <span class=\"nowrap\">",
"     inadequate/suboptimal",
"    </span>",
"    treatment for syphilis during pregnancy (",
"    <a class=\"graphic graphic_table graphicRef73418 \" href=\"mobipreview.htm?0/11/188\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. One compared single-dose benzathine penicillin with no therapy in asymptomatic infants at high risk of congenital syphilis (untreated mothers with VDRL &ge;1:32) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/16\">",
"     16",
"    </a>",
"    ]. None of 11 infants in the treatment group developed congenital syphilis (defined by IgM Western blots and VDRL titers), compared with four of eight infants who were not treated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/16\">",
"     16",
"    </a>",
"    ]. In the second trial, treatment of asymptomatic infants (normal physical examination, normal CSF evaluation, normal long-bone radiographs, and no visceral abnormalities) with either single-dose benzathine",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/46/14054?source=see_link\">",
"     penicillin G",
"    </a>",
"    or 10 days of parenteral procaine penicillin G was effective in preventing clinical evidence of congenital syphilis and decreasing RPR by at least fourfold [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/17\">",
"     17",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Single-dose therapy is contraindicated for asymptomatic infants born to women with",
"    <span class=\"nowrap\">",
"     inadequate/suboptimal",
"    </span>",
"    treatment (",
"    <a class=\"graphic graphic_table graphicRef73418 \" href=\"mobipreview.htm?0/11/188\">",
"     table 3",
"    </a>",
"    ) unless the infant has undergone appropriate evaluation (CSF quantitative VDRL, cell count, and protein; CBC with differential and platelet count; and long-bone radiographs) and has completely normal results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The evaluation is necessary to exclude CNS syphilis, which requires a full 10-day course of therapy. Treatment failures with single-dose therapy have been reported among infants who developed clinical findings of syphilis after incomplete evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The frequency of such treatment failures appears to be low but is unknown. (See",
"    <a class=\"local\" href=\"#H21000497\">",
"     'Mother not treated or inadequately treated'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21001160\">",
"    <span class=\"h3\">",
"     Ten-day regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two alternative 10-day penicillin regimens for the treatment of congenital syphilis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aqueous",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/46/14054?source=see_link\">",
"       penicillin G",
"      </a>",
"      50,000",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      intravenously (IV) every 12 hours (for infants &le;7 days of age) and every 8 hours (for infants &gt;7 days of age) for a total of 10 days,",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      Procaine",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/46/14054?source=see_link\">",
"       penicillin G",
"      </a>",
"      50,000",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      intramuscularly (IM) as a single daily dose for 10 days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The levels of penicillin that are achieved in the CSF after IM procaine penicillin are lower than those with IV aqueous penicillin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/22\">",
"     22",
"    </a>",
"    ]. However, the clinical significance of this observation is unclear, since there have been no treatment failures reported after treatment with procaine penicillin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A full 10-day course of penicillin should be administered, even if the infant initially received",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/38/38503?source=see_link\">",
"     ampicillin",
"    </a>",
"    for possible sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. If more than one day of penicillin therapy is missed, the entire course should be restarted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21003096\">",
"    <span class=\"h2\">",
"     &gt;1 month of age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who are diagnosed with congenital syphilis after one month of age (including those with late congenital syphilis) and children with acquired syphilis should be treated with aqueous",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/46/14054?source=see_link\">",
"     penicillin G",
"    </a>",
"    (50,000",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    intravenously every four to six hours for 10 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In addition, for children with congenital syphilis or findings compatible with central nervous system involvement, some experts suggest that the 10-day course of aqueous penicillin be followed with a single dose of benzathine penicillin (50,000",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    intramuscularly).",
"   </p>",
"   <p>",
"    As an alternative for the child with positive syphilis serology, but no clinical manifestations of disease, and normal CSF studies, some experts would treat with three weekly doses of benzathine",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/46/14054?source=see_link\">",
"     penicillin G",
"    </a>",
"    (50,000",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    intramuscularly) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21002576\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21002583\">",
"    <span class=\"h3\">",
"     Jarisch-Herxheimer reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Jarisch-Herxheimer reaction generally consists of fever 2 to 12 hours after initiation of therapy for active syphilis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/23\">",
"     23",
"    </a>",
"    ]. However, cardiovascular collapse, seizures, and death also have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/24\">",
"     24",
"    </a>",
"    ]. The Jarisch-Herxheimer reaction is thought to be produced by the release of endotoxin-like compounds during penicillin-mediated lysis of",
"    <em>",
"     T. pallidum",
"    </em>",
"    . It is rare in newborns but can occur in older infants and children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21001167\">",
"    <span class=\"h2\">",
"     Special circumstances",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H284805075\">",
"    <span class=\"h3\">",
"     Missed doses",
"    </span>",
"    &nbsp;&mdash;&nbsp;If more than one day of penicillin therapy is missed, the entire course should be restarted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Effective treatment of syphilis requires maintenance of a minimal inhibitory concentration (MIC) of 0.03",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    of penicillin in serum (or cerebrospinal fluid) for 7 to 10 days. (See",
"    <a class=\"local\" href=\"#H21001146\">",
"     'Penicillin therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21001174\">",
"    <span class=\"h3\">",
"     Penicillin allergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penicillin is the treatment of choice for congenital syphilis. There are insufficient data regarding the adequacy of treatment with agents other than penicillins (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    ). For the",
"    <span class=\"nowrap\">",
"     infant/child",
"    </span>",
"    who requires treatment for syphilis but has a penicillin allergy or develops an allergic reaction that is presumed to be due to penicillin, the US Centers for Disease Control and Prevention and the American Academy of Pediatrics recommend desensitization and then treatment with penicillin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/46/23274?source=see_link&amp;anchor=H1969477#H1969477\">",
"     \"Allergy to penicillins\", section on 'Desensitization'",
"    </a>",
"    .) If a nonpenicillin agent is used, close serologic and CSF follow-up are necessary. (See",
"    <a class=\"local\" href=\"#H3146933\">",
"     'Follow-up evaluations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21001188\">",
"    <span class=\"h3\">",
"     Maternal coinfection with HIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants born to mothers who are coinfected with syphilis and human immunodeficiency virus (HIV) should receive the same evaluation and treatment as those whose mothers do not have HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/3\">",
"     3",
"    </a>",
"    ]. There is insufficient evidence to determine whether such infants require different evaluation, treatment, or follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3146933\">",
"    <span class=\"h1\">",
"     FOLLOW-UP EVALUATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants and children who have reactive serologic tests for syphilis or were born to mothers who were seroreactive at delivery should be monitored for clinical or serologic manifestations of congenital syphilis; those who were treated should be monitored to assure adequate treatment response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/3,4,6,25,26\">",
"     3,4,6,25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H284805145\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants who have reactive serologic tests for syphilis or were born to mothers who were seroreactive at delivery should undergo evaluation for manifestations of congenital syphilis during regularly scheduled well-child care visits during the first year and beyond (for manifestations of late congenital syphilis) (",
"    <a class=\"graphic graphic_table graphicRef67809 \" href=\"mobipreview.htm?10/17/10526\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef81529 \" href=\"mobipreview.htm?35/25/36251\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Evaluation for hearing loss, ophthalmologic abnormalities, and neurodevelopmental problems should occur yearly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/19/44344?source=see_link\">",
"     \"Evaluation of hearing impairment in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/59/24505?source=see_link\">",
"     \"Visual development and vision assessment in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/49/26394?source=see_link&amp;anchor=H18501566#H18501566\">",
"     \"Developmental-behavioral surveillance and screening in primary care\", section on 'When to perform developmental-behavioral screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21003182\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactive serology in the infant does not differentiate between the infant&rsquo;s antibody response to infection and transplacentally acquired maternal antibody. Serial monitoring of the infant&rsquo;s serology is necessary to ensure an appropriate treatment response or exclude congenital syphilis. In children diagnosed with congenital syphilis after infancy, serial monitoring of serology is necessary to ensure appropriate treatment response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21003421\">",
"    <span class=\"h3\">",
"     Nontreponemal tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quantitative Venereal Disease Research Laboratory test (VDRL) or rapid plasma reagin (RPR) should be performed every two to three months in infants born to mothers with syphilis, including infants who were seronegative at birth whose mothers acquired syphilis late in gestation (whether or not the infant was treated with penicillin), and in children treated for congenital syphilis after infancy. Serology should be repeated until the test becomes nonreactive or the titer has decreased fourfold (equivalent to two dilutions) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/3,27,28\">",
"     3,27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The infant&rsquo;s VDRL or RPR titers should decline by three months of age and be nonreactive by six months of age if the infant was successfully treated or not infected (ie, if the reactive test was caused by passive transfer of maternal IgG antibody) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/3,29\">",
"     3,29",
"    </a>",
"    ]. The response may be slower in infants and children treated after one month of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H80100293\">",
"    <span class=\"h4\">",
"     Treatment failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment failure, or failure of maternal treatment to prevent congenital syphilis, is indicated by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Failure of the VDRL or RPR titers to decline, or",
"     </li>",
"     <li>",
"      Increase in the VDRL or RPR after 6 to 12 months of age (or treatment in children treated after the neonatal period)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In such circumstances, the",
"    <span class=\"nowrap\">",
"     infant/child",
"    </span>",
"    should undergo a lumbar puncture to obtain cerebrospinal fluid (CSF) for VDRL, cell count, and protein, and be treated with 10 days of parenteral penicillin, even if he or she was treated previously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21003190\">",
"     'CSF evaluation'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H21001146\">",
"     'Penicillin therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21003428\">",
"    <span class=\"h3\">",
"     Treponemal tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treponemal tests (eg, microhemagglutination test for",
"    <em>",
"     T. pallidum",
"    </em>",
"    [MHA-TP] or fluorescent treponemal antibody absorption [FTA-ABS]) should not be used to evaluate treatment response because they can remain positive despite effective treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/3,30\">",
"     3,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, treponemal tests can be helpful in establishing a diagnosis of congenital syphilis. A treponemal test should be performed after 12 to 15 months of age in infants who had reactive serologic tests for syphilis or were born to mothers who were seroreactive at delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. If the treponemal test is reactive, it should be repeated at 18 and 24 months of age. A positive treponemal test at &ge;18 months of age (after the disappearance of passively acquired maternal antibody) confirms the diagnosis of congenital syphilis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/2,28\">",
"     2,28",
"    </a>",
"    ]. Children who have a positive treponemal test for syphilis at &ge;18 months of age and did not previously receive treatment should undergo full evaluation and treatment. (See",
"    <a class=\"local\" href=\"#H21000520\">",
"     'Evaluation and management of children &gt;1 month of age'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21003190\">",
"    <span class=\"h2\">",
"     CSF evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serial cerebrospinal fluid (CSF) evaluation is necessary for infants and children whose initial CSF evaluation was abnormal (ie, reactive CSF VDRL or elevated CSF white blood cell count or protein without an alternative explanation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/3\">",
"     3",
"    </a>",
"    ]. CSF should be evaluated every six months until the results are normal. A reactive CSF VDRL or abnormal CSF white blood cell count or protein that cannot be attributed to other ongoing illnesses requires retreatment for possible neurosyphilis with 10 days of parenteral penicillin therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21001146\">",
"     'Penicillin therapy'",
"    </a>",
"    above.) Neuroimaging studies may be warranted in children with persistently reactive CSF VDRL, elevated CSF cell count,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    elevated CSF protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13027163\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, the case fatality rate for congenital syphilis is between 6 and 8 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Approximately 90 percent of fatal cases are associated with lack of prenatal care or inadequate prenatal care.",
"   </p>",
"   <p>",
"    Appropriate treatment of early congenital syphilis within the first three months of life prevents some, but not all, of the late manifestations of congenital syphilis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Interstitial keratitis (",
"    <a class=\"graphic graphic_picture graphicRef52740 \" href=\"mobipreview.htm?31/13/31954\">",
"     picture 2",
"    </a>",
"    ) and anterior tibial bowing (&ldquo;saber shins&rdquo;) (",
"    <a class=\"graphic graphic_picture graphicRef81604 \" href=\"mobipreview.htm?41/58/42927\">",
"     picture 3",
"    </a>",
"    ) may occur or progress despite appropriate therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Syphilis infection may persist for life. Treponemes appear to persist in extracellular loci with little or no inflammatory response elicited. A history of syphilis or treatment for syphilis provides relatively minor and unreliable protection against subsequent infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/36\">",
"     36",
"    </a>",
"    ]. Active disease after reinfection is common, regardless of nontreponemal antibody reactivity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3146940\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measures to prevent congenital syphilis include screening of pregnant women and international adoptees, contact tracing, contact precautions, and monitoring of close contacts of infectious patients for clinical or serologic evidence of disease.",
"   </p>",
"   <p>",
"    Prevention of acquired syphilis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/9/37017?source=see_link&amp;anchor=H36#H36\">",
"     \"Pathogenesis, clinical manifestations, and treatment of early syphilis\", section on 'Screening and prevention'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/48/776?source=see_link&amp;anchor=H27#H27\">",
"     \"Pathogenesis, clinical manifestations, and treatment of late syphilis\", section on 'Prevention and screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13027292\">",
"    <span class=\"h2\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of congenital syphilis are preventable with routine prenatal care, screening of pregnant women for syphilis, penicillin treatment of infected women and their sexual partners, and appropriate monitoring and interpretation of treatment response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/5,37-42\">",
"     5,37-42",
"    </a>",
"    ]. Screening and treatment of syphilis during pregnancy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/61/4057?source=see_link\">",
"     \"Syphilis in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/61/4057?source=see_link&amp;anchor=H10#H10\">",
"     \"Syphilis in pregnancy\", section on 'Maternal screening'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/61/4057?source=see_link&amp;anchor=H21#H21\">",
"     \"Syphilis in pregnancy\", section on 'Maternal treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, current screening practices have limitations. Lack of prenatal care is the most important. Among the 431 cases of congenital syphilis reported to the US Centers for Disease Control and Prevention (CDC) in 2008, approximately one-third were born to mothers who did not receive prenatal care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/31\">",
"     31",
"    </a>",
"    ]. Although the CDC and the American Academy of Pediatrics recommend that newborn infants remain hospitalized until there is documentation of the mother&rsquo;s syphilis serology (at least once during pregnancy and ideally again at delivery), adherence to this recommendation may be difficult, particularly when an early discharge is planned [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/3,4,43\">",
"     3,4,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The possibility of false negative results of nontreponemal serology is another important limitation (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/44/39624?source=see_link&amp;anchor=H20#H20\">",
"     \"Diagnostic testing for syphilis\", section on 'False negative test results'",
"    </a>",
"    ). A negative maternal nontreponemal test at delivery does not exclude incubating syphilis or primary syphilis if it is too early for maternal antibodies to have reached detectable concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Infants born in such circumstances continue to escape detection until they become symptomatic, typically at 3 to 14 weeks of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/2\">",
"     2",
"    </a>",
"    ]. Repeat maternal screening at the first postpartum visit may be warranted for mothers who engage in high-risk behaviors or reside in areas with high prevalence of syphilis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13027299\">",
"    <span class=\"h3\">",
"     International adoptees",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syphilis testing is recommended as part of the evaluation of internationally adopted children, even if they are reported to have received evaluation and treatment in their home country [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/23\">",
"     23",
"    </a>",
"    ]. Congenital syphilis may be undiagnosed or inadequately treated in developing countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2514356\">",
"    <span class=\"h2\">",
"     Isolation precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard precautions are recommended for infants with suspected or proven congenital syphilis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19658?source=see_link&amp;anchor=H2#H2\">",
"     \"General principles of infection control\", section on 'Standard precautions'",
"    </a>",
"    .) In addition, gloves should be worn when caring for infants with skin or mucous membrane lesions until 24 hours of treatment have been completed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/47\">",
"     47",
"    </a>",
"    ]. Moist open lesions, secretions, and body fluids (eg, CSF, blood) contain spirochetes and are infectious [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2514376\">",
"    <span class=\"h2\">",
"     Close contacts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persons, including hospital personnel, who had close unprotected contact with a child with early congenital syphilis before the child was diagnosed or during the first 24 hours of treatment should be examined for syphilitic lesions (ie, chancre) two to three weeks after contact [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/4\">",
"     4",
"    </a>",
"    ]. Serologic testing should be performed and repeated three months after exposure, or sooner if symptoms develop. Immediate treatment (",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?18/37/19029?source=see_link\">",
"     penicillin G benzathine",
"    </a>",
"    50,000",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    intramuscularly as a single dose; maximum dose 2.4 million units) may be warranted if the degree of exposure was substantial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H80101129\">",
"    <span class=\"h1\">",
"     REPORTING REQUIREMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, congenital syphilis is a national notifiable disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/48\">",
"     48",
"    </a>",
"    ]. However, reporting requirements vary by state. Reporting to the US Centers for Disease Control and Prevention by the states is voluntary. For reporting purposes, congenital syphilis includes stillbirths due to syphilis, cases of congenital syphilis detected in newborns, and cases of congenitally acquired syphilis in infants and children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/11/37049/abstract/1\">",
"     1",
"    </a>",
"    ]. Reporting of syphilis to state or local health departments permits contact investigation, appropriate follow-up, and identification of populations at increased risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/37/27217?source=see_link\">",
"       \"Patient information: Congenital syphilis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12404253\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The US Centers for Disease Control and Prevention and the American Academy of Pediatrics Committee on Infectious Diseases provide guidelines for the evaluation and management of congenital syphilis (",
"      <a class=\"graphic graphic_algorithm graphicRef51559 \" href=\"mobipreview.htm?21/62/22499\">",
"       algorithm 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef80812 \" href=\"mobipreview.htm?20/42/21166\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21000446\">",
"       'Evaluation and management of infants &lt;1 month of age'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of congenital syphilis should be suspected in all infants born to women who have reactive nontreponemal and treponemal tests for syphilis and",
"      <span class=\"nowrap\">",
"       infants/children",
"      </span>",
"      with clinical findings compatible with congenital syphilis (",
"      <a class=\"graphic graphic_table graphicRef67809 \" href=\"mobipreview.htm?10/17/10526\">",
"       table 2",
"      </a>",
"      ). The initial evaluation of infants &lt;1 month of age should include (see",
"      <a class=\"local\" href=\"#H21000461\">",
"       'Initial evaluation'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Venereal Disease Research Laboratory (VDRL) or rapid plasma reagin (RPR) titers (the same test that was performed on the mother)",
"     </li>",
"     <li>",
"      Physical examination for evidence of congenital syphilis with darkfield microscopic examination or direct fluorescent antibody (DFA) staining of suspicious lesions or body fluids (eg, nasal discharge); and",
"     </li>",
"     <li>",
"      Pathologic examination of the placenta and umbilical cord with specific fluorescent antitreponemal antibody staining (if possible)",
"      <br/>",
"      <br/>",
"      Additional evaluation depends upon the findings from the initial evaluation (",
"      <a class=\"graphic graphic_table graphicRef80812 \" href=\"mobipreview.htm?20/42/21166\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21000468\">",
"       'Subsequent evaluation and management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital syphilis is proven or highly probable if the infant has examination findings compatible with congenital syphilis (",
"      <a class=\"graphic graphic_table graphicRef67809 \" href=\"mobipreview.htm?10/17/10526\">",
"       table 2",
"      </a>",
"      ); VDRL or RPR titer that is &ge;fourfold the corresponding maternal titer; or a positive darkfield (",
"      <a class=\"graphic graphic_picture graphicRef72322 \" href=\"mobipreview.htm?19/58/20399\">",
"       picture 1",
"      </a>",
"      ) or fluorescent antibody test of body fluid(s), placenta, or umbilical cord. Such infants should be evaluated with cerebrospinal fluid (CSF) VDRL, cell count, and protein; complete blood count (CBC) with differential and platelet count; and additional tests as clinically indicated (",
"      <a class=\"graphic graphic_table graphicRef80812 \" href=\"mobipreview.htm?20/42/21166\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21000475\">",
"       'Proven or highly probable disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that infants with proven or highly probable congenital syphilis be treated with 10 days of parenteral penicillin (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21001160\">",
"       'Ten-day regimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants born to women with syphilis or a history of syphilis remain &ldquo;at risk&rdquo; for syphilis even if the infant has a normal physical examination and VDRL or RPR that is nonreactive or less than fourfold the maternal titer. The evaluation and treatment of at-risk neonates varies depending upon the mother&rsquo;s history of syphilis and syphilis treatment and the treatment plan for the infant (",
"      <a class=\"graphic graphic_algorithm graphicRef51559 \" href=\"mobipreview.htm?21/62/22499\">",
"       algorithm 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef80812 \" href=\"mobipreview.htm?20/42/21166\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21000482\">",
"       'At-risk neonates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that infants who are at risk for congenital syphilis be treated with parenteral penicillin (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The regimen varies depending upon the clinical circumstances (",
"      <a class=\"graphic graphic_table graphicRef80812 \" href=\"mobipreview.htm?20/42/21166\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21001146\">",
"       'Penicillin therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants and children who have reactive serologic tests for syphilis or were born to mothers who were seroreactive at delivery should undergo monitoring for clinical manifestations of congenital syphilis at well-child care visits throughout childhood. VDRL or RPR should be repeated every two to three months until the test becomes nonreactive or the titer has decreased fourfold. Serial CSF evaluation is necessary for infants and children whose initial CSF evaluation was abnormal without an alternative explanation. (See",
"      <a class=\"local\" href=\"#H3146933\">",
"       'Follow-up evaluations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Measures to prevent congenital syphilis include screening of pregnant women and international adoptees, contact tracing, contact precautions, and monitoring of close contacts of infectious patients for clinical or serologic evidence of disease. (See",
"      <a class=\"local\" href=\"#H3146940\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Centers for Disease Control and Prevention. Congenital syphilis (Treponema pallidum) case definition.  file://www.cdc.gov/ncphi/od/ai/casedef/syphilisccurrent.htm (Accessed on September 30, 2010).",
"    </li>",
"    <li>",
"     Dobson SR, Sanchez PJ. Syphilis. In: Textbook of Pediatric Infectious Diseases, 6th, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.1826.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/3\">",
"      Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Syphilis. In: Red Book: 2012 Report of the Committee on Infectious Diseases, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. Vol 29th, p.690.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/5\">",
"      McFarlin BL, Bottoms SF, Dock BS, Isada NB. Epidemic syphilis: maternal factors associated with congenital infection. Am J Obstet Gynecol 1994; 170:535.",
"     </a>",
"    </li>",
"    <li>",
"     Kollmann TR, Dobson S. Syphilis. In: Infectious Diseases of the Fetus and Newborn Infant, 7th, Remington JS, Klein JO, Wilson CB, et al (Eds), Elsevier Saunders, Philadelphia 2011. p.524.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/7\">",
"      Centers for Disease Control and Prevention (CDC). Congenital syphilis--United States, 2002. MMWR Morb Mortal Wkly Rep 2004; 53:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/8\">",
"      Mascola L, Pelosi R, Alexander CE. Inadequate treatment of syphilis in pregnancy. Am J Obstet Gynecol 1984; 150:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/9\">",
"      Ricci JM, Fojaco RM, O'Sullivan MJ. Congenital syphilis: the University of Miami/Jackson Memorial Medical Center experience, 1986-1988. Obstet Gynecol 1989; 74:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/10\">",
"      Reyes MP, Hunt N, Ostrea EM Jr, George D. Maternal/congenital syphilis in a large tertiary-care urban hospital. Clin Infect Dis 1993; 17:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/11\">",
"      Beeram MR, Chopde N, Dawood Y, et al. Lumbar puncture in the evaluation of possible asymptomatic congenital syphilis in neonates. J Pediatr 1996; 128:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/12\">",
"      Moyer VA, Schneider V, Yetman R, et al. Contribution of long-bone radiographs to the management of congenital syphilis in the newborn infant. Arch Pediatr Adolesc Med 1998; 152:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/13\">",
"      Alexander JM, Sheffield JS, Sanchez PJ, et al. Efficacy of treatment for syphilis in pregnancy. Obstet Gynecol 1999; 93:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/14\">",
"      Conover CS, Rend CA, Miller GB Jr, Schmid GP. Congenital syphilis after treatment of maternal syphilis with a penicillin regimen exceeding CDC guidelines. Infect Dis Obstet Gynecol 1998; 6:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/15\">",
"      Sheffield JS, S&aacute;nchez PJ, Morris G, et al. Congenital syphilis after maternal treatment for syphilis during pregnancy. Am J Obstet Gynecol 2002; 186:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/16\">",
"      Radcliffe M, Meyer M, Roditi D, Malan A. Single-dose benzathine penicillin in infants at risk of congenital syphilis--results of a randomised study. S Afr Med J 1997; 87:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/17\">",
"      Paryani SG, Vaughn AJ, Crosby M, Lawrence S. Treatment of asymptomatic congenital syphilis: benzathine versus procaine penicillin G therapy. J Pediatr 1994; 125:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/18\">",
"      Christian CW, Lavelle J, Bell LM. Preschoolers with syphilis. Pediatrics 1999; 103:E4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/19\">",
"      Chakraborty R, Luck S. Syphilis is on the increase: the implications for child health. Arch Dis Child 2008; 93:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/20\">",
"      Beck-Sague C, Alexander ER. Failure of benzathine penicillin G treatment in early congenital syphilis. Pediatr Infect Dis J 1987; 6:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/21\">",
"      Woolf A, Wilfert CM, Kelsey DB. Childhood syphilis in North Carolina. N C Med J 1980; 41:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/22\">",
"      Azimi PH, Janner D, Berne P, et al. Concentrations of procaine and aqueous penicillin in the cerebrospinal fluid of infants treated for congenital syphilis. J Pediatr 1994; 124:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/23\">",
"      Woods CR. Syphilis in children: congenital and acquired. Semin Pediatr Infect Dis 2005; 16:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/24\">",
"      HOLZEL A. Jarisch-Herxheimer reaction following penicillin treatment of early congenital syphilis. Br J Vener Dis 1956; 32:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/25\">",
"      Ikeda MK, Jenson HB. Evaluation and treatment of congenital syphilis. J Pediatr 1990; 117:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/26\">",
"      Rathbun KC. Congenital syphilis: a proposal for improved surveillance, diagnosis, and treatment. Sex Transm Dis 1983; 10:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/27\">",
"      Hardy JB, Hardy PH, Oppenheimer EH, et al. Failure of penicillin in a newborn with congenital syphilis. JAMA 1970; 212:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/28\">",
"      Rawstron SA, Mehta S, Marcellino L, et al. Congenital syphilis and fluorescent treponemal antibody test reactivity after the age of 1 year. Sex Transm Dis 2001; 28:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/29\">",
"      Chang SN, Chung KY, Lee MG, Lee JB. Seroreversion of the serological tests for syphilis in the newborns born to treated syphilitic mothers. Genitourin Med 1995; 71:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/30\">",
"      Singh AE, Guenette T, Gratrix J, et al. Seroreversion of Treponemal Tests in Infants meeting Canadian Surveillance Criteria for Confirmed Early Congenital Syphilis. Pediatr Infect Dis J 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/31\">",
"      Centers for Disease Control and Prevention (CDC). Congenital syphilis - United States, 2003-2008. MMWR Morb Mortal Wkly Rep 2010; 59:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/32\">",
"      Gust DA, Levine WC, St Louis ME, et al. Mortality associated with congenital syphilis in the United States, 1992-1998. Pediatrics 2002; 109:E79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/33\">",
"      PUTKONEN T. Does early treatment prevent dental changes in congenital syphilis? Acta Derm Venereol 1963; 43:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/34\">",
"      Stamos JK, Rowley AH. Timely diagnosis of congenital infections. Pediatr Clin North Am 1994; 41:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/35\">",
"      OKSALA A. Interstitial keratitis after adequate penicillin therapy; a case report. Br J Vener Dis 1957; 33:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/36\">",
"      Pavithran K. Acquired syphilis in a patient with late congenital syphilis. Sex Transm Dis 1987; 14:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/37\">",
"      Coles FB, Hipp SS, Silberstein GS, Chen JH. Congenital syphilis surveillance in upstate New York, 1989-1992: implications for prevention and clinical management. J Infect Dis 1995; 171:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/38\">",
"      Mascola L, Pelosi R, Blount JH, et al. Congenital syphilis. Why is it still occurring? JAMA 1984; 252:1719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/39\">",
"      Desenclos JC, Scaggs M, Wroten JE. Characteristics of mothers of live infants with congenital syphilis in Florida, 1987-1989. Am J Epidemiol 1992; 136:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/40\">",
"      Webber MP, Lambert G, Bateman DA, Hauser WA. Maternal risk factors for congenital syphilis: a case-control study. Am J Epidemiol 1993; 137:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/41\">",
"      Southwick KL, Guidry HM, Weldon MM, et al. An epidemic of congenital syphilis in Jefferson County, Texas, 1994-1995: inadequate prenatal syphilis testing after an outbreak in adults. Am J Public Health 1999; 89:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/42\">",
"      Warner L, Rochat RW, Fichtner RR, et al. Missed opportunities for congenital syphilis prevention in an urban southeastern hospital. Sex Transm Dis 2001; 28:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/43\">",
"      Martin D, Bertrand J, McKegney C, et al. Congenital syphilis surveillance and newborn evaluation in a low-incidence state. Arch Pediatr Adolesc Med 2001; 155:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/44\">",
"      Dorfman DH, Glaser JH. Congenital syphilis presenting in infants after the newborn period. N Engl J Med 1990; 323:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/45\">",
"      S&aacute;nchez PJ, Wendel GD, Norgard MV. Congenital syphilis associated with negative results of maternal serologic tests at delivery. Am J Dis Child 1991; 145:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/46\">",
"      Staat MA. Infectious disease issues in internationally adopted children. Pediatr Infect Dis J 2002; 21:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/11/37049/abstract/47\">",
"      TUCKER HA, ROBINSON RC. Disappearance time of Treponema pallidum from lesions of early syphilis following administration of crystalline penicillin G. Bull Johns Hopkins Hosp 1947; 80:169.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System. file://www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm (Accessed on August 12, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15400 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-210.101.131.232-2A3F076F4F-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_11_37049=[""].join("\n");
var outline_f36_11_37049=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12404253\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12404245\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21000446\">",
"      EVALUATION AND MANAGEMENT OF INFANTS &lt;1 MONTH OF AGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21000461\">",
"      Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21000468\">",
"      Subsequent evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21000475\">",
"      - Proven or highly probable disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21000482\">",
"      - At-risk neonates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21000490\">",
"      Infant VDRL or RPR nonreactive",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21000497\">",
"      Mother not treated or inadequately treated",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21000504\">",
"      Mother adequately treated during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21000512\">",
"      Mother adequately treated before pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21000520\">",
"      EVALUATION AND MANAGEMENT OF CHILDREN &gt;1 MONTH OF AGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H80101538\">",
"      EVALUATION OF SIBLINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21001146\">",
"      PENICILLIN THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21002590\">",
"      &lt;1 month of age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21001153\">",
"      - Single-dose regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21001160\">",
"      - Ten-day regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21003096\">",
"      &gt;1 month of age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21002576\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21002583\">",
"      - Jarisch-Herxheimer reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21001167\">",
"      Special circumstances",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H284805075\">",
"      - Missed doses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21001174\">",
"      - Penicillin allergy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21001188\">",
"      - Maternal coinfection with HIV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3146933\">",
"      FOLLOW-UP EVALUATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H284805145\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21003182\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21003421\">",
"      - Nontreponemal tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H80100293\">",
"      Treatment failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21003428\">",
"      - Treponemal tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21003190\">",
"      CSF evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13027163\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3146940\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13027292\">",
"      Screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13027299\">",
"      - International adoptees",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2514356\">",
"      Isolation precautions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2514376\">",
"      Close contacts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H80101129\">",
"      REPORTING REQUIREMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12404253\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/15400\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/15400|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?21/62/22499\" title=\"algorithm 1\">",
"      Congenital syphilis evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/15400|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/58/20399\" title=\"picture 1\">",
"      T pallidum darkfield microscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/13/31954\" title=\"picture 2\">",
"      Interstitial keratitis in congenital syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/58/42927\" title=\"picture 3\">",
"      Saber shins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/15400|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/42/21166\" title=\"table 1\">",
"      Evaluation and management of congenital syphilis in neonates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/17/10526\" title=\"table 2\">",
"      Clinical manifestations of early congenital syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/11/188\" title=\"table 3\">",
"      Inadequate treatment of maternal syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/25/36251\" title=\"table 4\">",
"      Stigmata of late congenital syphilis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/46/23274?source=related_link\">",
"      Allergy to penicillins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/31/17914?source=related_link\">",
"      Congenital syphilis: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/49/26394?source=related_link\">",
"      Developmental-behavioral surveillance and screening in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/44/39624?source=related_link\">",
"      Diagnostic testing for syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/19/44344?source=related_link\">",
"      Evaluation of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35258?source=related_link\">",
"      Evaluation of sexual abuse in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/25/18837?source=related_link\">",
"      Laboratory monitoring of patients undergoing treatment for syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/44/26312?source=related_link\">",
"      Neurosyphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/9/37017?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of early syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/48/776?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of late syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/55/12150?source=related_link\">",
"      Pathophysiology, transmission, and natural history of syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/37/27217?source=related_link\">",
"      Patient information: Congenital syphilis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/61/4057?source=related_link\">",
"      Syphilis in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/59/24505?source=related_link\">",
"      Visual development and vision assessment in infants and children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_11_37050="Pulmonary hemorrhage in GPA";
var content_f36_11_37050=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55999%7EPULM%2F58121%7EPULM%2F61100%7EPULM%2F51436%7EPULM%2F62407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55999%7EPULM%2F58121%7EPULM%2F61100%7EPULM%2F51436%7EPULM%2F62407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary hemorrhage in granulomatosis with polyangiitis (Wegener's)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 296px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ill-defined nodule with an air bronchogram due to hemorrhage and necrosis in granulomatosis with polyangiitis (Wegener's).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Amiodarone pulmonary toxicity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 343px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomographic scan obtained without intravenous contrast reveals a high-attenuation right upper lobe consolidation (upper panel). Images from the upper abdomen (lower panel) demonstrate increased attenuation of the liver parenchyma. The attenuation of this lesion is the result of iodine deposition from chronic amiodarone therapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rounded atelectasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 258px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAECAXMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD508DeFb3xn4gi0fTJrWG5kRnDXLMqYHuqk/pXqMf7NHjF+mpeHx9Z5v8A41WH+zOQPixYZGf3UnH4CvtcF1ccDbgYx1z3zQI+Rj+zL4yAz/aXh/8A7/zf/GqE/Zm8YPu2ar4cbacHFxNwfT/VV9gp0APPtTqYz4+/4Zj8Z/8AQT8Pf+BE3/xqj/hmPxn/ANBPw9/4ETf/ABqvsL3rnPEuv/YrF5bZ1jiVtjzt6+i+/vRYR8tT/s1+LoP9Zq3h0H0+0Tf/ABqo4/2cfFcrlYtW8OuR1xcTcf8AkKvYofEc91es0ZeWNWLZc5LH3rT0vVjB+82hWzkkmiwHh6/s1eMGYgan4fyP+m83/wAaqQfsyeMiONT8Pf8AgRN/8ar6k0fVRdxhnILH0rZjbJ44JosM+Q/+GY/Gf/QT8Pf+BE3/AMao/wCGY/Gf/QT8Pf8AgRN/8ar7CooEfHv/AAzH4z/6Cfh7/wACJv8A41R/wzH4z/6Cfh7/AMCJv/jVfYVFAHx7/wAMx+M/+gn4e/8AAib/AONUf8Mx+M/+gn4e/wDAib/41X2FRQB8e/8ADMfjP/oJ+Hv/AAIm/wDjVH/DMfjP/oJ+Hv8AwIm/+NV9hUUAfHv/AAzH4z/6Cfh7/wACJv8A41R/wzH4z/6Cfh7/AMCJv/jVfYVFAHx7/wAMx+M/+gn4e/8AAib/AONUf8Mx+M/+gn4e/wDAib/41X2FRQB8e/8ADMfjP/oJ+Hv/AAIm/wDjVH/DMfjP/oJ+Hv8AwIm/+NV9hUUAfHv/AAzH4z/6Cfh7/wACJv8A41R/wzH4z/6Cfh7/AMCJv/jVfYVFAHx7/wAMx+M/+gn4e/8AAib/AONUf8Mx+M/+gn4e/wDAib/41X2FRQB8e/8ADMfjP/oJ+Hv/AAIm/wDjVH/DMfjP/oJ+Hv8AwIm/+NV9hUjEgEhSx9AcZoA+Pv8AhmPxn/0E/D3/AIETf/GqP+GY/Gf/AEE/D3/gRN/8ar7CooA+Pf8AhmPxn/0E/D3/AIETf/GqP+GY/Gf/AEE/D3/gRN/8ar7CooA+Pf8AhmPxn/0E/D3/AIETf/GqP+GY/Gf/AEE/D3/gRN/8ar7CooA+Pf8AhmPxn/0E/D3/AIETf/GqP+GY/Gf/AEE/D3/gRN/8ar7CooA+Pf8AhmPxn/0E/D3/AIETf/GqP+GY/Gf/AEE/D3/gRN/8ar7CooA+Pf8AhmPxn/0E/D3/AIETf/GqP+GY/Gf/AEE/D3/gRN/8ar7CooA+Pf8AhmPxn/0E/D3/AH/m/wDjVH/DMfjP/oJ+Hv8AwIm/+NV9gZwOpPrmhHDcd6Bnx/8A8Mx+M/8AoJ+Hv/Aib/41XnPj7wDqnge9mtdWuLKWSJ0jJtndgSysRjco4+U1+g56HnFfI/7VG3/hI9Q2kY8+34Hr5cuf6UAeA0UUUgPU/wBmkE/FewA/55SfyFfbkXEYDDNfEf7NAZvi1poUZJjkGPwr7fjTAxk8GmA9RjHP4U6jrWbql88X7q1ZfNALMTyABQBB4p1600HTzNdMGkfiOIH5nP09K8O8V6rcanIjXHypnKopO1RVvxnfNq+qNc3LOkQYCNQc7RWPdR26W6Bp9wckEselMRlw3UkL7kcoO2K1LPU38sxTzfNkNuAx+FZ32STYssciTJgkBTkj61VUhULLgf3setID0Xw54je3cKrK3P3jXpelast7GhQhJGGSor5zgmeHDluc9u9dl4Z17G3dN5ZB4bPb0pge8QNuXtn0qSsTw7qKXsKlGDEjHHetukAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQA1wSBziqd2YreNriTCyIjFWbrwM4q3M6xRM7HCqMk15x8SfFdtb6QbewkVruUEE9dg6HNAzd+H/jCLxRYus4ji1GEkPED94eoFfN/7VMufFuoRkEYktj7fcmq7YXl7okkd9pdwROnLSdifeuL+OviSLxL4hnvUIEki26sgGMFFkyf/AB4UCPLKKKKQz1P9mn/kreljcFBR+fwr7hjB+bP5V8Nfs3f8la0nPTD5/Kvuhh8xxTAq6nOYLNyjhJGGEJrzrUtcRbe7Jyzudjt2Ndb4ikFxOtrGxExGUOOB65ry/wAbajCiraxLmVOGccAn6UxHN3+oW0bFRbK5A4+Y/L7/AFqOSKPULJY7RszKctGR6+lZl0hibDq2W+bPrUS3MsMsMiNtcd/agB0u+zuXWNijA7cHp9KEYOc/KH/iH8JrWu4odRt1uo+Zk5cY6msJkLMQRtc9qQFqSFoYI2WQKGqFVKLuQZ+bnBp9spd2hZDtK7uTnFNMrn5FVQqnoOM+9AHXeCfFEml6lBFcsTCCPbrXv9tcR3UEc8LAo4yK+VAoKYAJI/ir1b4SeKzJINIvpS7KMQu5/wDHR696APWqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAxPGd0bXw/cMuMsMZ9K+a9XvzLe3GAGZz9/PGK9o+NWsCy0m2sAcSXGXz7A14TeBXiUBWJJzwetAEUbnymYkrG3yEkda8i8XOsniK9aP7u8D8gK9l1WWOy8NWUYiaSZ5GL7f4B2rxbxMuzXLsDP3u/XoKGMy6KKKQHpf7OzbfirpR/3v6V92nqeMV8Kfs6Y/4WtpWfujOfzFfdjf6w/U0wOM8aXpsLeWVAIpmUsG6cDt+NeFXGpTX940oXljlj2Ar0b4oaoouJ4Dlju5UnkDHWvNYrt33RokXkj72Fwce9MRds4kvLpY54RHHg5YNuH1pbjQNsasl0ksT8r8uMVH9skdWS0iijQD5mjHP41YtL0wRlNoumK5HPT8qAJtCtRZGVZbiBkfg5zlafqWlW6uhgkR1HDOp70+2s1uGUyw+Rv53BiwH1FWpIobeVore7jltm6nZgk+ooAzIdLeKykuQqlVJReefpWK9vIx3GOWMA53MpUH8a6yZFgsLdEZmjaVsjPI461k6vfXl5bLDPM0kMRwqHoKAMxMBJAcDHOe1LBM8M0M1szJPGQ6OvY+1PtguGjkQh3GB3qJyUBiRehwSKQH0f4K12PxBoMNypBuEASZB1Vh6/XrW9XhHwl1dtL8UG0lci1vv3eB3kxwf0r3YdweqnBoAWiiigAooooAKKKKACiiigAooooAKKKKACig9zUMUxlclI/wBzziQt948dF9OvPtQBNRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRVPWL1dO0u6um6xxkge+OKAPCvjDqJ1DxbcQkjFiPLTJ/OvPRMoD5TLYwDn7p9as6zePc6jc3ErF2nlMjMT39Kpu+3ayoQrevf6UDHOfPZFuUOW4X5uv4V5V44hNv4nvIyu0grkfgK9c0PSotU1gNJI4WHEh9Bg15V8RbmG68Yag9uP3YcJnP3iB1oA5qiiikB6X+zuSvxU0ph2P8AUCvu1/vt9TXwf+z5n/haGl4YryOf+BLX3I/2hryZ84hUlQB3pged694A1HX9dlvJriGCGQ4O05I/Ckn8C+GtHhX7dqgRlH7wAZLfhWt478Vnw9pjxQuDeTcIT1H0rxa51Cd7t5ZmctLyWzkkmgR6Q0Pgy3QG1tbm7HQvHLsz+BpB4k0WwXZp3h2If7U6KxP5c15gDMEIZsktwR6U5J2Vwok+bk5NMD0aXxbYXUBSTSbeAseTEpH9ajNtot7NGto8kTSYLBl/SuLtdRkmeNXEYiUZJ2CtJLpIn3tHNuzlHQ9KAN24t4nlltkmWRgvHGMAe9cbfIICVDZy2QR6Vom+tMlXE3zAjfjPWsq4tl8v/RZWmji+bkdBQA/T50WeMY3fMSzHqBjtVSN1MzsgySSaSCRo9zuOD0bv+VT6akJMwKN5oiZhzxmkAWFzLBqdrcRvtljlDAn1r6gt3MttDISCXjViR3JFfKscXyZkLb+vHb619HfD+7+2+DdNlJXeEKsB2wx/pQB0FFFFABRRRQAUUUUAFFFFABRRRQAUUUUARzRLMuyTPl5+ZR/EPQ+3t36HjIqSiigAooooAKKKKACiiigAooooAKKKKACiiigAry34xeKksxDpVrMhc/PPjqBnpXous6jHpenSXMvJAwi/3m7CvmXVUv8AxH4kv7gQPLMWIIHY5oA5xs3E0mw7mZiQMcCtbTNLm1CNFZvLgj+9Iwxgd8eta9tpWmeF7UjU5fPvpCWEEXVfwrN1q/lv0VHJgtWOY4h02/40AWIpNP0qK6WBiyMSAQeWP+HtXh/jqOKPxLcmFdquA+PcivRbsARyLGpZsYRc15Xr6CPV7lFYkK2OTntQxmdRRRSA9J/Z9APxM07PTIz/AN/Er7jS5x9sdiFVJGAZuBx618NfAJgnxHsmPONv/o2Ovsrxyxi0ieC1bEkzkkfXrTEeV+LLpfE2vyCORNkPCuDkMe9ZtnoltNPJaLeq86nIypAWut0LwuIrT7RfvbWVhCGLzHh5Cee/Bri9a1XTXuWgsUKwbtrOPvSH3xTAhvtO+wG4E9yjSIMhazI2hBEjQrJGhDEt0b2rTglinU+fEI7bG3LHniql2tvK0UdmubbeFc98+tADZtUWZ3mhtkt0ZsCNeij2zR9rZ2xkccHnpWYxihu5QHDIpxUlpsMisWjJPfNIC/Iwa3MSqck5981FDJLbRGLLKX+8VOMj0pl3KisApJzUvmJJIPlwQBk0AJJGGiXIkORkgDjj1pbSP/SFaDIJHzbuKckciXDNE7eWV+6amtEmknTav+femBUlOZGbfk5xjFeyfBG+8zSb+ydsvFIHA9BjFeQSGMzSNEiKo4z0rtfg1fm08UG3Lfu7mPy+fX2pAe5UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUhIUEsQqjqTS9a85+IfiZin2LT51jiSUCeXPUd8UAZ3j/AMRWV5dugd2itsrlOVJ9PrXls3i1rWTyrGNgJGOSFyy+5FGrX8cl7tt5iloHLFmz83vWClzDGXSIIZWJ+b+M/SgCW7MqzM8haV2IIZj1qtLJJO2ZG6cg9gfam3EwElsjGR3VMADn5vSgHzGyVIXOSD60DIJmH2WZnlZBHyxz/OvLvEMtvNq072m4xHGC2OTjk17LBc2P2K7gS1wZGDbz6ivJ/G0k0mvymeKOIhVCrGMDHb8aAMCiiikB6F8CmCfEC0ZgCoMec/8AXaOvu4wh72WSVFIU/KT2r4K+DMnleNIGPT92P/I8VfZXjnxdDo2lSuDJ9pcFAi9RnjNMRwXxb8QjVNT/ALMtroR2kJ+ZVUjcw75rzt5I7eMSQxLJliAzDIzTZ5Gvbh2V97Mcs7nnPrVeRhBHtVt/OT6CgC0ZXuECFXMwBIPYCo4maCQK0mQ3GF5qobh3QhsqAeCPSn2rATCQk7RyWoAJpVwY/JxzkHv+NMVgojUIT68/pTvMZmZmXJPfHaiNkaXHVfU9qBlkIHTaivxz71dhicOpcgAkcN3FQ27LGjtJLxxgDmrtvNbNdW6TthJGAYnPAoEXtUQQTwqu8b0DKu3gfjR5nkkzStlyuFwelVvEF4ZZ8xtuCfu0Y9No6VVt2doP3vQ9c0wJrQ28IaSaJpcggAHgN2z61q+C5UtPFWmXM0oBEoO0cAVhy71i2KUKhsjB5P8A9epYpPIdJPKLspBznBoA+pPpRXKeCvFkGux+RM6JeBcrH0yK6ukAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFRXM8VpbSXFy4jhjGWY9hUd5dx2kTPIyqqjLEn7vvXhXxE8Vz67dvZQzyR6ehIPYy+/0GKAN7xp8SZLl2s9D3QWoOJLnI3N/u+1eX6hdPezvK+4qBhQD39TUTspCKMZTjdnqPpUa4LqFJYkngcUAUbosflZDlvyqF4cgsU5Xg4OOatliIHMoLDPyhe47mqzMsrbEKqfQnk0DEEgBUBQHx949qQcLgPlOSRQwKwlD94nkLzShduQOCOfWgCA7mwFLbT828dvavMvFUjS65cFjuxgZ/CvUUffDLKwJUE7QvHPpXlvidQurykIU3gNtJzQwMmiiikB2/whUnxahUAlUQjP/XaOvcfGNw08cjTSFnikKY7nmvD/AIPKX8Z26DIDNCpPsbiLNe8+O7SW18V6kiRlYllJQkcY9aaEcHPKy5WIbVI59c02OCZlLKhZe4q1Kro5k2lmY/NxTZpTJhdxU57HFAyFo3CkOV4GME8in7PLgCjax6kA1BsYyY5Lg/e7GlJ6Zxz0C0ASmNhGf4dx9etPSzn2fIobd6VDhvmwjthf4RnFL52wBWUsB2DYxQBduIDFCmIpAB69qYDGjKJCS3UsOcVa0eeOcmy2NunYKjM+cE/WqeoWc9hO8M2ODt470CLqzR3KNCQSf4Gz0/CopIpbEFZSxZu5/nVOYmG5LK5VlHy4+lbetXEWo6ZYXjgxzQIIW2LkHvn9aAM5RHJGdjlHXBy54NaV6sv25pcAQug27RwcCsgsrqNnJbjmtS3kxpbCRiWikEarnoDz/WgCS0vbmG7tLuFjGIXA4OOR2r2TwT4+i1RhZau6Q3ZOEkJwH9j6V4yAz2g2qCiPk5HWiKThiuWlyCMdselAH1GRiivHvCXxBurKMQ6oTcW443HkrXrdpcw3lrHcWzh4ZBkEf1oAmooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACms2CABlj2FLglhg9O3rXFfETxBPpmnSQ6ax89/ledRny/p70DOT+J3ibzrp9Ksj+7j/1soOd+e34Yrym+uX+0RwryQCS5H6f59KualDEZSX3PI5G7LEZJ9eeKqzIq5gUBWz90c5/GgRUZWFyueAcEE1fsIrYalLdTeYLe2XBG3jcRxRPp91mGOTaqZDLxkirF01xqDm3son8uIYkI4De59aAMAI01yS8hAc4C4+7S7RHdJEu1nBPO3tW/o+lyT6nFBEuQx5Ld/al1LSBZPulUeZuOKAOelYh9ysoYioraQvIoccg7fr/APWq/LFsPnOokkLcoOgptjB9pvozFC7uWIwtAyMwnypiQI0TnB4APrXlnjWHydbPffGr59ev+Fe8WXheaWxum1D9w7MrKkzDoDnHFeO/FpifFSgwrCq26BVXoRluaGBxVFFFIDt/hDkeLYypAOYeT/18w19i/FextpII5XASR/kLDvXx18IiB4tiLA43QdPe6hFfZ3xMZTYmM438lc9qaEfP98RDdSBHdQvGM1QwEw5y7dvareojEzGdwWPBxVJjGDhSTxjFAxVEmwlAME561LFGDKGePnYcANVV84TyyQfTNOIZP3gVsZxuPc+lAC5lhkLHzI/RVPX2qP5mcsBgfrU32iQxByefoKcroWVyCpxuzjr+FAEtk6/aFdYwZl5jbvmtDUpI7qGNpBtnzkk+tVBC0c6vuAJ+fNWJYJJooLi3IcdX9j2oEUvLZnLSptxzk+lXoGE8RgVfvdB0H1qK/kLhfMBQfeY+/tUcS/Ij5wM8c4zQBbsLG2uLtYL2SWCMnlkxnivTotC0C28L3T28lre3hBMJmkIkL46ADgmvLrZGd2G7JT5ixHQVuHU5/sNo0MUCokpIfYN+cdQe1MDMikmWzulkiKMG4A5xzU2n3MbXMnnJhShAx1xinrKWSUQiVnkbO9jke9JbaLqUha5t9NvJrdW2mWNMqD6GgC022Ux/Z4/3QG0j+99a9F+Fd1LbXE1vLKfJfGFY8H6VwFnBc2MkqahaywtgELINuRXV+Dna6mMMBCKjbVPf6ZoA9ioqppckslinnjEikoeOuKtUgFooooAKKKKACiiigAFFFFABRRRQAUUUyVyqnYMv2oASaeKGMvJIqqO5NZmo+IdOsIBLcSkE/dQck1Ql8R6f/a66bfhEc8/OAQa5b4wa1plhp9slt5E1853BYwCQn94n0oA1b/xql5ahNPHkLKdhuC2dp9PrWmttp1zoktrLLFcXPlNI231Azn9K8I0i8vGkWPy4pIZHLhOdise5r1fwj4c1N9LVJbqG0tpFLNJC2529OD2pgeKSuZby5KEFACwzyeDWf9peSM4BEjcb/QVveI7ezTV76G3kDNHKY2kU8Map6Zo8mp30EXzCNWBLjIHHakB01sxttLivpF/ejAV2H+RWjpdil2ZHvL2OISHKeWoPHocfzrmviAdQuLmKw0iyuJoUx5gQ8DHtS6HoetwRCWTT7q0jx96QYz9KYHb3j6T4XtWktYw92y/Jl93PrjtXmV7qH9qX7SX0kyoQSqxnBzXSXOkiHMt47NMfx4rm763tmuXYnY3lFYwPU0AJaXNpBDIpRmAGTv6ip7PW0igZdOAikbPJXgfTNY0qCG4SOU7QEG7POajWK3RQ32hIm9HPGPSkMNTk1GSaOWa5ld3HyqHIX8a8z8cyzy66ftRJkWJVGTnivV5YJLSMq00dzE6edHtP3PY15X4/Xb4gbLs5Mak57deB7UAc3RRRSA7X4THHiuPnHMHOM/8AL1D/AJ9utfaPxMty1oJgFK4IYnt0r4t+FAJ8UDDKuBC2W6cXMJx+lfcvji3N14fnyPmADYz04poR8zapGxuWaPyxg55PNVTC3lbtyOT94A81e1BHe6lAAIBIOOOKoQwEkbTt9HHFADDJLCpPyqSe4zWjDdrfWS2l0oyjb1lQBR+NMuZ4FsxDHAskucmZid1Vi0uU8tDgckUASPbSKWgZ1AxuDYwCB6VFDukcRxRyTE8YAzW1Z3r3Upt7uMHzPuFVxgenFdN4a0ZoLkufLXbyoIyW9qAMuy8Ka7I/mmCMpt5LNjA7CpbXRdQ0e6Es/l+W3ysNwI5r27RLhrnTyj28AZB9xl4auV1/TLGYSM8CreSyZ8roiD2pgcLf2mlaxlrBik8KgEOflz9K5q6sbuPPm2xCqcKwHB+ldRd24N5DCGEMAblVHoata5r1nNNJaGxJVAEVw+O3WgDjoDNHG4YMN67MkdqktRNJA8US7nPCgVPdhpTtf5EUcBetbPhi3RbaS4ZSGQ7QT2zQBDoGiytf28MzbEklAYdcD1zXtFxqieFdMs7f7LJcozlE8n5R65Nc94HsYbnVW8z5jDGJQfUZxXd39nFdxp5q5MfK0gPO9f0u9v1vhcM891IVaKSQkpGnUqvpWh4H0aPSowL2JPmYSRv3J966K6ify/kVdhOG4ByKdploYYmjdt6liRu5KigDaJJOTzRSL90Y6YpaACikBB6EGloAKKKKACiiigAooooAKKKKACgEg0UUAeOfFmzWPxRp8kR8uQRM7OTjcMmuPubR7+UO7x7I+R82c17J8S9Gg1LRfPYKtzbglWPdO4rw+W3Y7o7dcnoWUdPpTAnjmg07EsbiRAf3kQHOPUH9a6Cx8Vizs3S3eSRJXBjZjkCE9cVytp5ttzLGAJPkXGcKDxk1Vlfy45Y3O9RmIN/eFAHQX8OmpqX+j2a7pAJGEgwpz3+tb/hoW8syeUI1B5BU8fSuF1W4Vmh+dlZUAbae3bmk0/Ubq0mAhnjwBlY+5/8Ar0Ae+aXbwR3PmiIE46svWs7x14gt7RFh8r5V+ZsEc8dK830bx3qcUpNwfMiBwEBJP0NdzPb2Pi62ZLG3QOyZILYbOOeKAPJdQ8SSatLIUVollI246gVTtooEnUXIkLlt2W6Y9/auxtvhxqdldrFDZx7BwuZAKyNb025tzMLi0MIX5dxbPPv7UAchd+dLcNLJGVUkhPYVAigTMJsMAcEVpXMM8kBlRsxqcM3YVXiiSXO1sMBwW9fWkMIduZI2crHINvfIFeWeOIHtteeOR95CLgn07V6q1q0cSNJJCTJnbtbPSvNfiQpGuwswAZ7ZGIB6ctQBylFFFIDrvhiceIxjOf3OMdv9Ih5r781dTNo9yMgkxZyO5wK+APhu23X2JJHyx9P+u8VfoLb4kgRGHyNEv/oIpgfL+pQFLuf5eQ2cnr1qrMFEREzhDMN3y8//AKq3/HFnJp+u3K4+8x4z0FcsqKWO5RgDgj1oEOFqs2EjmBbGF4xW9aaLcaaiXl4nneYuFiUdPrWfZobNormQFpQconoPWu/8O+MYbvXYYr2AXJkHytjAFMDk7eJV+Z7WeJc8KV+Yn6elbFvr66YITLA5ZjhYyCCfrWh8RvEkf2tYYI4yF4by0Cso7c1x8E0+qXMC+WcRAyNJj5gBzgmgDvbvx5JpNvG7WwaZhgQqeg9c1y2s+LdSmufMZowHXP3fuisLXruK9vA8Bcqq7W9jUEu6RVC/McAZbjFADjq9w05kkYtg1esLDUdZPmWtrPIC3zMqkr+dMtLFLucRzsI4Y03zN0zjsK9d8IanaaVp8JFrI6ScQxRABj7nPWkBwkfhXUIf3t5GqRKP4TlvoRXWfD/SoLmSWGJVaOP5trHk/hXXS2lxrO2VS1rBNwVx86+/FcyfDcvg+5udY/tGEknZCCcMwPbB6n6UwO/sNMt7K4lnhQLJIgQ4HYHNXqixJJaL8+yZkB3Y6NiqGk6g0krWOoOo1KMFyoXaGTP3h2pAXfsibCqsw44zzioZVMJWQuMp0NVfEtje3lkP7NlaO4U8rv2hx6D3ryXUtb17SybO/kZZY2+5Ic8H19aAPY4L+DAUvk9/rUF1rMEAJOT2AFeNy+JLp1wirGcZYjI3Gu28C6VcalDHfahK7Qk5Ax97HamB3On7niMzZxLyoPYVaoNFIBpcCRUw+5gTkKSox6noKdRRQAUUUUAFFFFABRRRQAUUUUAUNeRZNHu0cZUoRXj2laUraobZcFwScZ/Gva7lIpkEM+Cj5GD0/GvKrOAQ/ElYYHiCo2x+cAg+nvQA/wASeEmuNFlltkVZYR5hCjG7A6CvMri0fyx8hUj+EnAJ75r6gZY02x8DPQHvXk/xL8L3FttudNj32+S0oHBUn0pgeVsBbwpC5DFAckdap3RS5WObc0ckYwDjrWu9jNeZiZFjfPDY5NZ81lLGqRS9VY7sUgITJcQFJ1CqrfxdefpW7ofiy9sLyOW3k8uRjtO3IAFYsiqsRUhth6Me1UA20hxkkHFAHttt8TbKBFXUInvJVb76/My1j+KvF2n6vYyvbRzRMcAiRCDXndlBm6UJId7AuARUFvfmdxvXcrdFx96gCDzQk0iIWweR3BouZWBDEqvGMKMYq27wXCERq0D4wFYYGar3FlJBNtuWUYHO3vQMc0Imt/lX5CMofSvLPH5b+3FV8/LCoGfTJr0+Cc288b2zbirgncOPrXnHxOuBdeJvOAALQruwMDOTQByVFFFIDq/hvzrz+0aH8pozX6A2snmW0AH/ADzQk9f4RX5//DUbvEDj/pkP/RsdffemNiCEKOPKX/0EUwOA+KWmI7pdQgCYrySOteSNAftiNJIuQcFQvBr6H8Y2IvdDm2oGkQbs968Euh9k1IylCSuQF9KYjMu5nmvWbzBwMAgYAqXRXFtqCTlgqRdc+noKreS+NrA8HqeKVo1YLHECzA8ikBqa2gk1mR7hyIGQED14qG2vpFt5EUBI3G1FB5GfeptQlSe+NvJgJGvDnrnHSsp5EaYIwIGccDpQAQRszOyKVCDk54J+lSoDG+Gyz/eA7VDCAGZwrKQcAjnNXrdEmXyWjZJG5D85UemKANjRLQXl2gun2xOAzZ6Z9K9du5tM0q1s72aSI/JtQbh8gA4wPevHbuZYTBDngDBI71DfXEl6VMkjlI+iE9qYHq+g+NraeG8kdvs7xAmMFSwYemKn8PajD40kKalEPPtH82JB9wj6V5dprMmm3kgk2k5UHPzCu7+EeyK5VdxMkyNn3xQB6mTkk1XlsreW9ivHjX7VEuxZO4X0qxQOopAH0rmfHXhpfEGnh4FH9oQj922cbh6GtuzhuY5ZGmm3RschDztq3QB89C2kbUYtPaPZcFxEwYc5zXv1japZWUFtEoVIkC4HrjmucvvC32nx5ba5lBbrEBIvcsucH9R+VdUTkk0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZviHP9luVcIQRgk15zaRP/wsKw81FlMyguQPfrXWeO7hI4Iw4JKkFQeF+tYHhi2u7q6vdQ3oz+XtDg58tc9V9TTA1vFmqanZ6jZNFA7WayEeanToetUb7xZJHbXL3caStGdp2nKnjtXeTW8cunSQOVMLRkbiRjp1rxLUbuKDQbuzGJZIWO+X+8RnpQBf0yK18VJNbSI1vIx3ROq9W9PaofHGiSpFAtzCPt0ICAqQBIOgqt8KPFFjY3K2eqtGgckxyt1PtXXeP9Y0u+t18gl7mMEA4x16UAeKarbXEM7xNbyIicMNw4rKk2xYVQQAclj6Vsai0xjEk5JuA2NzHHH0rJmkklcvwBjHI9PakBIGbzhIz4HA2juKddXC2cjOoVYX+Y98fjUMbhIxNMpZMYQe/r9KlgRZbFtxSR3Y5VugoGC22yRZBlmb5gM1NYXENzGbe+bbKTxIx6exqtLK8qbRI0LIylSBxgdqLyXzbpiwG6Ybs46GgCzLZR20jLJIXyMrs715b8SVK6/GO32dcY+rV6pdO9xbJLgbkGxe2cV5d8S0C6xbNxva3XIHbk0AchRRRSA634Zc+ImHrD/7Olfdtq8kSwoQc+WmR/wEV8J/DE48RsR18g4+u5a++7ZFn0+2OMP5MZP12jimBOmCOQNpHINeKfEjw7LperGeAMYLg7lPYGvZ4jk7W4Pqaj1fTrfVbCSzulDq/wB1j1U+tAj5iuWCySBnLED5sdM+1QRbVZPnGc5zXTeL/DV1oF7Is8RMTE7XHQj1rnFt975KHA568D60AGrvLJfPLnK5yCB0qu4ZZOOWcZx71alO2NwrBnHzY9qrgFmOWB/u4NADohISoJKYPA7mtrToZYIpruZTvPTPSs63gIhLAbfm2rkda0rpt6LGGO1FHGe9MCvKBdSGbYgbgBc8ULE0b7XxvJ5CnP61GYijoSv1561ciG5f3SAEHJYelAF+whH2XyfKZ5HY4APT616f8PtKk0lTLMqs8qkD/Z+lcx4P0xPsUEjENO7MeT1Ge1ek6HZ+TKz7iyIu1MHjmgDXQMFG7rTqKKQBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUjEKrMegGeaCwAyePY1578R/GUVjA9jp0iyTsCrkdvpQBynjnU5dS1meG2m8xmTaEBztbNdzaajaaF4O2y7UuDDj5fXFeK6RdJHqEd3cOYwrk5HO9q3PE+pG/0poT95mGCGxjmmBhp4g1mKKG3N/dSQTK0hhLDaq56Vo2My3GlSGQgRliBzwK5mUbOd3lyKNoBOd1bd1FHF4SuI92yVsFcepIoAx7rR5Y5QSRKiksrjHy/SpIpZhblpZmG1shz/ABe1V7LU2s3kjlPmxtgYHPart88L2glji6HLY5xSAfEY77ck0iGXGct0I9KwJ08hiu4dTx3HtUskwVFYFhz8vGKfeiKQI8kZE+zc5Hc0AUHldhtmHyqPkUdqnOR80YC7QDVR5UGW5Bxkq3aprMFtP1CZpVZVkRQM8jgGgZZu2ErJNGMg8P6A0Rp9oCcbGBwpx1pjSzDRzbxsUJmD52+napo5pXfeSp8tRjgDNAEltGWkWEbyDyRXM/HfSjpx0CZ49sl1bs547AjA/WvWPhroTa9qSvKMQxHc7AYHHaub/bEgWLVfDnljEYtmVcdMcUCPnOiiikM6n4dPs19iOvkt/MV97aLeLJYWayYEjQoOv+yK+A/AhI104OD5L8/lX2/4dKyWFruAH7lOeQT8opoDr5PL2Y/WliIZMHhv1qjZzgNtkwBnGavIRkkck96AKusabaaxZvZ6jFujbo3dT6ivDPGvhK98N3DHmaxkOUlXn/vr0r6BYbhjv61DPDHcwPb3caTQMMNGwyCKBHywY8yM6EZ2hQPWlSGMyMWcfL1AGK9N8Y/Daa1llvtBDzW+NzW/BZfoMdK85kikjLQlGSUAgo4wQaAEtXkublB/yyjOQPSpo182UkMFUk7gOppsZkXYp2qoGDgc1Ns8phcFf3RGdvemBH5JSY7cuAcjccZFXrJjHC7EhRISvPPFVpFiMqSSEsrLnj+Va8z2v9m21miMsqlmLgfez0FAG38Prtv7ctYvlEChhl+eT6V7NBEIY9iADnOOleC+FxLa6nGzYKK4YqDzXvcMonhSVTkMAaGA+iiikAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVR1zUI9K0a8v5fuW8Zc1erkfiyk0vw71qO2QvI0agADtmgDzPWfiFfXivDEShfjg4xXGTT+Zcq9ySZh1XdnNVZ0O5ZEcHjoKrmOVQXVDvzmgDSna4mSOAwISGLYUcj3qC5u2PyMjFQcn296SSLFikzl1mflMEg470y1SZ43aNfMdU+bJ/hoAGi8yX5YjIzjIOSMV0HiEKdPjitW3ZCqW9enas/SXtYElvLtpGjC7UWHgZpNEmF3ZXUUq/6QxOz/d5pgZT2pEpSR1TnGR3NOsbk29w0MkqmJ/lORUUy7UeIbsqcEY709/Mu0LGMMyge3SkAt/bzQkxyEmIHjA6VVNwQ4VCMAen6VoXryyRw3LH5tmCg6Cs2Z4ihGAreo4GaBkfMoYnBx3x1qXTSd8kMmxYmG45/vdqiCLbgQpv9gQOadGpDoWDEdCCMUATR5TzPN3kJ90g8Ve0vTpNTv4La0iMk8jAYHUDPJNR2cL3Di3jVnlkOEVRnNe/fDHwWPC9h9r1DbJq9wBuwP9UMfdoA3/C+gQeH9FhsoQvmkAzMO5xXzt+2T/yFtAXOAkLAe+f/ANVfUQ+RSW5Jr5b/AGwo2S+0Euc7o2wD2oEfONFFFIZveDJooNaElwwSIRuGJOAMjA/UivuHTrOS1020AzLH5MZyox1UV8D2z7FnH96Pb+or66+BHxNm1zw5BaarGGmstts86nc78fKxH93AwT2poR6rC8m8I6fIBkHua0LW4IOz+HsRUUtkly3nW8gKt12NkN+NRRSbAV/PPagDYjbd3ye1ONZ9vMAqknIJ49avo4cZ4z6UBcFDK3H3e3PSud8ReDdI12RppENvdnrNCACT6mukpoZS7KrKWXG4A8jPTNAHjOpfDXWLJ2a08i9hXkYJ3n8KxP7B1FUaO40y9ibOP9UcH/61fQdKHboGP50AfPzac0QSO4jeQr1Urt2/jUiWDX0n7pSrLwMnrXulzZWt0c3NtFK3qygmqJ8OaP5vmCwjD+qkincDyrSNNmhuw0sciSD5WOOvvXrmilBYRJGSwA5JpG0bTj/y6gfRiKsWlnBaLtt1dR6M5YfrSAsUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAIQD1z+BxTLiFLm3mgl/1cyNG30IxUlFAHzH4o0Kbwzrb2N1CfJU/uHzkOnY/WsnyyHDyOQu4fIO9fSvi/wAM2fijTDa3fyTJkwzAcof8K+fNb0i50LUpLLU4mDjO1+zD2NAFLXXea7VhtEaKQu3oBUVtCyIrAE7uPrSyY+z71zleEz/hRpyTfasElvlJA7DigBuoSRsqwKT5K8xvj73rS6JLLbalFcRRDbGcsG5B/CoAGa1Ro5Nwjyqj0BqzpkYNwftL+WjDGVGTQAzVp4rq9lurRWSFuWQ+vfFV9NYNBc7nKyMMikgUrcSRMuFJIA/lUkKKsNzEXDTKhPAx+FACWsky6YEkaOQBt2wtjNUZ9gKsqBmfOPSrVtGWEQlwMDk/hTvK2wosyrsBO0jqT6UAV0ixbBw6lt4GCMlfxrU0jTb3WbyK006A3NwTlti5AHqa6jwZ8OtV1tA11G2n6c5yZXGHI/2Qete3eG/DmneHbJbbS4BGP4pW5Zj3NAGF4A8C2nhVBNKwudUcfNL/AAx+y12bfKMgbnPSncKvFMBJG49fWgYbBuDMcmvl79siUPqOgoFACRtz619NzP5q7Vz15NfL37YKqmpaCBgsYmyccnpQI+c6KKKQxQcZra8K+I9S8M6nHe6VcNG4I3x5OyVf7rDuKxKUdaAPr74X/FSz1hJN80Gm33B+wzOsdu+evldy3tXs0Rt79FY+bHMRuEci7XUf7vXFfnVp16beRSzlNvKuPvIfUV7d8Ofjcmm3NvbeKriea0jG2O6tkImX/fPVl9h+VMR9RlfIYq3Oe9SwXAjGF+Ze5Neb2nx3+H7wLHf65H5vOXSyuNmO3/LPOcVBL8avh0simLxCroOubK5B/wDRdAHr6ncMjpS15JD8cvh4nP8AwkG055/0O5/+N1cX48fDggZ8RYP/AF5XP/xugD0+ivMR8ePhx38R/wDkjc//ABuj/he/w3/6GP8A8kbn/wCN0AenUV5j/wAL3+G//Qx/+SNz/wDG6P8Ahe/w3/6GP/yRuf8A43QM9OorzH/he/w3/wChj/8AJG5/+N0f8L3+G/8A0Mf/AJI3P/xugR6ZvHmeXht23dnHGM46+vtTq8x/4Xx8N/8AoY//ACRuf/jdH/C9/hv/ANDH/wCSNz/8boA9OorzH/he/wAN/wDoY/8AyRuf/jdH/C9/hv8A9DH/AOSNz/8AG6APTqK8x/4Xv8N/+hj/APJG5/8AjdH/AAvf4b/9DH/5I3P/AMboA9OorzH/AIXv8N/+hj/8kbn/AON0f8L3+G//AEMf/kjc/wDxugD06ivMf+F7/Df/AKGP/wAkbn/43R/wvf4b/wDQx/8Akjc//G6Bnp1FeY/8L4+G/wD0Mf8A5I3P/wAbo/4Xv8N/+hj/APJG5/8AjdAj06ivMf8Ahe/w3/6GP/yRuf8A43R/wvf4b/8AQx/+SNz/APG6APTqK8x/4Xv8N/8AoY//ACRuf/jdH/C9/hv/ANDH/wCSNz/8boA9OrJ8R+H9O8Q2nkajCGYfclUDen0NcP8A8L3+G/8A0Mf/AJI3P/xuj/he/wAN/wDoY/8AyRuf/jdAzlfE/wANdV0t3fTyb61JOzYpLgf7QFcdPaXVixims7mEZ5zGwr1wfHj4cDp4j/8AJG5/+N1Wn+NPwsuM/aNZhlz/AHtPuT/7ToEeVCBYw20MqsvOQRUU0YWAjzTg45r0+X4r/B6YYkv7Vv8AuHXP/wAbpsXxV+D8JUxanCuOf+PC5P8A7ToA8vTY1zmN0lbcGGD83FalloOqTztJbaRqDeceX8htpH1xXpQ+NXwrAA/ta2wP+obcf/G6nT47/DdFCp4iCqOwsLkf+06AOZ0j4Xa5d4+3NBYRnkOCHOPQrXoPhr4daLorJPKjX12BgvMSU/746Vif8L4+G/8A0Mf/AJI3P/xuj/he/wAN/wDoY/8AyRuf/jdAHpuBhQAAFGAB0H0pa8x/4Xv8N/8AoY//ACRuf/jdRyfHf4dnhfEXH/Xjc/8AxugZ6dI6r16e3eojKJQCQVUV5gPjl8OwVJ8SFiP+nK5/+N0rfHH4clufEX4/Ybn/AON0AejvJuXEbBDj65r5k/a8TFzoDliTsccjk16xH8cPhorbj4j3NnOTY3PH/kOvAf2j/H2jeONWsD4fuDPa2ilQ+x03577WUYoEeM0UUUhhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rounded atelectasis in the right lower lobe. The lesion has a curvilinear connection to the right hilus, a so-called comet tail. Adjacent pleural thickening is present, which is characteristic of rounded atelectasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cavitating bronchogenic carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 321px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The irregular internal wall contour and the wall thickness of the cavitating lesion are suggestive of malignancy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Small subpleural cavitating lesion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 278px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEWAW4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5q/4STXP+gzqX/gU/+NdcuieMCB/xUMoz2N7N/hXndfVHw98GXvinUAqgxWUfM07che+B7mgDznwv8OfiL4lujDpmtuwHLSPfTKi/U4rsG/Z9+KSnH/CW6cfpqV1/8br6m0HRbHQdOTT9NhEUQGWbjLn1NagAGMgZ6ZoA+RR+z58UiM/8Jbp3/gyuv/jdL/wz38Uv+ht07/wZXX/xqvrrHqBn1paAPkT/AIZ7+KX/AENunf8Agyuv/jVH/DPfxS/6G3Tv/Bldf/Gq+u6KYHyJ/wAM9/FL/obdO/8ABldf/GqP+Ge/il/0Nunf+DK6/wDjVfXdQ3t1BY2zXF3KsUK9WagD5K/4Z7+KX/Q26d/4Mrr/AONUf8M9/FL/AKG3Tv8AwZXX/wAar6E1T4laJaOq2vmXef4kG0A/jXEap8T9WeW4SEwwwscJtX5gPrRYDy+T9n/4nR/6zxlpSf72qXQ/9p0z/hQ3xJJH/Fb6Pz/1Frn/AON10F5repXB8yW+uGY5OXcmoBfXW1WaZmJHHPSiwrmYP2fPiieR4v0zH/YTuv8A43R/wz38U/8AobdO/wDBldf/ABquhXxDqUaqi3s2FHA3Hirlr421yFuNWuSo6KWyKLBc5L/hnv4pf9Dbp3/gyuv/AI1R/wAM9/FL/obdO/8ABldf/Gq9W0b4rXsSLHqFpHcLn/WhiGx9K7bTviJ4evFXdcyQSHqrxNgfjiiwz5z/AOGe/il/0Nunf+DK6/8AjVH/AAz38Uv+ht07/wAGV1/8ar6uttW065RXgv7ZlPTMgB/KrisrKGRgynoQcg0gPkX/AIZ7+KX/AENunf8Agyuv/jVH/DPfxS/6G3Tv/Bldf/Gq+u6KYHyJ/wAM9/FL/obdO/8ABldf/GqP+Ge/il/0Nunf+DK6/wDjVfXdFAHyJ/wz38Uv+ht07/wZXX/xqj/hnv4pf9Dbp3/gyuv/AI1X13SEgAliABySe1AHyL/wz38Uv+ht07/wZXX/AMao/wCGe/il/wBDbp3/AIMrr/41X1JN4m0OHcH1S1LLwVWQE1h3nxI0G2maMG4lI7xpkH8aAPnf/hnv4pf9Ddpv/gyuv/jVH/DPfxS/6G3Tv/Bldf8AxqvaNS+K5WbGmaasqY/5bOVJ/Cs2T4samP8Alwt1z0wScUWA8p/4Z7+KX/Q26d/4Mrr/AONUf8M9/FL/AKG7Tf8AwZXX/wAar0xfiprG8jyYfcEVFJ8UtffPlCCPHrGDRYDzj/hnv4pf9Dbp3/gyuv8A41R/wz18U/8AobdO/wDBldf/ABqu7m+J3ifJVp4AD2ESjFU5viD4kljYm/UgHONgGaLAch/wz38U/wDobdO/8GV1/wDGqP8Ahnv4pf8AQ26d/wCDK6/+NV2emfE/xBbP+8uI5UPUPGCa9E0D4q6TfyrBfwy2UmPmkcgrn8KLAeEf8M9/FL/obdO/8GV1/wDGqP8Ahnv4pf8AQ26d/wCDK6/+NV9b288VzAk9vIssLjKuvQipKAPkT/hnv4pf9Dbp3/gyuv8A41R/wz38Uv8AobdO/wDBldf/ABqvruigD5E/4Z7+KX/Q26d/4Mrr/wCNUf8ADPfxS/6G3Tv/AAZXX/xuvruk4I5GaQHyG/7PvxTEbsviqwcqMhF1K6y3sMx4rznUPDXjfT7qS2u9dmjmjYqym9m4I/Cv0CPt1rzv4seBI/EdlJqGnpjV4V+glUDoc+lAHxPrg8UaNapcXWu3bo7hB5d5KTnBPfHpXQ/BvXdXn8T3Sz6pfyqLNjh7hyM709TUXxQheDSIkkVlcXKghhgj5Wql8FP+Rquv+vJ//Q46APP6/TzQtKtNF0qDT7CPbDEMdckn1NfmHX6lR7R92gA2AgYyrCnjOOTk0EgYzS98UAFFFc74i8Y6RoSlbi4EtzjKwxck/U9BTA6KqOqatYaTCZNRuooBjIVmAZvoOpryfUPirqE94VsIoLa2II+Zdz/n/wDWrzvU9Tur+6Ml9PJOxPBds4osI9T8R/FT52h0KDC9PPl659hXnGva3d6xetdXkrO5AHsMVjOx/h6d6a7c53ZHamBcjRnlROS0hxn0plwyJM0flkup2k5/Wn6e7C5jwQG6c1BIWNxKS2G3nk0AI8jMBGRwDTSwwPbtUbBiQSfxp5DcAcgUAOUgknkCpY9vzqSo9DioQCTwBT1RlXJHOevpQA6JSytsLYA55pd4CgEEkVIk8kZKoQUPXjqKERJEkZ32sPujHWgBpY4Xgj3roND8X6vpAWK1upPJU58tj8tY9tCLjKsdu1S2fYVCWLhdowo4B9aAPVNO+K85+W+sIOB9+Njz+GKkuPiyFlHk6bG6+rSEEfpXlbqwJkAwp4xREu9txDbAcE/0osB6Hf8AxQ1W4kU2UMNqmOn38/nXofgTWLzWtGNxfqvmBiA6gDcPoK8W0DR59VvVjgjdgOg/pXvuh6eml6ZDaoANo5x6mkwL9NkRZI2jcZRgVI9RTqKBnk/iP4Y3HnSz6PcB4y24ROfm/OuN1Pw3qmn7vOspVbHLZyDX0VQ2GGGAI9CM0XA+W1geNQzj5gevp7VIZUEXkyRKSeQ6jmvo7VtD03VrcQ3tpGyA5G0bSK4LV/harStLpl3158t1/rTuI8eCZfc/BzztFS3VuRbJLDJkE8rnkV1XinwndaPChnQkkdQv9RXICJo5SqBjjqvrmgCs4M0hYNyo9agizv3ZU85GTzV3UbZraZlmjaNuo57e9ZzFWbcykN2xQAT52MUwXJ5qBXG8KeWx1q2kBlSRolJVBk+1U0BB+VSMdxSA6/wT4v1Lw3dBreUSwMR5kMnIYeg9K968KeL9N8RQxiCQRXZHzQNnI+h6Gvlu3EUhlLOVf+Dngmr9hdSwB3hkkSRCCHUkYNAH1xRXh3hb4sajBF5OqwLfoDzPuKsv5A5r1PQPFuja7GDZXkYlxzFIdpB/HrQM3qKOlFABQDjmiigD5f8A2xvC9vZaFY69aKkYuL5IJowMZcxyEMPwU14j8FP+Rquv+vJ//Q46+kf20f8Aklul/wDYZi/9ET183fBT/karr/ryf/0OOkB5/X6lxHKdK/LSv1LTO3n8qAH0jMqIzuQqqMlj2FKOeleO/FnxwHd9G0yT9yOJ5UP3j6Aj0oAZ4/8AiNJNLJZaJIY4FO1pl+8/rj2ry6e4aSYszuWJye/NRPIrYA7jjFNSQpnGDnjpVCJVJzuOdppjfez3oBYIeck/pSLnnIH4UAKcMpOeaeFQDJPFNAzkYOR1p7FAF2545NADk3SOogQ7ieAOTURBEjiThgcHPrVmzvp7K5M9q3lv2IAP86gaVpJWklO53OScd6AJ1hiC/NMuO9QoVD/Kdyjp70rxsBlRwfQZpikRHAHPpQA9c+YTgAH0p7cxndvDHGMdK3PCXhi78TSyrp7pujGZNxxt9Kz9T0ybTL+W0vGCvGcHByP0oArwlViJYAsOnpUltGZZAFdVH+0cCkRYwjAKW9D2qN2jI2gdKAOj0rUdM0iRXubFL6VQVKu5Uc/SsS9ukubqSWGBYFdiVjU5A9qrja5Hr71KLcF+T70AOjJlj7j+Vdf4Q8Jza86GONo7VWBeQ9Kl+H/hKbW7gSXG5dPQ5f39q9vtLaCzt1gtYlihX7qL0oAp6Jotpo0Hl2ifMRhnPU1pUUUhhRRRQAUUUUAFFFFAEdxDFcwtFcRrLG3BVhmuE8S/DyyufNutP/cuFz5QGQfoc139FAHyRqaOl5JFNnepw24moo5I4+JIvMwc9ccV638XfBi+cdXskAjYHzVHUN7V43cLIp+YNt7DvQIsW2rT2yTLAiiOThgeaoyPscAMMdeKViu/Eak9sEUnkP8AxkcDnPUUAG4MdqY9RxTo5NoZDnBpu3eUQLk5yMU94WljYng5FAEtu2IiqMRz0HQ1bs5nRw8YYSKeCnaqUSmGMAtyfalViHOwnJ/CgD2bwV8SXjaCw1kmVSQgm7jPHJr11WDKGQhlIyCOhr47hmeMhnyWzxjtXvPwp8bpqccej3+EuI12wyE/6z/Z+tAHplBoooGeBfto/wDJLdL/AOwzF/6Inr5u+Cn/ACNV1/15P/6HHX0j+2j/AMku0v8A7DMX/oievm74Kf8AI1XX/Xk//ocdIDz+v1NAwABX5ZV+pVxNHbwSTzELHGpZiewFAHE/FLxU2hab9jsSDfXC4JHWNT3rwCZ2MhZss7ck+9bfjDVZNZ8R3d00m5dxSPn+EdKwVcKzMFyTxzVCFypgJxiQH9KjBz259c0kYJwA2O5z608hQRyB9KAFXkkMDjFIQ3HGMUoJ2YGAfWnjCqfmzz2oAtaHdLp+oxXM0YnVPvRkfe/OjVZIptSmktIzFbscqp5qmfmNWI2Bt2UE7yd2SOmO1AEatGDg5z2FGWMTBlBNG9j1AznrSlj5S84bPWgAWRkXKsyt7UsswlUMUCso7d/c07DSsTGAcLkj2qNHIGWUbetAGnpF7c2MEz20vltMMAhueKovI7zPJN8zN94E81PdXf2q7W4McUS7QoRFwvAxnHrUIjkJMjYx03djQAyO4kjV9h+TPTFS252lXKYVumRUC7zJjge4q0rPIixyLgL09qALEsBjkwEwjDI+ldz4L8C3OpSpPer5VjwSx6t7CoPB/hS68QtE8w8u1hAXcw6j2r263hS3t4oIhiONQqj2FDAbZ2sFlbpb2saxQoMBVFTUUUhhRRRQAUUUUAFFFFABRRRQAUUUUAQ3dtFeW0lvcKGjkGCCM/jXzX430VtI1q5hKkKGytfTVeZ/GnTo3sbe92/MCQxoA8EdHGWi/h6tjvTQWYjcc7jznrV3Z5YdQcqx/KoH8tQVBJP0oEXNJltLC6MtwhY4wox0qlduryYRiVPNQNjHJJ/Pmp7dYg7F2LccY45oAjZHfaMgL3J6VPPbxxxKPMJkOOB0FQSksNqtleuBUkQRQSWORxg0ANbaeVPTt7Vd0+8n0u+t7uByskRDowrN2ryoJHfBqcYCqGdiq88UAfVvhXWofEGh21/ARl1xIvdW71r14z8C9VSO+vNNOC04DKfQKD/jXs1AzwL9tH/klul/9hmL/wBET183fBT/AJGq6/68n/8AQ46+kf20f+SW6X/2GYv/AERPXzd8FP8Akarr/ryf/wBDjpAef1+i3xd1k6b4ZNtA+Li7bZtHXZ3NfnTX2B8RfEv/AAkPiCSWFmWCDMUBU9Vz1poDkZcbhtLYFNWJ5FYgZ2jJq0rI0ErMrbgBgj1qkk8sUm6J2XIIOO+aYhygFPUdKVIuFLZwTxSfPGyAxlSRuwRjI9aUOWB3Z9uKQDmOPr6Yo2nB6gEc4pE+Y4B59xirlrEtzIIMbHJ4amBWAAjwe/505MBTg4PrSXI/eHDfd4xikXATAOT6UAOJ6BtrD196CNmc4Peo0jDKTnAHUU4McBTtx9KAOk1rSbG20XTr6zuDI88WZox0Rsnj9K51gNmQRg9s1fl3Q6aLScSK8zB4x2IqgqB02jPmKeR2oAM5wAetOkWRdq557jPFQc7s5AxxnNPU8ZPXPWgC3CihH8yNi2PlKtjFami2EuoanaW0SGQSOFIHXBNULNIZJI0ld9rddq5Ne8fDrwzZ6Tp4v4jJJNcgMvmptMY9KAOm0rToNKsIrS2BCIMcnJJq5RRSGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcl8UBb/wDCJz/amCrkYPfOe1dbXn/xmdxoECrjazHcDQB4VKYyW8nIX17mqsTCNyQiORzg9KmDtFIGcZjzyB3FSCFJJt8PMLfpTEUurEKpBPbFBibbgYGOSO+al5QuwI4qMvvJYn5zySKQE1rAs8UifMJiPkQAncfrVfJikClQ20jjNWbe7ltf3kfD9FYdRVXZmQtwCeSe9ABcyiSZ2IUFugAH5VHHMEfcqhsdiKJGIlJ8zIHUH1pUjMjqo2jcc5JxQB03gbVZdH8R2dygCAtt3f7J619QBldQ6HKsAQR6GvkGBthYBhkcDHNfTHw31ZtY8JWssgAkg/cNg/3QOf1oA8p/bR/5Jbpf/YZi/wDRE9fN3wU/5Gq6/wCvJ/8A0OOvpH9tH/klul/9hmL/ANET183fBT/karr/AK8n/wDQ46Qzz+vpG2jZ0MpOE6Emvm6vomGQugO87QOBTQmXZZITuEEbJkADJzz3NVxGWG45GPSpvJkSMSOPkb7p9aY25h8uRzz6UwItzMc72ZgMLnsKmVgqdTuP6U5ozHIA5UsRnANPMplVUdgEU44FADF2sRnnnpT42Ecisp+YGu80fwPZalo8t/Z63A7LGcxFNpDde5riWtWjuHt5CAykjcKAGXxikl3W4YZ6rjvVcBlIxxU8uAq4B385YU3DbhwCDxmgByBdoyehz9aaqqVZj1PQYpeRycHPGDTizYIQHHagCaIqzwM+TJGQRnsKdIscjTOvyyE8elX5dF1C3sUv5bcrbuMBiDioI7ZpFXyRvkbqmOv0oAyjGY03noODmgyAsmU5xyBVi6Dwt5cimOTOWUjkfUVErLyAnz5yDQBo6ajQ3Ebry5YYBr6Z0eOSHSLKOfHmrEu7HrivAfh9psmp+I7SNslA4dhjOAOf6V9FHrSYBRRRQMKKKKACiiigAooooAKKKKACiiigAooooAK8w+OLlbHT1B67zt7HpXp9eS/G28ja4tLVxwiE7seuOlAHk+22YKX3KfTHeoSNi5EnyOcY6GnyeSQm123A96mvIY3k8wKMY9OM0xFeYKFOw5X1qvsLcL9c1YjTcvOSe601VAyMA+ntQBXm+UAZBY0mEKEYPmZHOeKufZHdWaMPJjqVXIFQiEJHktvPpSApsfvEAE9OlPVysPVWZuPcU9kPJJwD2piId4Ax9aAFhVQTuIUjrXqHwO1w2uuTafcSZju0CxAHgMO9eVv5vmMWZST7da09IuJrW7t54X8t43B3Dg9aAO4/bS/5Jbpf/YZi/wDRE9fN3wU/5Gq6/wCvJ/8A0OOvoj9sCcXPwe0KbJJfVYCT6n7PNmvnf4Kf8jVdf9eT/wDocdIZ5/X0JZB8JtXP+z618919CWjEomCckdqaA0pY7lFaG4JXZgiNj93NJHG4jIBLKeSB0/GoyXkwHctjjJPNWWu3jsTZoy+UX3k4+Yn6+lMRWYYAwoHvTeg47061xLMqSSBQeMkcVoT6XeWkavLCTE3KuEyCKAKcJdU+UuoJ7MQKsvbSoSHzISobKnOM025ZSwWPoFyRjiuq+GF/YWeutHqyr9mnXZmXotAHJxxqchgc/WlCrI58o7io5B4xXX+OPDUmmX9zfWRV9KDgJJnPJ7VykkUdxOksLeXIoy3p9aAICoX7wKgnkmrk0AihDRSiRH/iHY0l0CzKmVIHf3p32eVUZvvBefl5FAH0Z4ftrbUfB9jbThZbeSAKw68/414vqVrPoPicRRpiWGU4Vucrn5f0rt/h/wCKLLS7Sz0m8yjTNuVyehI757cVl/Eq2afXWu1BC4HIHJGKQHG+IfPu9Wu5riBEmkbLADocVhXUZh2EDpwR710duytPI1wSFK5DHncfSqcxZJS6xrgcgMM0wPUPg7octvazapdRsjSjbEp9O5r0quM+GmutqWkeRdyR/aIThQoxla7OkMKKKKACiiigAooooAKKKKACiiigAooooAKKKKAEJABLHAAyTXz/APELXm1nXZ8oHt4zsix2Ar2HxzqX9meHrhkkCTSDYn9f0rwHcYmAnIyxyD/WhCMouRdIpZeuT8vSpoVSRmMsuEBOUx1pJ1iy7BieSckdTUNpIhky7AN60wLlubRNRgkmjlaBWAdUbBYegrt9N8Bw69qQl0x2i01vncO2WTPbNef3rZjDQLuLHAPvXS6H4s1DR9Jks7eYoHXkgDOe/NAEniq+g8PXFzo+jmOZOBLIRnJ9q4q4O8hl+Qkdql2+ZenfNncdxYjvTblFMrHIyDk88YoArHcQFfJ44NPeEghsbBjnPWtbRr6CwlnlubcTS7R5IOCAfpWTf3Bup3mdlSRjynYfQUgI2AABxkH9acH6/LgAZxmpFspjbmXgIOnrULJJJs3fIenPegDoP2h3L/s8eGHdizNq0fX/AK5XFeK/BT/karr/AK8n/wDQ469m/aCGP2efDaEDMerxrkf9cZzXjPwU/wCRquv+vJ//AEOOkM8/r6CtMmNMMFwO9fPtfQNmpVF+XJwKaA6HTotOkdY9RnmhB/jhUN/Oq91FbxzTR2cm+IPiOV+GI9xVN0KhN/RgdvvTchUwUbPp2zTETzRpGAN4MvoOn511/hjx3f6Tbizuooby0CkeW6rx+OK41YwYd5kQEfw96aMtIBuAx2FIDr3u9M1O6xBYFHc5xv4FZ809uHkjSDawOA2c4xVHTpEjjuVJAYpgMO9VxMu0qRxmmBqz6he3tv8AZDLIYs7trOdp98Vm/vFfgDg4PvUsShtxQMxxgYHOaYjGIEEkk8MCOlAG9pL+HhbAanHetMM58pwBnt2r0T4bPoJ0XUzMLdtjN8su3dsx/OvG2G3Hp9auW0ksIcxMVVxyAetAHQSLba7cMkUkFtcRSZiaY4UoOgro9e8RSW21Lxre5lmQJJ5TEqmBgY5rg7KE3VwqAYfqOcUkyu0h8zkDg0Aa0aecRGjp5THjc3f1qCZUhkZZVyy9BnhqpwcKVV8N2PpUiTl7PD4aQH/WHrigDd8HXaWPiGG5ErJEHA2jvXvqMrorqcqwyK+aLWYBflTBByCRyK928B3X2nw7CGcNKv3vakwOiooooGFFFFABRRRQAUUUUAFFFFABRRRQAUhIUEsQAOST2pTwCewrzrx/4xiW1aw047mc7ZW7qKAOX+IviD+2NUMULH7LD8qY9e9caFeeQxEAuvJJHQVLcSCWffGCMc81HGnnO0gIjLD52piInhjuIvKBUTAngdGHtWZHZvPP5US5Yd8V674A8DQXSfbr2XzIP4Ap5JqX4l6ho2jWf9n6dHCl8RglVyVH19aAPIyXhBR8KycAg9PpVRpSAAuCSSc+9SuSTtJyCM5PNRGPuhBGetACRyjy23oMnjd3FMAwhydy9RnvVu3geQ7YdjHGSu2onULMFkUgfxYFADY4DKjNwNg5JPT0qm3JxwOeasltnmIQwJ71DJsJAK5B5yfWkAnPRWbGcgZqaT5fl3ZA9qiXau44INPkZnIJB6dfWgCf42StJ8AtNDOW2a9EB7f6PNXlfwU/5Gq6/wCvJ/8A0OOvVPjVay2/wA0xpQQJdeiZc+n2eavK/gp/yNV1/wBeT/8AocdJjPP6+gdPaRfLZSAVAxk18/V9AWzeZHExAQqoBx0poDaudTvLqMR3LoUToAoGPxqmGP3QAc00spAUEjHJpwjLcxjj1PegQ1SFXoTz0qxDI8Sts2Hd1yM4ojt0YZmkwPahRCm75txFMB9vKUDYXJbihxiXJTr1Ao8yEKML+NTxXMMbfNDuB6/NigBsEjxk7HMZHzDb60wuzMzPlpGOcmpxLauhLRlOfXNIwtmIAyPfNAEY/wBZggnkcrVl87uAcDjPcU5reSLPlkSL7CnNEWGcMCeTz1oAbDPGsitINw6EE4pRKjhQrYB/iqrPG0XUEmmISUG0ADNAGxpstrFqUIvFLwK4MgHcVY8SyWMmpMdEDLZ7QVRs5zjnr71l+VtKhXUsy7ixPT2qONmEu1sADqfWgDRs5SAC5AA5J9K7T4f699j1iON3fyJDt2g4/GuADDzQFDbRx06irsM3l/cGMHgZoA+mevI5B5FFcd8O/EaatYC0lf8A0qEYwR2+tdjSGFFFFABRRRQAUUUUAFFFFABR69qBXmHxI8ZfJJpmk3CqOksqHJPsPagCT4gePVtC+n6M2+XpJKvb2FeWmaSfzJHDmRjknNZ6SOkrSOdzHv1zU1vcb7WdEY5bnOOfypiCW7ZLeOONd0n8TVBE7ynywCBnn2FVsEsQqOG69DVvTLO4vVuGjPywLvIzgt2xQBu2fiy8sLdrexunjgiHKxnjJrBuC9y73E8c4nkO7e6HDfjXS2EMmpwWjW9nEJsN5ihR82OlYeqy6kksn9pQLCwbCoAAAvpQBVhYQ3cdzJGGVOeOn0qq+6VnKIQpbOPqaedrKxDHaOdh9fao43cHO7A647UAdD4Y12bwy9ywtIp5iNvzkcDFZmrayNVl8+W3WKctkquMEVntJJOd0g3Ox7d6gjUecVYk49OtADixdwzL8tLJ5fl4IIlzlT2xSBfMRiz7WU8EdaHyCpbBx29qQDNkm1iqFh1JHardmgmlgj3Hc7BePepLNwbWURuRMegxwRV3wnD5/iTTomX71wgz75pga/7VtkdP+B/h21ON0eqQg49fInrwH4Kf8jVdf9eT/wDocdfSX7af/JL9M/7DMX/oievm34Kf8jVdf9eT/wDocdSM8/r3uwUvFHtB6V4JX0HpzKltEV4baMmmBdWIRIC53MfSmvM5O3oo6Ypr5ABZgzEce1MZHIAAoEIH4yxO01IDn7oBz0pwjAViMEDvT4I8rkqcdM44zQArALgKQRjJ+tOcRtENoyzdSe1T28CSrMWcBkAKrtzuNQlcfeHzZ4FMBFQqfnJC479/pUsBVDkqG3etPKvcMglKoAMAnoKt6vaJBdhIJo5l2KfMT7vTpQAi4dVJBTd+VWYN5mjiYeZGTjb0yPrVe2WSeSOKMNIw4Cj19K9R8O/D24uLWCe9k+zBvmKfxj8MUAebzWZvZjHbjEp+VY//AK9RHSLi2m+ztGTcKpeRf7uK9ou/hzZFVltLiVbhTuG4jBIrR8N+EILC6u7+/Aur65yGLDIVcDilcDwJIjhmMZx3GaZEyrJhkLsAflr0n4n+FDY30F7o1lJ5Mq7XjiUkK3r7VxMmnXzM8klnPGhHLtGQP5UwMoMFAJLDjbxV+2eL7QoKkgL1Pc0jRMnlidWG1cBSuMj1pbGGS6uVjjjd2zwEXJ/SgDT8H6lJp+uQSxNJtMgDL6819Eg7lDYxkA4rzrwR4F+zFb7Vl2yFg6QkcjHrXo5yT0pMYlFFFABRRRQAUUUUAFFFFAHDfE3xP/ZVi2n2km28nX5mHVF/xrxq3EdxdlZZY4l2Fi755PpXqXxS8OzXVydTgjLptAkIGcY715TdwKrEL84B6bcc00IqsuGOGUjsFqS2YWj+aqCRznDN/D9KSP5W5Uc9D6VLGAZo4yN6lh04/GgCe0vxAk1zPGk80oKgP1wazZ55IULhTGeoVegq9r1rHa3r/ZZ4px32jGB6VnOPOkVXYE44VTQB2vgDxfFoVtdXd9B587LhCeMdfauX1bVZtXv59QvDuMrbtvTb7VSXHksoDkDsO1MZOFLEdenegC3BBZXEGZLnyXzwNuc04aK8yk2cq3B9Mhf5mqHllstsYn26UsYeMo0ayLIvJJ4AoAQW81vOySxsrRnpjv8AWpLedrK/WeNI3cD7rjI5q0+r3fkGKR94c7jkDis8Mkr5kTJPRgelAGzpvh1tXi32FzC10QXa353H6dqoS6LfJd/Zns5VlzjbgZzVeKZ4JfMtS8TqeCrEGtTUtYvwI2M7FnQbm7j8aAM64tDbyGOUhGXsOua0fAxLeL9IBY8XKjHrWJ5pYkyksOpJOTXQfD9fM8Z6KBg5uVOcYoA6L9tP/kl+mf8AYai/9ET182/BT/karr/ryf8A9Djr6S/bT/5Jfpn/AGGov/RE9fNvwU/5Gq6/68n/APQ46kZ5/Xv2mSEW6DaD8orwGvojQbSS4hgVSoIUMQxxmmgHrGC3JCBupPard9ElrIqxzRzoVB8xOn0pJ42SSQMo+9jHpUW4tCEKABTkU7CGoUjIAUkuePWrjSSR2nktkJvyQKgjHzqQBuBwKvCCeUqqoWy393OTQBDZP5dwkicc4NTX0YW8fad6E8E8VsDwtrUKGR9KuMMAVO31705PD2pyyxRS2Fx1+9jp9aAMFFXzcqDj0I6V0/hnwvea7cqsFu3lDku3ArrPC/w6Et4smpyHC/MI17jtmtvxt4ut/DEX9kaNGpugMFV6R5/rQBJpGkaB4UVrrU5IheBs5PO36CtrUPG+iWcKu10ZHddyoqnJFeJ3Vrc3kD3l7crI7HDjdl0PoR2qrq2oG6uItmBEkax/XFFgPffDviiy12Ux2qSK6ruYN2rL+I93rdhpL3OlSBIU5covzAVJ8LtOjsvCdvcAkzXg8yQn2JAFdVcbPs0vmhDHtOQ/T8c0hnzfP4414urSajPwPu7iBXaahe654j+HlnNZpLJJFIFdIj8znPGa5LVPBmpm6uruUW8Vq8rMH80EgEntVs62dO0YaRpksnk53STK20yMOhHcfSmI34/Cd3qWl2R1C6htNRL+W0UzYcD3969K8NeGrHw/axx2sQecD552HzMfr6V8+i/u1uFd7mUzA7vMkYtW3F4h1q8AiOo3MYHA2yMOPzoA99WWJ5CgmjZx1UMCR+FeYeKfG+oQ3U1rZyCJkcqCmDXN6TcjSNct7kyGUlx5jHvzzTfEdzDea3cTpbESSH5TEAFA96LAbvh74h6jHeCPViLmA8E7QpHvxXq9tNHcwRzQMHikUMpHcV86W48wFZBgg8kCvV/DMl7eeCZxpkjxzwErFgcuQAcfrSYHcUVyXg2/8RTSeRrtmwUAnz2Xbg+nvXW0DCiiigAooooACAQQwBUjBB6GuK17wFZXfnT2TPHK/Jj4wfYV2tFAHztf6Z9lupkaIgRDo/BPtWcts4JkMRU4JyeBivXPiX4Vvdba3uNJCiUfLIBwT71zN5oVrHGvh+71aCTVmUthGwA3UIfc9KdxHlF9dNNKVjGyIHKj2qGFGnnURq3me3cVq6noWp2dzNDcWcoeNiD8p4rQ0XSrjTY2vb4S29yR/o8eMZ9SfwNAGfPCLZ281hnjCjvVVp5FSQwxgDHRuSKs30RO4tjIOSQetVZkkAIjPysnzEdqAKayzB8q7E98HAqXzJV+87Y7gmoBxzt6dumamEm6NtzEEngYpASQXrRsRJGrqeAGGasie1mOChj/AN3tVWK3LTLHGd8jj5AeAKrkMjdMOD0pgaJtZYzuQCRTzuXnFNWVnzBORu7Nnr7H2qG2uZIBsjYlTyVqwskF4m0L5cnqT1NAFaaOPaVYMkgPQDg1o6BK0Gtae0OVZZV2ketVJxIqh3UsBwGBrW8DWz33inTolRnHnqW9hQB0H7ZbM/wn0Zn+82rQk/X7PPXzj8FP+Rquv+vJ/wD0OOvpH9tEAfC3SwOg1mID/vxPXzd8FP8Akarr/ryf/wBDjqRnn9fQmmMZLWAlcthQPXPavnuvonQhDHZwtKrtwAMHp700Bck3uxJZsj+dOS3mup1S2RpJGwNo5phZVkkwMjrzXT2N9aaToqm0Qtqc4PmSHpGPb0piLdnH4f0kRrrG6W5GC0cfzAH6iuni8f6LpVj/AMSXS1MxPO8Hj8TXlLq8rSSOWd25JPJ/GpbhwUjReCoBPvQB3kvxM1O5uCCI4oSDgbAcGsKfxfqrguZ13scA7AP0rnHbIUAD3pTtfap2gjp6UAe0eFfiFFF4baTU4v8ASYchXGAJPSvKnuJ5rq41B3MszPhQ5yWz05PpVKOV2hMbElQeB2q9bSK8K7lzg7uTgDFAEctw8UTxmT9+53SjPRveqDMCQwYfjU94BLckq5Jbk+lQhdnXB9B6UAfQ3w21S3uvCVjG80azwRlZFJxjk81x/wAUfFxvAdL0pwbZTmWVT98+g9q4C3vpraAQrMVEnzNt4/Corlh5a3CyguW2+WVOR70WAWWSSYxC9mZ16YHOMdKZJJE5CKT/AL2OaidsvksCSOwpkaEfeHB7+lAFmPYdwcgoB36mtFpEWdfIj+QgfNnk1f0/TzeSW9rHZA6VgNPf7eYyeuT6Zrf1TwtpWnT2iWOqR3AlUk/OCePpQBk20bTQNdS/djO1eOprsfDmj2txdpu3Ty7Q8pKkAA9APWptF0BLmyeOKLaTxkj5T7mu7s7aO0to4YlACKFyKVwOR1nwd9vnJgSG3HaQY/8AQRXQ+G9KGi6Ulp5olYMWZwuMn6VqUUDAknrRRRQAUUUUAFFFFABVeK8tprh4I50M6cMmeasr94V5NHctZ/ES6nkOQsjY9OpoA7m88YaNY64ul3VzsuWxzjKg+hNeReJvCWvWni+GSQif7ROHW5D43AHv6Vx2r3El7rF7Mzt5rzMQQeeteo+JNXvIvAvh5gztI0P7xj1yMCgR6rBbILaITRxu4QBiQDk49a4Txh4Glv7ia+gvAIwMiJgfl+leb6P4l1LTNQ+0wXT7m4ZW6Eeh9q9e0LxPpnirTJLaV1t7l12yQucDPqp70AeKxadAby6gvL2K3WFGYPICQ7Doo9zWBceasZiA2KTuyOuK7vxl4Vu7G9uXjZZoo/mLZA4/xrhyAquqg5cdz0pgUCA2MmpYooVWU3LOylcx+Xg4b0PtUrRxsQAD05560lzbFIg0bZZv4M9vWgCBFaSP5ZCcdR6VG+PNHLFQMg1ehZoLWeMIgeRQBuXJ/CqpGYwTgHPPFIBr7dokUkP2ApZ8MAwdskenerX2KRWQAcuNyrjk014mAG75Sp5B60wFs/O8vDMCp6AgV7N8FdECW8+syLtZ8wopHIxzn9a8y8K6PLrWrW9nbruaQ5dlGdidzX0rptlDpthBZ2wxFCgQe+O9JgeF/tpf8ku0v/sMxf8Aoievm74Kf8jVdf8AXk//AKHHX0j+2j/yS3S/+wzF/wCiJ6+bvgp/yNV1/wBeT/8AocdIZ5/X0XpCmSyiz/Co6+lfOlfT8WkyabHYrOrKl1As0W7+JD3poCvsJYbsYpZXLELwAO9XJLcRsRtYqOSapzKgc44JNMRJbRTShyg4QZJJ7VGInfGBnJ9asREsEBxtU9AetE4DjcuF9gaAHW/lm2mV8edkbSemO9RMuC2ACSOPY062xvIJ49PWp7ny43VY8kFckehoAgtYmmmjiU4LkL7VveKNGn0G+/s2UjCrnd/frISYRzxMnDowYH1rpPE91/b10l/d3O24ePiPb1oA51bdfsCTNLGxLlBCp+ce+PSoU2iVfLBx6N1ps9q3mfNlCOmO9TquYGLEAtj6igBHB3bhnA6j3pwQyBclQPQ0LC7lVjfJY4A7mlWJYbpDPvwpIIoAkkiDFRDFhe5FNl8vzVwhIXrUkkhjXbHKQvU4qKLaWGXKk9qALdrNMrPbwyP5co5UHFbmg28uqanHDBuyh2hiO9YMEMsdzHNHIAOzV6X8KrgXOpXsUyI8mBN5p6jBxgfnQB6TY2/2W0hh43IgDEdzU9FFIYUUUUAFFFFABRSEgDJ4HSloAKKKKAFXqK8C8XX7r4nvZtpRBMwPPvXu15KYLO4lX7yRsw+uK+aNbu5p7stcnzGklzheckmhCZ6D4Q8B6dq8keqvc+ba5yYlyDu9zXY/ELQ21Lw00dkscZtf3oQDGVAzgVpeH4rLRfDFqqukNvHHvZnIXk8n8a5jVviLpUmg3LQrKJ5VaFEI7kYzQB40JfskpMuwt12uM1DHLN9oWdJBGFO5WJwBTr2cOxDKPmOQ1RIgZUV3yeT6YpgdDH4nvJY5Yb9mubaQ8hudp/vCudvdk0xWIbSp7DkjtUgmkJUooOflPHApz7Wl8+JCuzGc+1AFbG2PMmR6I3Gaa5WcrmIIwHABzmux0LVNJvLgt4gslKH5VMKhce9bt94H0LUZI5vD+sQrnlknc8fkKAPMN4Zt105GBjkVWQjaTnd6cV1uveF763uX22xuYVA/eRKStc5cRGNiFRVPQg0ATaJbteX8KuxCqeTnoK0LiAXl07CZd+7YsYUjODxVaxQKDASy71/h7+xrvfhboA1bV2vLxFe2s+x/ib+H+VAHc/DnwwND077VdIo1C4GWwPuD+7XY0E5OaKQzwL9tH/klul/9hmL/ANET183fBT/karr/AK8n/wDQ46+kf20f+SW6X/2GYv8A0RPXzd8FP+Rquv8Aryf/ANDjpAef1+hMnhqPxF8NdEkRP9OgsEaHHJbCj5PxxX57V+mPgM/8URoJX/nzj6f7ooA8BhkliuWMy7ZFyhRh3FY9zE4k3bc5OeDXrPxU8MSwXTa1ZbRauAJUH8Df3vxrzG8s2jWFoiSsgzzxiqEO0t7fzxFfofKY8shwVr0OXXPCWm6E1nYacbuUrgyyqDz65615rNb7JPLDbsDJbNSxR7kYRjDD+H1oAuTeW1w86wqquMooHSs+YEncyHd16da09MYC5gkuMGCJxu/wpmquk9zK8fEbOSoHGBmgDOjX94rgYGea07rMm0qSSBiPPpVWySN5ijlgoBJye9TO8ikFeT0Ue1AFOQHceSCB8xHOKJAFAOPkI496lZHEZkUnJPzL6U/OUUYBz2P9KACFvIaKRR05B9DUcx8ycu5yDzmnM0hbGBt6fSp1tHESsXj8vPY8mgCvJEwAJX5T79asQt5i4jVVwu0lh0rS0HSxf6pLbRLJIqQs6YHJIqGHTpZPNUlFYMUKk4IP0oAuxi2cQWULKQTlnI716f8ADvRW02TUJJ4isgcRxuOjJ14rgNB0oJI17In+h2rKWZ/lLn0HrXsehyLc2ZvY1Kx3REqKTnAxSYGjRRRQMKKKKACiiigAoqO4mit4XmnkWOJBlmY4Arj9X+IelWMbeQss8g4AxhT+OaAO0qhrWr2Oi2jXOozrFGO3VmPoBXmc/wAQ7zUoJdrnTlQZVoFDlz6c1wF5dvPdNNfSSzSZyN7E5osI67xd46udSndbJmt4dpQL3Knru964ln8qQXCLlk5+bnn1qrISZGdlYIWwD2zTbcM0Mi5ZsHJ47UwNW81y61SNY724mMbDlAeOOlZVw7FVjByoOeaIJYgd08bNgYUA4z70hV5Y2K/MM80ATWIt2EpuTt4Hl7emagvMeaHUAE/3TwKYg3DGBgdqVXQ9eMnp7UAT2kkkBhVpP3byfMoGcivT/EvgVI9NtLvS3ASRAZPfIGP615bHtCMHGBn5fatSXXdTNrDZi9l8mPoitQBs3ngvVLXTjeXMcIiAycSrn8s1yJWUzBI2eMseNpxkVfn1O/ysT3MuCPutgj+VMintZWVL/wAxEByXjXOKAJtP8Q6npUm+C4wU42SZZW/Cm39zLeTfb7mJR5x52DCg/Sob7TvIcSQyxTwezZYfUU+Bp5Y4olOIlGSD6+tAE1laTmeJdp3SsFTuWz6V9C+FtGj0LRYLNdplAzK4GN7Vw3wo8PmV/wC2bsZWMlbcHnJxgnH416hSYBRRRQM8C/bR/wCSW6X/ANhmL/0RPXzd8FP+Rquv+vJ//Q46+kf20f8Aklul/wDYZi/9ET183fBT/karr/ryf/0OOkB5/X6V/DuUSeB9CBbLC1UfkK/NSv0l+HQVPA+gsRz9mGDQB0l1bw3dtJb3KLJDINrKwyCK8L8WaDJpGqz2k0Un2FiTBJjtXvNZ+u6XDq+nyW020Ej5XK5KmnsB813FkYcg5AHTd6U60hklYBdzAAnIrqNS0W7tJZbXUoWUo3yN/eXsar2ZRJBBEPJyMkvzTEY1ghLuuHZCNxwOnvWidGkI85gdmM8c5Fd/4e8JWzNFepeRzRyptbYMKD6Yr0FdPtFgEQt4goXbkIM0XA+bpY0jdfLY7jxjFSy2ssEPmzq6semR+tek+J/CsEMbuFVXRwYjtGCPU1Xu9AgvfDIubvVmjKkrtlIC5HZaAPN5wCd4LYxz2qpLAwlTDkj+Va9yMklpGk2/LgjqBUUQUJvYDap4x3oAqzAM6hPlwMYNSQoCNrMAwPHofpTbhhJIBjG45wBWl4e05dQ1KCzYlTKw2kLk4zzQB6F8P7WLQtFvdcv49p+7DuHJGB0+p/lXE3Mq6jrNxcxRBRM5dmA+5k13virWdN06bTdIAL2trIqzKPQVJq0mj3/hy/n0+Fbe22hVfbgyNnoO4pAczp7ya5e2Ok2ro9vE2cE8kdWr2KCGO2gjggUJFGoVVHYCuO+G+g/YLJr+5jX7RP8A6s7cFV/+vXaUDCiiigAooooAKKKKAOa+I2T4QvABkFkz7fMK8MuIXZlQcgng19E67p6aro91ZyZxIuRjrkcj9RXgU6G1lkgmR1mVipDDG2hCKt7Mw+RlVGRQBs4z71Vs7K41fUILa2jZ5ZDjj+H3NPv4gXUoWLHvSWtxNpql7dzG7cFx1/CmBN4jshp072PnpOIT85U5AYelZYd4EV1OPM4wKUxlpzKzO6t8zEnkmkjdJZ0iBADMAQR0HrQBGAHYfIVPTPY0NEVO04BHUKa1degtbS4aOyuRcQrwroKowR7rZjvHmA56cmgBBG1vcBUwRjO7OagfDuwKnGc+lP3AKwLnnoKQy5B3YGBhcUAJG7bWRFypHU1MNkAGEPnDrk9aWz2rIuEWQdwelNnV97PG4ZOnPX6UANMyvL86syg+vP50kYcTNzhRyAfT0pYoTGFbcQT90EdK0LO3M6sGlAWPlyBnrQBShdYLsIiK8Nw4AdR0+tdfpfh+a/1dLG2BaMn5pFHCj1NZWm2Vx58cKqpDsAi7QST2+le4eD9BGi2G6ch72b5pG7Ln+EUAbNlaQ2NpFbWyKkUShQB/Op6KKQwooooA8C/bR/5Jbpf/AGGYv/RE9fN3wU/5Gq6/68n/APQ46+kf20f+SXaX/wBhmL/0RPXzd8FP+Rquv+vJ/wD0OOkB5/X6VfDghvAeidDi3Ar81a/SH4Yyg+CNLwwOFII9OaAOsAC5PNAORkUtJ34oAz9a0e01m28q7XkfccdVNeTa/wCF9TsbpTNADAMhJUbII98dK9qpksaTRNHMivGwwysMg0wPHfDWsXthKliG3QGTeq7ejdM59K9T0PU49TgcopDR8Nnuaybzwja+b5lgFiJ4KnoB7VsaLp8On2pESbGb7+eOaBGVbeIEvvEl3otzZbUQFQ7cgn0rhvHga1v201VCQhvMjVjuDA16yYIBKZzFGJDyZMcn8a83+IVkt9qUd20f3B5YweoHehAcfbRW8yGIp5zYP+rGCKiurKGW1T7Aku5V+dCf4q1bDQr0wS3ibWiUgBARk/1rd8P2rLvM1ntjc9M8n3pgebww3LziFIXab2HIr0LwJosum3B1K9niSUROIkJw2SO9dX/YQm2NEsaHuVUZI+tacOiwr8rqdo6Etk0rgecRaS13PLc3wkubpgWAjG4PJ6V03hbwxcuy3GsjZAhzHaEd/Vs12VtZ29qAIIwuO9T0AFFFFAwooooAKKKKACiiigArz74k+FTdo+qadHmdRmaNV5b/AGq9BooA+eYbMXS8b1kGOSOPxqjrsKpPHFA4PHzAdAa9a8XeFvKWS/0eIknLTQA9fcZ/lXm0tkk3mT5BJBYrjmmITxHoljpdpZNBfpdSzRK7xhgdhPUcVhpbwiZjHvYKO4/lViWy89QUYhzjCmuv8QW+nQeHdPuYITFdKCsqKMEntQBwU8TsvmjhehBx1pXjeNEc7Qj8AZGc1djKyTrHIu8SHBz1WruvaJcabdQwSwAM6B1f1BHSgDBRDIwG0EdfpUwWLepQbgDz6A1bmtoUBjJIc84xwfxqQWAECurBmb+EUAUrUot8HnB8s5yqcZqEoJS+3g5/GtO2sJpJAoRi7cAAZxXSaR4PuTcjz8QgjO885H0oA4oRzPtAB25xyOn1rqPDOjfaFkhgLO8mM+WM/hXW6V4PSSaSO2BYFsvK4wAPbPWvQdM0q105FEEaeYBguFwTRcDB8IeGhYn7bfRqLj/ljHj/AFQ+nrXW0UUhhRRRQAUUmRjPAHqaR2VY2d3CIoyWJwAPc0gPA/20Tn4XaV/2GYv/AERPXzf8FP8Akarr/ryf/wBDjr239rrxRFq/hKy0/ToXksbfU0Z7zB2NIIpQFU9CMEmvEvgp/wAjVdf9eT/+hx0Aef1+jPwwAXwXp4KY+/gj69c1+c1feXwj8f6O+gW2k6jL9lu4i2WkwsbAnIwc0Aerxt8oAHHrUgOR61HF5csSyQOGjcbldTkEetLhgeP/ANdAElFRRsR94E59OakUg9KdwFoPPWiigCvd2sd0oWRpAB/cbFU30OzfAfzm2nIy+a1KKAM6DR7OAKIVZMc8HrVsW0IJOwEnrmpqKAGoiou1FCj0FOoooAKKKKACiijtQAUUUUAFFFFABRRRQAUUUUAA4rmNf8JWuoSS3Fqfs9y4ywUfK59/SunooA8yTwdIiyRXjMhIGGVMgfjUOseHI5o44bZ2ZlB3EivUzyMEZHoaiNvCc/ulBPUgUXFY8bHhByqbJ9rng/Kcg11PiKymvNKsoLpQtxGuxZyOMD1rsJNKhdsq7p/u46+tT/Y0NssLEsFOQSOaLgeYW/hGCO3Y3dws8zEcJkYFWbfwvCs8c0If5Tyh/ir0dLWIYLqHI6ZFSrHGhyiKp9hRcLHL2nh8QzJPbwqnoMcituHTUyrTkOw9OlaFFAxFAVQqgBR0AFLRRQAUUUdaACimuVSItIVWMDJZjgD8a4bxX8TdF0IyQQn7bdocbEYbP++hmgDu+cHvXnHjvx1oFrbvDJcy3zK2Ps9o+3n0fOMivJPFXxK1zX2mhM4t7N+kMTYx+PU1wrysw+9znqetAC/Hrxlc+IfD1pZLZ2tjYR3iyrBbptUsEcAn3wTXGfBT/karr/ryf/0OOpfiMc6NDk5P2hf/AEFqi+Cn/I1XX/Xk/wD6HHSA8/q8NX1IdNQvB/23b/GiigDWtPHXi6zjEdp4p16BAMBYtRmUAfQNU3/CxfG3/Q4+JP8AwaT/APxVFFAAPiL42HTxj4k/8Gk//wAVR/wsXxt/0OPiT/waT/8AxVFFAB/wsXxt/wBDj4k/8Gk//wAVR/wsXxt/0OPiT/waT/8AxVFFAB/wsXxt/wBDj4k/8Gk//wAVR/wsXxt/0OPiT/waT/8AxVFFAB/wsXxt/wBDj4k/8Gk//wAVR/wsXxt/0OPiT/waT/8AxVFFAB/wsXxt/wBDj4k/8Gk//wAVR/wsXxt/0OPiT/waT/8AxVFFAB/wsXxt/wBDj4k/8Gk//wAVR/wsXxt/0OPiT/waT/8AxVFFAB/wsXxt/wBDj4k/8Gk//wAVR/wsXxt/0OPiT/waT/8AxVFFAB/wsXxt/wBDj4k/8Gk//wAVR/wsXxt/0OPiT/waT/8AxVFFAB/wsXxt/wBDj4k/8Gk//wAVR/wsXxt/0OPiT/waT/8AxVFFAB/wsXxt/wBDj4k/8Gk//wAVR/wsXxt/0OPiT/waT/8AxVFFAB/wsXxt/wBDj4k/8Gk//wAVR/wsXxt/0OPiT/waT/8AxVFFAB/wsXxt/wBDj4k/8Gk//wAVR/wsXxt/0OPiT/waT/8AxVFFAB/wsXxt/wBDj4k/8Gk//wAVR/wsXxt/0OPiT/waT/8AxVFFAB/wsXxt/wBDj4k/8Gk//wAVR/wsXxt/0OPiT/waT/8AxVFFAB/wsXxt/wBDj4k/8Gk//wAVR/wsXxt/0OPiT/waT/8AxVFFAB/wsXxt/wBDj4k/8Gk//wAVR/wsXxt/0OPiT/waT/8AxVFFAB/wsXxt/wBDj4k/8Gk//wAVR/wsXxt/0OPiT/waT/8AxVFFAB/wsXxt/wBDj4k/8Gk//wAVR/wsXxt/0OPiT/waT/8AxVFFAEN1478XXcZju/FWvTxnqsuozMD+Bastta1Vh82p3x+s7/40UUAN/tbUv+ghd/8Af5v8aQ6tqJ6392f+2zf40UUARXF7dXKBLi5nlQHIWSQsM+vNdx8FP+Rquv8Aryf/ANDjoooA/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small peripheral cavitating lesion in a subpleural location, detected only with high resolution CT scan.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_11_37050=[""].join("\n");
var outline_f36_11_37050=null;
var title_f36_11_37051="Stress fx XR classificatn";
var content_f36_11_37051=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F58048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F58048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Stress fracture imaging findings and severity classification",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Grade",
"      </td>",
"      <td class=\"subtitle1\">",
"       Plain radiographs",
"      </td>",
"      <td class=\"subtitle1\">",
"       Bone scan",
"       <sup>",
"        [1]",
"       </sup>",
"      </td>",
"      <td class=\"subtitle1\">",
"       MRI",
"       <sup>",
"        [2]",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       Normal",
"      </td>",
"      <td>",
"       Small ill-defined cortical area of mildly increased activity",
"      </td>",
"      <td>",
"       Positive STIR image",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       Normal",
"      </td>",
"      <td>",
"       Larger well-defined elongated cortical area of moderately increased activity",
"      </td>",
"      <td>",
"       Positive STIR and T2-weighted images",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       &plusmn; Periosteal reaction",
"      </td>",
"      <td>",
"       Wide, fusiform cortico-medullary area of highly increased activity",
"      </td>",
"      <td>",
"       Positive T1- and T2-weighted images, no cortical fracture line",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       Periosteal reaction, &plusmn; fracture line",
"      </td>",
"      <td>",
"       Extensive trans-cortical area of intensely increased activity",
"      </td>",
"      <td>",
"       Cortical fracture line; positive T1- and T2-weighted images",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     STIR: short-tau inversion sequence.",
"    </div>",
"    <div class=\"reference\">",
"     1. Zwas, TS, Elkanovitch, R, Frank, G. Interpretation and classification of bone scintigraphic findings in stress fractures. J Nucl Med 1987;28(4):452.",
"     <br>",
"      2. Fredericson, M, Bergman, AG, Hoffman, KL, Dillingman, MS. Tibial stress reaction in runners: Correlation of clinical symptoms and scintigraphy with a new magnetic resonance imaging grading system. Am J Sports Med 1995;23:472.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_11_37051=[""].join("\n");
var outline_f36_11_37051=null;
var title_f36_11_37052="Classification of cryoglobulins";
var content_f36_11_37052=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F51371&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F51371&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Contrasting features of types of cryoglobulinemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Type I",
"       </td>",
"       <td class=\"subtitle1\">",
"        Type II",
"       </td>",
"       <td class=\"subtitle1\">",
"        Type III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Essential (72 percent)",
"       </td>",
"       <td>",
"        30 percent",
"       </td>",
"       <td>",
"        70 percent",
"       </td>",
"       <td>",
"        57 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Secondary (28 percent)",
"       </td>",
"       <td>",
"        70 percent",
"       </td>",
"       <td>",
"        30 percent",
"       </td>",
"       <td>",
"        43 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"1\" rowspan=\"4\">",
"        Associated diseases",
"       </td>",
"       <td>",
"        LPD &gt;&gt;&gt;",
"       </td>",
"       <td>",
"        Essential &gt;&gt;",
"       </td>",
"       <td>",
"        Essential &gt;&gt;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Essential &gt;",
"       </td>",
"       <td>",
"        LPD &gt;CLD",
"       </td>",
"       <td>",
"        CLD &gt;&gt;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CTD, CLD",
"       </td>",
"       <td>",
"        &gt;CTD",
"       </td>",
"       <td>",
"        CTD &gt;&gt;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        LPD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Symptoms and signs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Purpura",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gangrene/acrocyanosis",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        + to ++",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Athralgias &gt;&gt; arthritis",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Renal",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neurologic",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Liver",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Type I: monoclonal immunoglobulin (Ig); Type II: mixed monoclonal Ig and polyclonal Ig; Type III: mixed polyclonal Ig. CLD: chronic liver disease; CTD: connective tissue disorder; LPD: lymphoproliferative or plasmaproliferative disorder; Essential: cases of symptomatic cryoglobulinemia that are not associated with a clear-cut CLD, CTD, LPD, or infection; Secondary: cases that are associated with a clear-cut CLD, CTD, LPD, or infection. + and &gt; indicate relative increasing frequency of occurence.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dispenzieri, A, Gorevic, PD. Cryoglobulinemia. Hematology - Oncology Clinics of North America 1999; 42:2507. Copyright &copy; 1999 W.B. Saunders Company.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_11_37052=[""].join("\n");
var outline_f36_11_37052=null;
var title_f36_11_37053="Benign granuloma PET";
var content_f36_11_37053=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F82372&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F82372&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Benign granuloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 247px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal PET scan shows only very weak uptake of radionuclide in this benign lesion (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_11_37053=[""].join("\n");
var outline_f36_11_37053=null;
var title_f36_11_37054="Distal nephron segments";
var content_f36_11_37054=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F78299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F78299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    Hormonal responsiveness of distal nephron segments",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 187px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ADH: antidiuretic hormone; PTH: parathyroid hormone; ANP: atrial natriuretic peptide; CT: collecting tubule.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_11_37054=[""].join("\n");
var outline_f36_11_37054=null;
var title_f36_11_37055="Unstable forearm fracture";
var content_f36_11_37055=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F56680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F56680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    Unstable midshaft forearm fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Very unstable complete midshaft forearm fracture in a 14-year-old child. This fracture required open reduction and internal fixation in the operating Room. Both bones are 100 percent displaced dorsally and 50 percent displaced laterally. There is no intact periosteum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paula Schweich, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_11_37055=[""].join("\n");
var outline_f36_11_37055=null;
